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Chapter 1 
 
 
Introduction and outline of this thesis 
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This thesis focuses on burns in children, in particular on the epidemiology of children admitted 
to the Dutch Burn Centres, general therapeutic options to promote wound healing and on 
specific aspects of the conservative and surgical wound treatment. Since its foundation in 
1974, research is performed in the Beverwijk Burns Centre on clinical and preclinical aspects 
of burn wound care. Initially this mainly concerned surgical wound care issues such as wound 
excision and skin grafting techniques in the context of burn survival
1
. Later on, attention 
shifted to functional and cosmetic outcome of burn treatment, more specifically the treatment 
of partial thickness burns in children 
2,3,4,5,6,7
. Part of this thesis builds on this previous 
research. In the course of time research further expanded to other areas of burn care, such 
as the impact of burn disasters and selective bowel decontamination to diminish the risk of 
burn wound sepsis 
8,9.
 Nowadays many studies are initiated, supported and co-ordinated by 
the Association of Dutch Burn Centres (ADBC).  
 
Organisation of burn care 
 
Burn centres 
Burn care has become organised on a national and international level. Generally, countries 
have centralised their burn care in burn centres or at least burn units. In order to share 
knowledge among caregivers and to build a platform to exchange results of scientific work, 
national and international societies and associations have been founded all over the world.  
Developments in burn care and trauma treatment arose from large-scale incidents such as 
fire disasters and war episodes. Already during World War II, a burn facility was founded in 
the United Kingdom. In the Queen Victoria Hospital in East Grinstead, Archibald McIndoe did 
pioneering work in the field of plastic surgery in burn victims. One of the first hospitals in the 
US that provided burn treatment to patients is the Massachusetts General Hospital in Boston. 
In 1942, in the Cocoanut Grove Nightclub fire when 492 people were killed, dozens of victims 
with extensive burns and inhalation trauma were treated in the Massachusetts General 
Hospital. New methods of wound treatment, fluid resuscitation and treatment of inhalation 
injury were developed.  
 
Burn societies 
The International Society for Burns Injuries (ISBI), founded in 1965 was the first society 
dedicated to burn treatment. From its inception the ISBI promoted the total medical care for 
burn patients by the team approach. Some years later, in 1968 the second association on 
burn care, the British Burns Association, was founded. Although the name suggests that it is 
a national organization, the American Burn Association may be regarded as an international 
non-profit organization whose main purpose is to improve the lives of all people affected by 
burn injuries. This is realized specifically by giving care to burn patients, and also by providing 
education. The associating has 3500 members not only in the US, but also in Europe, Asia, 
Canada and Latin America.  
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At the beginning of the nineteen eighties in most countries in Europe burns centres or burn 
units were established and in 1981 the European Burns Association was founded by leading 
burn specialists in Europe. Its first congress was held in Groningen, the Netherlands, in 1986. 
Although its region encompasses one third of the world population and about half of the 
worlds burn patients, the Asian Pacific Burns Association, was only recently founded in 2004.  
The Euro-Mediterranean Council for Burn and Fire Disasters – MCB – deserves a special 
mention, as this organisation also focuses on fire disasters. The MCB is designated by the 
WHO as a WHO collaborating Centre for prevention and treatment of burns and fire disaster. 
Although a relatively small organisation, between a national and international association, the 
Australia and New Zealand Burns Association also deserves a special mention, as it 
developed the Emergency Management of Severe Burns course. This course on the first 
treatment of severe burns was introduced in countries in the Asia Pacific Area but also in 
many other western countries. 
 
Burn care in the Netherlands 
In the Netherlands, apart from the three burn centres; four organisations are involved in the 
field of burn care. The Dutch Burns Foundation focuses on burn prevention, public 
information, support of burn research and founded the Euro Skin Bank, which is an 
independent organisation as part of the Euro Tissue Bank nowadays. The Association of 
Dutch Burn Centres (ADBC) was founded in 2003 to improve cooperation between the Dutch 
Burn centres, especially in the field of research and education. Four research areas include 
clinical, preclinical and psychosocial research, as well as epidemiology and registration. The 
ADBC has boosted research on burn wound care and established a national burn registration. 
The Dutch Society for Burn Care, formerly the Dutch Burn Club was founded in 1974. The 
Flemish speaking Belgian burn centres also take part in this society. Its aims are the 
promotion of interaction between workers in the field of burn care by organizing meetings and 
symposia. Finally, the Foundation Child and Burn, offers part of the aftercare for children with 
burns by organizing burn camps and family meetings. Although it may seem fragmented, 
these organizations cooperate and cover almost all fields of burn care, each with its own 
specific field of expertise and focus.  
Details relating to national and international organizations on burn care are listed in table 1a 
and 1b. 
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Table 1a - International organizations on burn care 
 
organization  Web site founded main goal  Activities/secondary goals region Affiliation magazine congress course other activities 
International 
Society for 
Burn Injuries 
www.worldburn.org 1965 Disseminate knowledge and 
stimulate prevention in the 
field of burns 
Endorse regional and national meetings and 
congresses, award grants to professors taking 
part in courses and congresses in other 
countries and to members wanting to visit other 
burn centers, assist with the organization and 
financial support of educational courses in 
different countries. 
 
world WHO Burns biennial   
European 
Burns 
Association 
www.euroburn.org 1981 To encourage cooperation in 
the field of burn care 
throughout the continent 
To promote burn prevention, to study the 
prevention of burn injury and all other aspects of 
burn treatment. 
It also serves as a resource to facilitate 
communication and collaboration between burn 
care specialists. 
world   biennial   
Asian Pacific 
Burns 
Association 
www.apburn.org 2004 Compliments and supports the 
work of the ISBI 
 Asia 
Pacific 
Region 
ISBI  biennial   
American 
Burns 
Association 
www.ameriburn.org 1967 Improving the lives of 
everyone affected by burn 
injury through patient care, 
education, research and 
advocacy 
Stimulating and supporting burn-related 
research, education, care, rehabilitation, and 
prevention 
United 
States, 
Canada, 
Europe, 
Asia, and 
Latin 
America 
 J of Burn 
Care & 
Research 
annual ABLS National Burn 
Repository 
(NBR), Burn 
center 
verification 
Australia New 
Zealand 
Burns 
Association 
www.anzba.org.au 1976 Peak body for burns 
professionals in Australia and 
New Zealand 
 
To develop higher standards of both burn patient 
care and burn injury prevention through research 
and education 
Australia 
New 
Zealand 
  annual EMSB  
British Burn 
Association 
www.britishburnasso
ciation.org 
1968 Burn prevention, and the 
propagation of knowledge on 
the best treatment and 
rehabilitation following a burn 
injury. 
Disseminate knowledge and stimulation in the 
field of burns. To promote education in burn 
care. Support research and publication. 
British 
Isles 
  annual EMSB Prevention 
Committee, 
burn courses, 
Burns Interest 
Groups 
Euro-
Mediterranea
n Council for 
Burn and Fire 
Disasters 
www.medbc.com 1987 Creating a permanent 
dialogue on burns among 
specialists from countries of 
the Mediterranean basin. 
Encourage the highest standard of burn care in 
all countries 
countries 
around the 
Mediterran
ean basin 
WHO Annals of 
Burn and 
Fire 
Disasters 
annual   
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Table 1b -  National organizations on burn care 
 
organization  Web site founded main goal  Activities/secondary goals region congress course other activities 
Association of 
Dutch Burn 
Centres  
www.adbc.nl 2003 Improve cooperation 
between the Dutch burn 
Centres 
 
Improve the standard burn care, performing (pre) 
clinical research and educate medical personal 
the 
Netherlands 
   
Dutch Society 
for Burn Care 
www.nvbz.nl 1974 Improve the contact of 
those involved in research 
and treatment of burn 
patients 
 
Arrange meetings, publications and maintaining 
contacts with related organizations in the 
Netherlands and abroad 
the 
Netherlands 
and Belgium 
Twice a year   
Dutch Burns 
Foundation 
www.brandwonden.nl 1971 Prevention of burns and 
keep the suffering as a 
result of burns to a 
minimum 
Improving the treatment, nursing, care for and 
assistance to persons with burns, enhancing the 
quality of life for persons with burns, burn 
prevention 
 
the 
Netherlands 
 EMSB Exploitation of the 
Euro Skin Bank 
Foundation 
Child and 
Burns 
www.kindenbrandwond.nl 1990 Support of the Dutch Burn 
Centres, aftercare for 
children with burns 
Additional treatment for children admitted to a burn 
centre, family day, burn camps. Aftercare for 
children and their families 
the 
Netherlands 
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Epidemiology (Chapter 2) 
 
The Netherlands are a relatively small country with a high population density of 400 
inhabitants per square kilometre (April 2012) 
10
. Since 1995, a growing number of children (0-
17 years) with burns was admitted to the three burn centres, which are located in non-
university hospitals. Burn centres have a national function to provide high-quality burn care to 
all referred patients and to ensure that beds are available for burn patients. A study on the 
epidemiology of children admitted to the Dutch burn centres was therefore justified. Not only 
is the number of admissions important in this respect, also the length of stay will determine 
the number of available beds. Moreover, the need for surgery is relevant for allocation of 
operating time and staff. In addition to the availability of burn beds in ‘normal’ circumstances, 
the effect of a burn disaster, associated with a high number of burn victims in a short time 
period, will influence the distribution of burn patients over burn centres and non-burn 
hospitals. After the Volendam disaster in 2001, where 245 peoples were injured, Welling et al 
did extensive studies to the effects on the primary triage process and the management of the 
management of burn victims in general hospitals.
11,12 
Therefore, we did an epidemiological survey on the admission of children in the three Dutch 
burn centres over two time periods 
13
. All existing databases of the three burn centres were 
combined, corrected and analysed. Our assumption on the increased number of admissions 
was confirmed by the data from the three burn centres for the younger (0-4 years old) and 
older children (5-17 years old). For adult patients, who were not further studied, there was 
only a minor increase. Recent data from the Dutch burn centres show that this trend has 
continued since 2007. Until 2011 the number of primary admissions in burn centres per 
100.000 population continued to rise (Figure 1). The proportion of burn-related primary 
hospital admissions in specialized burn care has increased in 2008 (Figure 2). 
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Fig. 2 - Proportion of burn-related primary hospital admissions in specialized burn care 1995 
to 2008 
 
 
This study on the admission of burned children in the Dutch burn centres showed many gaps 
in the databases and differences in definitions, hindering comparison of the data. Therefore a 
national burn registry, named R3, was set up under the auspices of the Association of Dutch 
Burn Centres. In the near future, when this database will be linked to the electronic patient 
record of the individual burn centres, data collection will be more accurate and less time 
consuming. 
 
Cryopreserved and Glycerol preserved allograft skin (Chapters 3 and 4) 
 
History 
In 1974 the Beverwijk Burn Centre was founded in the Red Cross Hospital according to the 
model of the Shriners Burns Institute of the Massachusetts General, headed by Prof. John 
Burke, chief of staff. Burke developed a system of infection control in hospitals by establishing 
dedicated bacterial-controlled nursing units.  A specialized team that consisted of surgeons, 
intensive care physicians, burn nurses and a team of paramedics treated the patients
14
. 
Improved survival of victims with extensive burn injuries and a reduced hospitalization time 
were the most prominent early benefits.  
From the beginning the Beverwijk burn centre was collectively headed by the Surgery and 
Intensive Care Division. Initially, the founder of the Beverwijk Burns centre, Prof Rudy 
Hermans, investigated successfully the possibility of early burn wound excision in 
combination with immediate skin transplantation to improve survival
1
. 
  18 
Treatment strategies were not only focussed on survival of the burn patient, but also on the 
cosmetic and functional outcome of burn wound treatment
3-7
. Partial thickness burns in young 
children, mainly scalds, often resulted in hypertrophic scarring, even after spontaneous 
healing. Early tangential excision gave a better cosmetic result, but timing of the procedure, 
blood loss, estimation of the extent of the excision and morbidity of the split skin donor site 
were the major disadvantages of this method
2,15
. Crucial in the early tangential excision 
method was the timing of surgery. Janzekovic had introduced the concept of early tangential 
excision in partial thickness burns in 1961.
15
 As the final depth of the burn wound could only 
be diagnosed on the third to the fifth day post burn, the operation had to be postponed to this 
time slot. By covering the wound with a Vaseline-impregnated gauze, bacterial colonization 
and desiccation subsequently led to deepening of the burn wound. Application of silver 
sulfadiazine cream reduced colonization, but had no effect on desiccation
16-17
. 
 
 
Scald treatment with allografts 
In order to prevent deepening and desiccation of the wounds, further research was conducted 
on scald burn injuries, an important cause of burns in children. In the wake of Miller et al
18
 
allografts were applied for the treatment of partial thickness burns, mainly in children with 
scalds. Miller used viable allografts that were harvested one to seven days prior to application 
and then cryopreserved according to the method described by Zaroff 
19
. Compared to 
treatment with silver sulfadiazine cream or early tangential excision and autologous skin 
grafting, the main advantages of allograft application were observations on immediate pain 
reduction, reduced deepening of the wound, reduced need for secondary autografting, 
shortened hospital stay and a noticed reduction of hypertrophic scarring 
5
. 
This development was an important stimulus for further developments of burn treatment with 
membranous dressings 
 
Allografts in treatment of full thickness burns 
In addition to the application on partial thickness burn wounds, the cryopreserved allografts 
(CryoPA) were also used for the coverage of widely meshed autograft skin on freshly excised 
deep burns, the sandwich procedure
20
. CryoPA provided satisfying results in the treatment of 
partial thickness wounds but in covering excised and widely meshed autografted wounds the 
outcome was disappointing due to early rejection of the allograft, which occurred before 
reepithelialisation was completed. This was overcome by conservation of the human cadaver 
skin in 85% glycerol. In a clinical study, where glycerol preserved allograft (GPA) was applied 
as part of the sandwich procedure, in 54 grafting procedures in 39 patients the 
epithelialisation rate was 95% at 5 weeks after the operation
21
. The authors assumed that the 
apparent attenuation of allograft antigenicity conferred by the action of 85% glycerol might 
have contributed to the results. This assumption proved to be correct in an in vitro study on 
the immunogenicity of glycerol-preserved human cadaver skin
22
.  
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Indications for Glycerol preserved allografts 
In a retrospective study, published in 2002, almost 20 years after the introduction of GPA, 
four types of applications were described in156 patients in the time period January 1996 to 
July 2001
23
.  
- The first application was the earlier mentioned sandwich grafting, whereby meshed GPA 
was used as an overlay over widely meshed autograft split skin or micrografts made by 
the Meek Wall technique in extensively burned patients. In 70 patients, 129 applications 
were included in the study.  
- The second application area was the treatment of partial thickness burns with GPA as a 
membranous dressing in 57 cases.  
- A third retrospective study concerned the treatment of non-healing wounds with GPA. In 
55 patients the results of 88 applications were described.  
- Finally the results of a lesser-known use of GPA were studied; the temporary coverage of 
a wound after scar release. In the first days following a scar release the surface area of 
the resulting wound could increase, due to relaxation of the wound margins. It was 
therefore recommended to delay the autografting of the wound for some days. In the 
meantime desiccation and wound colonisation was prevented by application of GPA to 
the wound bed. 
GPA had become the gold standard treatment for partial thickness burns, especially for scald 
burns in children. However a comparative study on the outcome of the treatment of partial 
thickness burns with CryoPA and GPA had not been performed. We therefore conducted a 
retrospective survey to study differences in outcome, in particular the need for secondary 
autografting, of treatment of partial thickness burns with CryoPA and GPA
24
. In a 
retrospective study two time periods were compared. Although the need for secondary 
surgery was lower in the GPA group, the differences were not significant. 
 
Hydrofiber® dressing (Chapters 5 and 6) 
 
Until 1996 GPA was the gold standard for the treatment of partial thickness burns, especially 
in children. Although its results in wound treatment were satisfying, the use in clinical practice 
was somewhat restricted to burn centres and hospitals. Handling of strips of allograft skin was 
cumbersome and time consuming. Moreover, in some countries the use of fresh allogeneic 
skin became banned after a case of presumed HIV transmission in a patient treated with 
allograft skin
25,26
. The need for a synthetic alternative, one that lacked the risk of viral 
transmission and was easy to use, became obvious. 
In 1996 a Hydrofiber® dressing, Aquacel®, was introduced in the Beverwijk Burns centre. 
This Hydrofiber® dressing was initially developed for the treatment of chronic wounds. 
Hydrofiber consists of 100% sodium carboxymethylcellulose. It adhered to the wound by 
fibrin, allowing no dead space between the dressing and the wound
27
. Furthermore the 
material drained the wound exudate in a vertical direction; thereby wound fluids did not 
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disperse horizontally through the entire dressing, keeping the wound margins dry and 
preventing maceration of the intact skin surrounding the wound. These surgical principles 
prevented wound infection, even without the addition of an antiseptic.  
With a high number of children treated in the burn centres it was mandatory to continue 
investigating potential improvements in treatment. There seemed to be many similarities 
between allograft skin and the Hydrofiber® dressing in the treatment of partial thickness 
burns. In a retrospective study the first results with this new dressing were analysed and 
compared to the results of a previous study comparing Silversulfadiazine and allograft 
treatment
28
. The need for secondary autografting and the percentage of hypertrophic scarring 
appeared to be reduced with the new dressing. The favourable outcomes of this study 
launched a randomized clinical trial comparing the Hydrofiber dressing and GPA in the 
management of partial thickness burns
29
. In a two-years time period 80 patients, mainly 
children, with partial thickness burns were treated with GPA or Aquacel®, 40 patients in each 
treatment group. As end points of the study the number of patients in each group with 
complete healing (defined as more than 95% spontaneous wound healing) within the study 
period, the need for secondary autografting, and the scar quality were assessed. The number 
of patients with complete healing was not different between the study groups; in the 
Hydrofiber® group more patients required skin grafting, besides from a significant difference 
in skin elasticity measurements 80 days post burn in favour of the GPA group there were no 
differences. Based on this first randomized clinical trial conducted in our burn centre we 
recommended using GPA for the larger mixed depth partial thickness burns and Hydrofiber® 
dressing for the small partial thickness burns. 
 
Skin graft fixation (Chapter 7) 
 
Even today, skin autografting is still the mainstay procedure for treatment of full thickness 
burns. Technical improvements have allowed harvesting of thinner autografts. Nevertheless, 
fixation and bandage techniques have remained important for successful application of 
autografts. Parallel to the improvements of graft take and outgrowth in the sandwich grafting 
procedure the graft fixation techniques were studied and improved
30
. A newly developed 
fixation technique, using a nylon mesh (Surfasoft®) combined with stapling, proved to be a 
reliable dressing system for major skin grafts. However, for minor skin grafts, especially in 
children, staple fixation proved to be a disadvantage as sedation, analgesics and sometimes 
general anaesthesia were needed to remove the staples. Therefore, we investigated fixation 
by an open silicone mesh dressing, Mepitel®, in 45 split skin grafting procedures in 38 
children
31
. Mepitel® proved to be an adequate graft fixation. 
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Systematic review of the treatment of partial thickness burns in children. (Chapter 8) 
 
Evidence based medicine has become the general accepted paradigm in health care, and 
also in the field of burn treatment. Nevertheless, collection of the evidence is not an easy 
task. Clinical studies vary greatly in patient population, set up of the study, (lack of) 
comparative data, outcome parameters etc.   
Over the years, several developments can be noted in burn care in general, and in burn 
treatment of partial thickness burns in children more specifically. Therefore, we decided to 
conclude this thesis with a systematic overview of the literature on this specific subject. This 
review puts some of the previous chapters into perspective, For example, the successful 
application of cryopreserved and glycerolized allografts was the onset for the development of 
membranous dressings; nowadays an established and recognized treatment modality for 
partial thickness burns. Clinical science has made great progress in terms of design and 
outcome evaluation of clinical trials. Although there is still a large body of – even recent - 
clinical work that is presented as case series or uncontrolled cohort studies, more and more 
the methodological principles of controlled trials are applied in burn research.  
Despite the large variation in treatment modalities, several striking observations became 
apparent from the systematic literature analysis. One of these observations is that in general 
the different membranous dressings outperformed the topical application of the ‘burn cream’ 
silversulfadiazine. Another important observation is that outcome data on scar formation were 
hardly present in these studies. Since more and more attention of burn treatment shifts from 
primary outcome (survival, wound closure) to secondary outcome (quality of healing, strongly 
associated with psychological parameters and quality of life), further methodological 
developments in this particular field of clinical research are warranted. Brusselaers et al
32
, in 
a systematic review, evaluated the clinical importance of scar scales for burn scars, In a 
review, Verhagen et al
33
 gave an overview of the non-invasive measurement tools available 
for scar evaluation and van der Wal et al
34
 gave an overview of clinimetric requirements of 
available scar scales.  
 
Future developments (Chapter 9) 
 
Based on the results of the studies that are described in this thesis and recent developments 
in wound covering, excision techniques and better diagnosis of wound depth, a number of 
recommendations can be given for future treatment and research in children with burns. Fast 
wound healing, reduction of pain and patient comfort are very important outcome parameters, 
but reduction of scar formation is the main goal of all research. 
 
In summary, this thesis presents an overview on developments in burn treatment of children. 
The background, size and characteristics of the patient group are highlighted, as well as 
development of new treatment modalities over the years. Future research developments will 
focus more on quantitative outcome parameters, as measured by scar evaluation techniques. 
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Conservative treatment of partial thickness burns will be assisted by adequate burn depth 
assessment, followed by innovative wound dressing materials. Surgical management will be 
facilitated by more precise debridement techniques, application of dermal regeneration 
matrices and proper bacterial control. Overall, an important direction of new developments is 
found in the generation of new dressing materials that allow long term fluid control and anti-
bacterial function, thereby abolishing the necessity for painful and burdensome daily dressing 
changes.  
  23 
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Chapter 2 
 
Epidemiology of children admitted to the Dutch burn centres. 
Changes in referral influence admittance rates in burn 
centres. 
 
 
Burns 2011;37:1161-7
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Abstract 
 
Background: In the Beverwijk Burn Centre a remarkable rise has been noted in the number of 
pediatric admissions since 2000. To investigate if this is a national trend and, if so, what may have 
caused it, a retrospective epidemiological study has been undertaken. Materials and methods: The 
databases of the three Dutch burn centres were combined. Data on the population at risk for 
admission in a burn centre and data on burns related hospital admissions were added. Two age 
groups, 0–4 years and 5–17 years and two time periods, 1995–1999 and 2000–2007, were 
compared. Results: The mean number of pediatric admissions in the Dutch burn centres per year 
increased by 44.0% and 44.3% for the younger children (0–4 years) and the older children (5– 17 
years), respectively, whereas the number of pediatric burn admissions in other hospitals in the 
Netherlands decreased. The percentage of children that was referred from other hospitals 
increased in both age groups, and for the younger children this was significant. Conclusion: There 
has been a shift in pediatric burn care towards a greater volume of admissions in specialized burn 
care of especially young children with less severe burns. A possible explanation for the increased 
number of referred children may be the introduction of the EMSB course in 1998, since EMSB 
guidelines dictate stricter and generally accepted referral criteria.  
 
 
  29 
Introduction  
 
Epidemiological data on burns are published frequently. The majority of publications concern 
epidemiological data on burns in a specific country, a regional area or a group of patients. 
The results are used to achieve understanding of the aetiology of burns and subsequently 
establish effective prevention campaigns with the ultimate goal of reducing the number of 
severe burns
1–3
. Other studies concern patients admitted to a single burn centre or burn unit. 
Besides determining the targets for future prevention campaigns, the goal of these studies is 
to gain insight in the numbers of admitted patients, aetiology, duration of admission and 
mortality or for purposes of treatment evaluation, quality and capacity control
4–13
. Some of 
these studies concern a prolonged time span and attempt to elucidate changing number of 
patients referred to a burns centre, patterns in aetiology, and mortality
9
. In the Netherlands 
(population 2011 16.75 million, area 41,528 km2), the registration of burn patients began with 
the establishment of the first of three burns centres in 1974. The burn centres were housed 
non-university hospitals, located in the northeast, Groningen, in the midwest, Beverwijk and in 
the southwest of the Netherlands, Rotterdam (Fig. 1). 
 
 
Fig. 1 – Location of burn centres in the Netherlands.  
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Except for a recent publication on mortality and causes of death in a Dutch burns centre
6
, 
epidemiological studies of patients admitted to the Dutch burn centres have not yet been 
published. In the Beverwijk Burn Centre a preliminary analysis on the number of admitted 
children showed a marked rise in pediatric admissions from 2000 onwards. We wanted to 
identify if this increase in admissions represented a national trend and investigate the 
potential causes. Possible explanations for the rise in admissions included an increase in the 
number of children in the Dutch population and an increase in the incidence of burns in 
children in the Netherlands, or a change in the referral pattern. A plausible cause for an 
increase of referrals would be the introduction of the Emergency Management of Severe 
Burns course (EMSB) in 1998
14
. The referral criteria of the EMSB (Table 1) are more strict 
and binding than the formerly applied directives of the Dutch burn centres (Table 2)
15,16
.  
 
Table 1 - EMSB criteria for referral to a Dutch Burn Centre 
15 
 Burns greater than 10% Total Body Surface Area (TBSA) burnt in adults 
 Burns greater than 5% TBSA burnt in children 
 Burns of special areas - face, hands, feet, perineum, genitalia and major joints 
 Full thickness burns greater than 5% TBSA burnt 
 Electrical burns 
 Chemical burns 
 Burns with associated inhalation injury 
 Circumferential burns of the limbs or chest 
 Burns at the extreme of age- children or the elderly 
 Burns in patients with pre-existing medical disorders which could complicate 
management and prolong recovery or effect mortality 
 Any burn with associated trauma 
 
 
Table 2 - EMSB formerly applied criteria for referral to a Dutch Burn Centre
16 
 Burns greater than 25% TBSA burnt in adults or deep burns over 10% TBSA burnt 
 Burns greater than 10% TBSA burnt in children and elderly, regardless of depth 
 Mino burns associated with another injury or pre-existent disease that may increase the 
risk for complications 
 
The doctrine of EMSB and similar courses like Advanced Trauma Life Support (ATLS) has 
become the precept in most Dutch casualty departments and stricter adherence might have 
contributed to a difference in the referral pattern. To investigate these hypotheses, further 
analysis was necessary of the data from the Beverwijk burn centre, the data from the other 
Dutch burn centres and of the data on burn-injury related admissions to the other Dutch 
hospitals, particularly also in view of the consequences that the results of these analyses 
might have for the allocation of pediatric burn designated beds in the Dutch burn centres. 
Because all three burns centres had data sets on admitted patients as going back to 1995, 
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two time periods were compared; 1995–1999 and 2000–2007. In this retrospective study the 
results of these separate registrations were combined and analysed, focussing on children 
with burns. The aim of this study was to describe the epidemiology of pediatric patients 
admitted to Dutch burn centres in order to elucidate potential changes in the number of 
patients injured, referral patterns and characteristics of patients, as well as burns and 
treatment related characteristics.  
 
Materials and methods 
 
Population 
 
All children up to 18 years of age, with a primary admission to one of the three Dutch burn 
centres in the period 1995–2007 were included in this study. We focused on differences 
between two periods and between young children (aged 0–4 years) and older children (aged 
5–17 years). As young children have other activities and therefore often a different aetiology 
for their injuries compared to older children, the partition was made at 4 years old
1,13
. 
According to the Dutch law children reach adults status at the age of 18; therefore the upper 
age limit was set at 17 years. In the analysis, two time periods were reviewed, 1995–1999 
and 2000–2007. As a reference group, data on the incidence of primary burn centre 
admissions of adults (18 years and over) were included. 
 
Data collection 
 
Data on the patient (age, gender), the burns (site of the accident, aetiology, referral, the total 
body surface area (TBSA), the depth of the burn), and treatment related characteristics (need 
for surgical intervention, ventilation, length of stay and mortality) were derived from historical 
registrations of the three Dutch burn centres. After permission of relevant representatives 
from the respective hospitals the anonymous data were combined into one dataset and this 
dataset was checked for inconsistencies and missing data. These data were then corrected 
based on patients’ files, discharge records and operation reports. Data analysis was 
performed on the corrected database. To interpret the number of admissions in the Burn 
centres, proportions and incidence density rates were calculated as follows: the proportion of 
pediatric burn related hospital admissions in specialized burn centres was calculated by the 
number of the pediatric burn related hospital admissions in specialized burn centres in one 
year, divided by the total number of pediatric burn related hospital admissions in all hospitals 
in the Netherlands in the same year. Data on burns related admissions in all Dutch hospital 
were derived from the National Hospital Discharge Register (NHDR) and from the Consumer 
Safety Institute (CSI)
17
. All primary burn related admissions were extracted using the 
International Classification of Diseases (ICD-9) codes 940–949. A distinction was made 
between burns related hospital admissions in hospitals with a burn centre versus general 
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hospitals. Incidence density rates were calculated as the number of admissions in a Dutch 
burn centre in a specific age category in one year, divided by the total number of persons at 
risk in this age category in the Netherlands in the same year. The denominator data refer to 
the population on July 1st of a specific year, using the mean of the population at January 1st 
that year and the population at January 1st of the following year. Data on the population at 
risk for admission in a Dutch burn centre, being the total number of children aged 0–17 
residing in the Netherlands, were derived from the population’s statistics available on 
StatLine, Statistics Netherlands
18
. In the study periods the mean population was 15.98 million, 
with a share of 6.2% young children (0–4 years) and 15.8% of children aged 5–17.  
 
Statistical analysis 
 
Change in admissions were analyzed by the Chi square test for trend. Differences between 
time periods and age groups were analyzed with logistic regression, calculating odds ratios 
(OR) and their corresponding 95% confidence intervals (C.I.). Differences in median TBSA, 
length of stay and length of stay per %TBSA were analyzed using Mann–Whitney U. To 
assess risk profiles for a burn centre admission in children 5 years and older, we used 
backward multiple logistic regression. Data were analyzed in SPSS1 software version 17 and 
18 (PASW Statistics). 
 
Results 
 
Incidence of pediatric burn centre admissions 
 
From the first period (1995–1999) to the second period (2000– 2007) the mean number of 
admission in the Dutch burn centres per year increased from 113 to 163 for the younger 
children and from 50 to 71 for the older children, representing an increase of 44.0 and 44.3%, 
respectively. In patients over 18 years old the annual mean number of admissions increased 
from 290 to 303, a rise of 4.3%. The proportion of children admitted to specialized burn 
centres, rather than to general hospitals, increased over time from approximately 30% in 
1995 to almost 50% in 2007 in both age groups (p < 0.001). In the 0–4 years age group, 
almost 50% of all burn admissions in the Netherlands was to a specialized burn care setting 
(Fig. 2). The incidence of burn centre admissions per 100,000 population in the period 1995–
2007 is represented in Fig. 3. For the 5–17 years age group and the adults the incidence was 
about the same. However, it can be noted that the relative risk for a small child (0–4 years) to 
be admitted to a burn centre was up to five times higher than for an older child (5–17 years) 
and an adult (Fig. 3). 
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Fig. 2 – Proportion of pediatric burn related hospital admissions in specialized burn centres, 
over time.  
 
 
 
Fig. 3 – Incidence of pediatric burn centre admissions in the Netherlands, by age category.  
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Patient and burns related characteristics 
 
In the time period of 2000–2007, significantly fewer accidents occurred in and around the 
house (Table 3). Also, the referral pattern for the younger children changed significantly. In 
62.9% children were referred by another hospital, this increased to 68.8% in the second time 
period. In the older children the increase in referrals from another hospital was not significant 
(Table 3). In both age groups more boys than girls were admitted and this ratio did not 
change in the two time periods. In children aged 0–4 years, burn size decreased significantly 
over time and the percentage of these children diagnosed with full thickness burns was also 
reduced. In the age group of children aged 5–17 years, fewer children with burns over 10% 
were admitted (Table 3). The TBSA in young children decreased from 7% TBSA (IQR: 4–11) 
to 5% (IQR = 3–8) (p < 0.01); the mean burn size decreased from 8.7% (SD 7.6) to 6.4% (SD 
6.2) (p < 0.01). In children aged 5 years and over, median burn size was stable with 6% in 
period 1 (IQR 3–13), and 5% in period 2 (IQR 3–10) (p = 0.05). The mean burn size was 
9.4% (SD 10.0) and 9.5% (SD 13.4) (p = 0.86).  
 
Treatment 
 
In Table 4 the treatment related characteristics of children admitted to Dutch Burn centres by 
age group are summarized. The number of children that required surgery was significantly 
reduced for the younger children in time period 2000–2007. For the older children the 
requirement for surgery was also reduced, however this difference was not statistically 
significant. In both age groups the percentage of children that was ventilated has increased, 
but this did not reach a level of statistical significance. For children aged 0–4 years, the 
percentage of children that required a hospital stay of 7 days or more was significantly 
reduced. In addition, median length of stay and length of stay per % TBSA decreased as well. 
For the older children the change in length of stay was not statistically significant. In the two 
age groups and time periods mortality did not change. 
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Table 3 - Patient and burn related characteristics of young and older children admitted to 
Dutch burn centres, by study period. 
 0 - 4 years  5 - 17 years  
  1995-99 2000-07   1995-99 2000-07   
  
N=563 
% 
N=1300 
% OR (95%C.I.) 
N=248 
% 
N=571 
% OR (95%C.I.) 
Gender         
Boy 57.9 61.3 1.0  70.2 70.9 1.0  
Girl 42.1 38.7 0.9 (0.7; 1.1) 29.8 29.1 1.0 (0.7;1.3) 
          
Site of accident         
In, around the house 93.5 89.2 0.6 (0.4; 0.9) 71.6 64.7 0.7 (0.5;1.0) 
Other 6.5 10.8 1.0  28.4 35.3 1.0  
          
Aetiology         
Scald 81.4 85.5 1.0 (0.4;2.3) 23.4 22.4 0.8 (0.3;1.8) 
Fat 7.2 3.7 0.5 (0.2;1.2) 13.0 7.6 0.5 (0.2;1.2) 
Flame 7.4 6.1 0.8 (0.3;2.0) 57.6 62.9 0.9 (0.4;2.0) 
Contact 2.5 3.1 1.2 (0.4;3.5) 2.2 2.4 0.9 (0.3;3.2) 
Other 1.5 1.6 1.0  3.9 4.7 1.0  
          
Referral         
Hospital 62.9 68.8 1.3 (1.1;1.6) 56.0 63.3 1.4 (1.0;1.9) 
Self referral, GP, AED 37.1 31.2 1.0  44.0 36.7 1.0  
         
TBSA burned         
0-5 % 41.0 56.1 1.0  47.4 55.4 1.0  
>5 - 10% 32.3 30.5 0.7 (0.5;0.9) 20.2 20.2 0.9 (0.6;1.3) 
>10% 26.6 13.5 0.4 (0.3;0.5) 32.4 24.4 0.6 (0.5;0.9) 
Median (IQR) 7 (4-11) 5 (3-8) n.a. n.a. 6 (3-13) 5(3-10) n.a. n.a. 
         
Full thickness burns         
No 46.2 61.1 1.0  34.7 39.2 1.0  
Yes 53.8 38.9 0.5 (0.4;0.7) 65.3 60.8 0.8 (0.6;1.1) 
IQR=interquartile range, 25
th
-75
th
 percentile, n.a. =not applicable.  
Missing values 0-4 years period 1, period 2: site of accident n=53, n=64; aetiology n=35, 
n=24; referral n=38, n=180. 
Missing values 5-17 years period 1, period 2: site of accident n=37, n=42; aetiology n=17, 
n=18; referral n=23, n=56. 
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Table 4 - Treatment related characteristics of young and older children admitted to Dutch 
burn centres, by study period. 
 
 
 
0-4 years    5 -17 years    
 1995-99 2000-07   1995-99 2000-07   
 N=563 N=1300   N=248 N=571   
 % % OR (95%C.I.) % % OR (95%C.I.) 
Surgery         
No 61.6 73.4 1  47.2 52.0 1  
Yes 38.4 26.6 0.6 (0.5;0.7) 52.8 48.0 0,8 (0,6;1.1) 
         
Ventilation         
No 98.8 97.6 1,0  94.8 91.4 1.0  
Yes 1.2 2.4 2.1 (0.9;5.2) 5.2 8.6 1.7 (0.9;3.2) 
         
Length of stay         
1-6 days 31.3 48.1 1.0  33.2 36.8 1.0  
7-13 days 24.0 21.4 0.6 (0.4;0.8) 15.4 17.5 1.0 (0.7;1.6) 
14 days and more 44.8 30.5 0.4 (0.4;0.6) 51.4 45.7 0,8 (0.6;1.1) 
Median (IQR) 11 (5-22) 7(3-16) n.a. n.a. 14(4-26) 10(3-23) n.a. n.a. 
LOS per %TBSA, 
median (IQR)* 
1.5 (1.0-2.5) 1.4 (0.8-2.4) n.a. n.a. 2.0 (1.1-3.5) 2.0 (1.0-3.4) n.a. n.a. 
         
Deceased         
No 99.8 99.4 1.0  99.2 98.9 1.0  
Yes 0.2 0.6 3.5 (0.4;27.9) 0.8 1.1 1.3 (0.3;6.5) 
IQR=interquartile range, 25
th
-75
th
 percentile, n.a. =not applicable.  
* Mann Whitney U test difference between periods : 0-4 year p=0.01, 5-17 years p=0.60 
 
 
Risk profile 
 
We used a multivariate analysis to extract a risk profile for a burn centre admission in children 
5 years and older. Admissions of older children and adolescents are predominantly the result 
of an accident not being in and around the house (odds ratio = 0.4). The type of injury is 
primarily a flame burn (OR = 4.9) and not a scald (OR = 0.2). 
 
Discussion 
 
The aim of this study was to describe the epidemiology of pediatric patients admitted to Dutch 
burn centres in order to elucidate potential changes. Initially this study was a monocentre 
analysis performed in 2005 with equal time periods1995–1999 and 2000–2005. To present a 
nationwide analysis, data from the other two burn centres were included and recent data from 
the years 2006 and 2007 were added. However, as there were to many missing data before 
1995, the years 1993 and 1994 could not be included. Our assumption that after the year 
2000 the number of admitted children in the Dutch burns centres has increased is confirmed 
by this study. The mean annual number of pediatric burn centre admissions increased by 
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44%, while in the adult group the increase was only 4.3%. The proportion of pediatric burn 
related hospital admissions in specialized burn centres also showed an increase, as did the 
incidence rate (per 100,000 population). This means there is a shift in pediatric burn care 
towards a greater volume of admissions in specialized burn centres
17,18
. The peak in 
admissions of children of 5–17 years in 2001 (Fig. 3) is caused by the high number of burn 
victims from the Volendam disaster on January 1, 2001
19
. In this year the incidence of 
pediatric burn centre admissions shows a decrease for the children between 0 and 4 years of 
age, which can be explained by a shortage of capacity in the burn centres for an extended 
time, because the older children occupied most pediatric beds. Similarly, the proportion of 
burn related primary hospital admissions in burn centres (Fig. 2) decreased during that year 
as a relatively high number of burn victims was admitted to non specialized hospitals, since 
the burn centres were fully occupied and had no admission capacity. Comparison of our 
pediatric incidence to literature data is hampered by a lack of studies with clear catchment 
populations and differentiation in age categories, as described earlier by Burd and Yuen
20
. 
Three state wide studies from Australia, Canada en the USA presented incidence data of 
hospitalized pediatric burn patients varying between 29.7 and 76.1 admissions per 100,000 
population in young children (0–4 years) and 8–115.7 per 100,000 in older children (10–14 
years)
21–23
. Our data correspond tot the lower limits of these incidence data, given the fact 
that the burn centres treat a proportion of up to 50% of all hospitalized pediatric burn patients 
in the Netherlands. Incidence data of specialized burn care pediatric patients are hardly 
available. Sharma et al., in a single burn centre study reported an overall incidence of 
pediatric burn centre admissions in Kuwait of 17.5/100,000 in children aged 0–14 and 
34/100,000 in young children, aged 0–4
24
. These data are based on a single burn centre, 
representing 93% of all burn related hospital admissions. Children with burns requiring a 
hospital admission are more often referred to specialized burn centres than to general 
hospitals. As a result, more children with smaller and more superficial burns are seen in our 
burn centres. This change in burn size has been described earlier for American burn centre 
admissions
25
. In our study, the cause of injury shows patterns similar to those described in 
the literature. In young children (0–4 years) scalding is by far the most important cause of the 
burns, followed by flame burns and burns by hot fat or oil. In older children (5–17 years) flame 
burns are the most common, followed by scalding and hot fat or oil. The aetiology has not 
changed over time. However, significantly less young children sustained a burn in and around 
the house. The number of children referred from another hospital has statistically significantly 
increased in young children, but in older children the increase in referrals was not significant. 
In young children, burn size decreased considerably over time and fewer full thickness burns 
were diagnosed. In the older children, overall burn size remained the same, but fewer burns 
>10% TBSA were seen. It may be concluded that hospitals refer more children with smaller 
and less deep burns in the time period 2000–2007 compared to the time period 1995–1999. 
The possible role of the introduction of the EMSB course was not suspected at the time of the 
first analysis. Although the EMSB was introduced in the Netherlands in 1998, the awareness 
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of the stricter referral criteria became known only a couple of years later. An explanation for 
the increased referral of children may be an alteration in nationally accepted protocols on 
referral of burn victims. The organisation of burn care in the Netherlands started in 1970 with 
the start of the Dutch Burns Foundation (DBF). Prevention of burns, informing the public, 
carrying out scientific research in the field of burn treatment and management of the skin 
bank were the main goals of the DBF. In 1974 the first Dutch burn centre was established in 
Beverwijk, followed by burns centres in Groningen and Rotterdam in later years. Standard 
referral criteria for all three centres were established and published in 1980 and these criteria 
(Table 2) were sent to all Dutch hospitals
15
. They only served as guidance for physicians in 
the Netherlands who rendered the first treatment to burn victims and following these 
guidelines was non-mandatory. With the introduction of Advanced Trauma Life Support, 
ATLS, the emergency treatment of multitrauma patients in all Dutch hospitals was 
standardized through set protocols. In 1998 the course on Emergency Management of 
Severe Burns (EMSB) was introduced in the Netherlands. In this course, focussed on the 
emergency management of burn patients, the principles of initial treatment of trauma patients 
were similar as in the ATLS protocol. The guidelines for referral of burn patients were 
tightened and became compulsory for the physicians in the emergency wards. With regard to 
children, the ‘‘old’’ recommendations advised to refer children with burns over 10% TBSA, 
whereas the new EMSB referral criteria advise to refer children with burns exceeding 5%. The 
referral criteria are well adopted in the Netherlands. An additional factor also may have 
contributed to the increased referral of children with burns. After the Volendam disaster, burn 
care for children received a great deal of publicity and this exerted pressure to doctors to refer 
children to burn centres. Although the mean and median TBSA of small children with burns 
were reduced in time, the majority of patients is referred appropriately, according to the 
referral criteria
26
. Therefore the admittance of these patients to a specialized centre is justified 
and indicated. In addition, Dutch burn centres have enough capacity for children with small 
burns. Lack of capacity exists mainly when there is an excessive request for referral of 
patients with major burns, requiring Intensive Care treatment. Moreover non-burn hospitals 
lack a dedicated team of nurses and paramedics trained in the treatment as well as 
specialized aftercare of children with burns. As can be expected from the changed patient 
and burn related characteristics, the treatment related characteristics have also changed in 
the second time period. As the burns of the referred children aged 0–4 years were smaller 
and less deep, the number of operations and the length of stay have decreased. Remarkably, 
it seems that more children were artificially ventilated during their admission, although the 
numbers are small. Many of them were ventilated before being transferred to the burn centre. 
This is in line with the findings of Mackie et al., who recently described a mixed population of 
adults and children admitted in a Dutch burn centre
27
. Prior to this study, we had no 
indications of whether the introduction of the stricter EMSB referral criteria had any impact on 
our admission rates. Until now, it had not been studied if these stricter referral guidelines did 
result in more admissions. Knowledge of changes in the pattern of referral is important to 
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guarantee sufficient capacity, especially of the Intensive Care facilities, in the burn centres. 
This study also shows the superior value of a national burn registry, compared to single burn 
centre registries. Only on a national scale, the impact of changed referral criteria can be fully 
evaluated. In several countries, national registries have been set up. Examples of this type of 
registry are the National Burn Repository in the United States, the international Burn Injury 
Database in the United Kingdom, the Bi-National Burns Registry in Australia and New 
Zealand and the registry in the German speaking countries
27–30
. Since 2004 the three Dutch 
burns centres closely co-operate in the Association of Dutch Burn Centres (ADBC). One of 
the purposes of this association is the development of a common burn registration. Data in 
this paper were derived from a historical database including the three separate registries of 
the burn centres. In 2009 the Dutch Burn Repository R3 was initiated. With this new 
registration, trends in burn accidents, patterns of admissions of burn victims and data on 
mortality will become more easily available. Advice for burn prevention campaigns of the DBF 
and the CSI can be issued based on these data and the registry also serves as an instrument 
for quality improvement. Until now only data of admitted patients are included, but in the near 
future also data of outpatients will be registered as well. With the recent introduction of the 
electronic patient file (EPF) in the Dutch burn centres, data can be automatically linked to the 
R3 database. As a result, time-consuming data entry is reduced which increases both data 
collection and accuracy.  
 
Conclusion 
 
A shift in pediatric burn care towards a greater volume of admissions in specialized burn care 
has taken place especially with regard to young children with less severe burns. This is 
probably the result of changes in referral criteria, introduced in the late nineties. As a result, 
children receive optimal care by experienced burn care teams. 
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Part II  
 
 
Application of cryopreserved and glycerol preserved allografts in the 
burn centre 
  44 
Justification 
 
Introduction 
Since 1979 human allograft skin has been used for the treatment of burns and related 
wounds in the Beverwijk Burns Centre. Following Miller et al
1
 cryopreserved human allograft 
skin (CryoPA) was applied to partial thickness burns in children, mainly scalds. Its main 
advantages over conservative treatment with topical antimicrobial creams, like silver 
sulfadiazine cream, or treatment by early tangential excision and subsequent wound 
coverage by a split skin autograft, was the supposed reduction of hypertrophic scar formation. 
Hermans RP et al
2
 mentioned a reduction of hypertrophic scarring from 50% to little over 
10%. After its introduction by the Dutch Skin Bank, glycerol-preserved allograft skin (GPA) 
was applied to partial thickness burns. In order to determine if the results of treatment of 
partial thickness burns with GPA were different from the CryoPA treatment, a retrospective 
study was done
3
. In the group of patients treated with GPA the number of subsequent 
autologous skin transplantations decreased from 39.6% to 26.3%. Unfortunately, because 
data were missing, the incidence of hypertrophic scarring was not included in this study. In 
our later RCT
5
 comparing GPA and Aquacel® for partial thickness burns, hypertrophy in the 
GPA group was found to be around 17%. However, comparison of reported incidence 
numbers for hypertrophy should be interpreted with care, since no fixed definition of 
hypertrophy exists. 
 
Table 1 - Treatment of PT burns in several time periods in the Beverwijk Burns Centre. 
Period Number of 
Patients  
TBSA Treatment Secondary 
autografting (%) 
Hypertrophy (%)* 
1975-1978
2 
93 11.1 Conservative or early 
tangential excision 
53.8 52 
1979-1981
2 
106 8.5 CryoPA 39.6 10 
1996-2001
3,4 
57 7.9 GPA 26.3  
2001-2002
5 
40 7.3 GPA 15 17.5 
*Hypertrophic scar over 10% of the original burned area. 
 
Next to the application on partial thickness burns, more indications for the use of GPA were 
developed. An overview of the results of these treatments is given in our study published in 
2002
4
. 
 
Review on GPA and CryoPA 
Although numerous synthetic and semi-synthetic membranous dressings have been 
developed for burn wound treatment, human allograft skin is up to the present day used for 
several indications. Many pre-clinical studies, studies on composite skin grafting and on 
clinical application of human allograft skin have been published. In 2011 Hermans MH
6
 did a 
literature survey to analyse if the method of preservation of allografts would have an impact 
on the healing of partial thickness burns. In this study he analysed 12 studies on the use of 
allograft skin for partial thickness burns; six were on GPA, three were on CryoPA, one on 
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allografts in general, one on CryoPA or fresh allograft and one on lyophilised cadaver skin. 
He found no evidence that viability of the allograft would influence clinical outcome.  
 
Clinical studies on allograft skin since 2011  
We did an electronic search in Pubmed to identify further clinical studies on human allograft 
skin and burns from 2011 onwards (Search terms: human allograft skin and burns). This 
yielded 27 hits. After reading the abstracts and excluding the earlier mentioned review of 
Hermans
6
, ten studies were identified as clinical studies
7-16
. Seven out of ten were on 
temporary wound closure with allograft skin after eschar excision
7,8,10,13-16
.  
Kua et al
7
reviewed the effect of allograft viability on clinical outcomes in patients with severe 
(extensive and deep) burns. In these patients burn eschar was excised, after which the 
wounds were covered with human allograft skin awaiting autografting. Forty-eight patients 
were included in the study, twenty-five were treated with CryoPA and twenty-three with GPA. 
The results in terms of mortality rate and length of stay were favourable for the group treated 
with CryoPA versus GPA, however the differences were not significant. Lundy
8
 described the 
use allograft skin from a close relative in two children with extensive burns and inadequate 
donor site surface, in wartime circumstances. Matsumine et al
13
 in a letter to the editor 
reported on a strongly delayed allograft rejection in an immunocompromised patient with a 
severe burn. Chen et al
14
 investigated the effect of early burn wound excision (within 72 hours 
post burn) and subsequent allografting on the development of insulin resistance. Compared 
to the group of patients that underwent eschar excision after 7 days, insulin resistance was 
decreased. Gaucher et al
15
 in a preliminary retrospective survey studied the influence of the 
viability of CryoPA to the rejection delay after grafting in patients with extensive burns. No 
correlation was found. In a prospective observational study Philp et al
16
 studied the results of 
treatment of deep face burns by tangential excision, temporary covering with allografts and 
autografting in a later stage. Based on this study several recommendations for the treatment 
of deep face burns were made.  
Combining microskin autografting and allograft covering after early eschar excision allows re-
epithelialisation of the wound from the start of the surgical treatment. Chen el al
11
 show the 
results of this approach on burn wound care in 63 severely burned patients. Wound healing 
rate was 47.9% in 63.5% of the cases. This method resembles the Meek technique described 
by Kreis et al
17
. In the latter study an epithelialisation rate of 90% after five weeks was 
described.  Bosco et al
10
 from the Verona Tissue Bank (Italy), gave an overview of the clinical 
applications and results of GPA supplied by this Tissue Bank. Their GPA was used for the 
treatment of partial thickness burns, temporary covering of excised deep burn wounds and as 
temporary covering of excised necrotic wounds in patients with necrotising fasciitis. They 
conclude that despite developments in bioengineering techniques in recent years, banked 
skin is still the best existing skin substitute. 
Lindford AJ et al
12
, in 2011, in a case study of a patient with toxic epidermal necrolysis (TEN), 
compared the results of treatment with allograft skin and Suprathel®, a synthetic 
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membranous skin substitute. Suprathel® was easier to apply, showed less exudation with 
fewer dressing changes, a better pain reduction and faster epithelialisation.  
A recent development in burn care is the application of an acellular dermal matrix (ADM) 
produced from allograft skin. Pan et al
9
 report on 19 patients with deep burns where ADM 
combined with a thin split skin graft was applied to 34 anatomic sites. In a long term follow-up 
study, compared to control sites, there were significant differences in contour, contracture and 
texture in favour of ADM treated sites. At the moment, the Euro Skin Bank is in the process of 
developing a dermal matrix from GPA
18,19
. 
 
Conclusion 
Despite the development of synthetic and semi-synthetic wound covering materials and skin 
substitutes, human allograft skin still is indispensable for burn wound treatment, especially for 
extensive and deep burns.  All indications mentioned in our previous study
4
 still apply. 
However for the treatment of partial thickness burns or related skin diseases such as TEN, 
(semi) synthetic dressing materials may be more suitable in terms of ease of handling, 
availability and costs
5,12
. 
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Chapter 3 
 
 
The use of glycerol-preserved allografts in the Beverwijk Burn 
Centre: a retrospective study 
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Abstract 
 
This report describes 156 consecutive patients treated with glycerol-preserved allograft skin 
(GPA) in the Beverwijk Burn Centre between January 1996 and July 2001. Patients with burn 
and non-burn lesions are included. Age varied from 7 months to 90.7 years. Four different 
procedures have been identified: (1) sandwich grafting technique; (2) treatment of partial 
thickness burns with GPA as a membranous dressing; (3) improvement of wound condition; 
(4) scar release: a temporary coverage of release incisions with allograft skin to improve the 
wound bed and to benefit further relaxation of the wound primary to autografting. 
The main points of interest in this inventory are the results of treatment, the aetiology and the 
extent of the wounds treated with GPA, the day post injury the GPA treatment was started, 
the duration of the treatment, the number of allograft applications, the occurrence of wound 
infection and wound treatment before GPA application. Concerning the scar release an 
inventory was made of the anatomic sites that were involved. 
Sandwich grafting, which is the treatment of choice at this centre for extensive, full-thickness 
injuries, was performed on 129 wounds. 
The average burn size in all 70 patients treated was 35.6% TBSA with 26.9% full thickness. In 
all cases meshed GPA was used. Partial or complete healing was achieved in 57.6% of 
wounds. 
In the treatment of partial thickness burns, non-meshed GPA was used in all 57 cases. 
Complete healing without further treatment was achieved in 45.6% of the cases. Excision and 
autologous skin grafting was needed in 26.3% of the cases. 
Meshed GPA was used to improve the condition of 88 non-healing wounds. Spontaneous 
healing was promoted in 13.6% of the wounds, and the wound bed was successfully 
prepared for autografting in 39.8% of the cases. 
In all 52 scar releases a viable wound bed was obtained prior to autografting. Autologous 
graft take was 100% and no autologous re-grafting was necessary. Allografts in the popliteal 
space were changed most frequently. 
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Introduction 
 
At the Euro Skin Bank in Beverwijk, The Netherlands, human cadaver skin is harvested from 
organ donors within 10 h after death. Donors with a malignant disease, infection, skin 
damage or donors using steroids and some other drugs are excluded. After harvesting the 
skin is decontaminated by a saline solution containing streptomycin and penicillin. 
In 1984 the Euro Skin Bank introduced human allograft skin preserved in 85% glycerol 
(GPA)
1
. The antibacterial and antiviral properties of concentrated glycerol have made GPA a 
safe product; moreover the immunogenic reaction to GPA appears to be reduced
2-7
. 
In a retrospective study on the use of GPA in the Beverwijk Burn Centre over a 5.5-year 
period, four different indications for the use GPA have been identified. 
1. The sandwich grafting technique in which meshed human allograft skin is used as an 
overlay over widely meshed autograft or over expanded postage stamp autograft (Meek 
micrograft technique)
8,9
. 
2. The treatment of partial thickness burns with GPA as a membranous dressing
10
. 
3. Improvement of wound condition. In this procedure a wound bed in poor condition is 
covered with human allograft skin to prepare a wound for future autografting, or to 
promote spontaneous healing. Traumatic wounds, including burns, may fail to heal for a 
number of reasons, including exposure of poorly vascularised surfaces such as bone and 
tendon, wound infection and a poor general condition of the patient. Some wounds may 
contain remnants of epidermal elements in a partial thickness wound or a wound that was 
previously autografted. In other wounds demarcation of necrotic tissue is not clear. 
Following excision of excess necrotic tissue treatment is continued by the application of 
GPA; the wound is inspected every second day for adhesion of GPA. If not adherent, 
GPA is replaced until adherence is achieved. If sufficient epidermal elements are present, 
further spontaneous healing can then be awaited. In full-thickness injuries, an autologous 
split thickness skin graft can be applied. 
4. Probably the least known indication for the use of allografts is as an interim covering 
following surgical scar release. The open wound obtained following release, mainly 
comprising subcutaneous fat, immediate split skin grafting may be unsuccessful in the 
presence of superfluous exudate and post-operative haematoma formation. A recent 
study from our clinic showed a graft take of 83.2% (S.D. 20.6) under these 
circumstances
11
. To tide over the exudative wound phase and to drain haematoma, we 
have developed a two-step procedure. Definitive autografting is postponed and the 
wound bed is preserved with GPA until the GPA is adherent to the complete wound bed. 
With this procedure we have also noticed a relaxation of the wound within a week post-
operative (Fig. 2) and a flattening of the wound surface. 
Patients and methods 
 
Between January 1996 and July 2001, 156 patients in the Beverwijk Burn Centre were 
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treated with GPA. Demographic details are summarised in Table 1. Five patients were treated 
on an outpatient basis; all other patients were hospitalised. 
 
Sandwich grafting 
 
Seventy patients with extensive injuries were subjected to 129 sandwich grafting procedures 
(Table 1). Three patients (4%) sustained a non-thermal skin and soft tissue injury. The mean 
affected total burned surface area (TBSA) was 35.6%, with a mean percentage TBSA full 
thickness of 26.9%. The average wound area per treatment was 9.6% (0.5–40%). A total of 
119 procedures were performed on the 67 patients with burns. Of these procedures, 68 were 
primary stage operations, defined as excision and grafting within 10 days post burn. The 
remaining 51 procedures occurred later. Sandwich grafting procedures were employed for 
extensive, full-thickness injuries. The operative procedure generally involved the avulsion of 
wounds to fascia, although occasionally tangential excision was used. As a rule, procedures 
were limited to 15% of TBSA at each session; if necessary, procedures were repeated on 
alternate days, until excision and grafting were complete. Eighty-three procedures were 
performed using meshed autografts. The most frequently used mesh ratios were 1:6 and 1:4. 
In the remaining 36 operations the Meek-micrograft technique was employed. In these very 
extensive injuries, Meek micrografts were most frequently used at an enlargement rate of 1:9. 
Expansion rates of mesh grafts and Meek micro grafts are summarised in Fig. 1. The GPA 
layer was meshed to 1:1.5. In procedures involving widely meshed autografts, GPA was 
applied to the wound immediately after application of the autologous in a single procedure. In 
the Meek micro graft procedure, the allograft overlay was delayed for 5–7 days, until the 
adherence of the micrografts to the wound bed allowed removal of the pre-folded gauze 
carriers. During the intervening period, wounds were treated by dressings soaked in 
antibacterial solutions. Graft take was estimated between 3 and 4 weeks after the 
operation. Complete healing was achieved when no further operative treatment was 
necessary. Partial healing was defined by the necessity to perform additional grafting to 
residual defects of less than 10% of the original operated area. Graft failure was defined by 
the necessity for extensive additional grafting operations. 
 
Partial thickness burns 
 
Fifty-seven patients with partial thickness burns were treated with GPA (Table 1). GPA were 
applied to partial thickness burns on the first day following injury. 
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Table 1 - Summary details of patients 
 Sandwich 
grafts 
Partial thickness 
burns 
Non-healing 
wounds 
Scar release 
No. of patients included  70 57 55 18 
Mean age (range), 
years  
33.1 (1.3–89) 8.3 (0.6–56) 30.5 (1.6–90) 32 (2.1–78) 
No. of wounds treated  129 57 88 52 
Aetiology      
   Flame  54 (77%) 2 (4%) 36 (65%)  
   Scalds  6 (8.6%) 51 (89%)   
   Hot fat   1 (2%)   
   Flash burns  7 (10%) 3 (5%) 3 (5.5%)  
   Electrical/chemical    11 (20%)  
   Non-burn injury  3 (4%)    
 
 
Fig. 1 - Distribution of Meek micro-grafts and mesh grafts in the sandwich grafting technique. 
 
 
Prior treatment consisted of topical anti-microbial cream on day 0 to decontaminate the 
wound (silver sulfadiazine 1%), followed by cleansing of the wound and debridement 
of blister remnants preparatory to the application of non-meshed strips of GPA. If the allograft 
failed to adhere, GPA were reapplied until fourth post burn day. If GPA still did not become 
adherent, the wound was considered not appropriate for treatment with GPA and allograft 
treatment was abandoned. The average TBSA burn was 8.5% (1.0–33.0%) with 7.9% 
partial thickness. The average wound area per treatment with GPA was 5.6% (1.0–30.0%). 
Forty-three procedures were performed as a bedside treatment; nine patients were subjected 
to an operation and five patients were treated on an outpatient basis. Treatment of partial 
thickness burns with GPA was considered successful when 95% or more of the original 
treated area was re-epithelialised. In cases of partial healing, treatment was continued by 
excision and grafting of non-healed areas, by treatment with alternative membranous 
dressings, or by the use of topical anti-microbial creams such as silver sulfadiazine 1%. 
 
Improvement of the wound condition 
 
GPA were applied 88 times to non-healing wounds in 55 patients (Table 1). The number of 
treatments per patient ranged from one to nine. The mean total wound size was 35.0% (1.0–
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83.0%) TBSA. The average wound area per treatment was 3.6%, varying from 0.5 to 12.0% 
TBSA. In all patients meshed GPA were used. In 58 cases topical anti-microbials had been 
used previously; in 21 cases treatment with GPA was performed after a previous autografting; 
in four cases no topical treatment was used prior to the application of allografts and in five 
cases pre-treatment is unknown. Treatment with GPA was considered successful if the 
wound healed spontaneously at the end of the treatment, or if only one subsequent 
autologous skin grafting was sufficient to close the wound. 
 
Scar release 
 
In 18 patients (Table 1) contractures in 52 anatomic sites were released by double Y-incisions 
(Fig. 2a–f). After incision of the scar, soft tissue was separated until maximal joint motion was 
obtained and the tension of the scar relieved. Subsequently strips of meshed GPA were 
applied. The neck was most commonly involved, where 11 scar releases were performed, 
followed by the axilla region (nine scar releases) and the popliteal space (seven scars). Six 
scars were released on various sites of the trunk: five contracture sites involved the shoulder 
and the groin was site of contracture in four cases. Other sites of contracture involved scars 
on the arm, the leg or the eyelid (Table 4). The scar release with temporary coverage by GPA 
was considered to be successful if subsequent autografting resulted in a satisfactory take and 
outgrowth. 
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Fig. 2 - The use of GPA in scar releases.  
    
  
(a)      (b) 
  
(c)      (d) 
  
(e)      (f) 
(a) Constrictive scar at the dorsolateral side of the left knee. (b) Release incisions, with GPA 
application; full extension of the knee not possible. (c) GPA in situ 6 days after application, full 
extension of the knee. (d) GPA removed. (e) Covering of the wound with a meshed split skin 
autograft. (f) Result after 6 months, full extension of the knee. 
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Results 
 
Sandwich grafting 
 
Complete healing was achieved in 30 procedures (23.5%); partial healing was achieved in 44 
cases (34.1%). Extensive re-grafting of the original grafted area was required in 48 cases 
(37.2%). In four cases the result of the sandwich grafting procedure is unknown, three 
patients died before the outcome could be documented (Table 2). In the 119 burn cases data 
relating to primary stage operations and secondary stage operations are also shown in Table 
2. Of the 92 cases in which re-grafting was required, the average number of days between 
the initial operation and the re-grafting operation was 23.4 °æ 11.6 days (5–60). Wound 
contamination was diagnosed in 63 grafted wounds, in 31 patients. In 54 of these wounds a 
re-grafting procedure was necessary. Mean hospital stay in the patient group treated with one 
or more sandwich grafting procedures was 72.8 days and varied from 13 to 347 days. The 
longest hospital stay involved a non-burn patient with extensive skin and soft tissue damage. 
 
Table 2 - Results of sandwich grafting procedures in burn and non-burn cases 
Further treatment 
Burn and non-burn cases, 
no. of treatments (%) 
Burn cases 
Primary stage, no. of 
treatments (%) 
Secondary stage, no. 
of treatments (%) 
Healing  30 (23.5) 14 (20.5) 12 (27.4) 
Re-grafting small residual 
defects only  
44 (34.1) 27 (39.7) 17 (33.3) 
Re-grafting extensive defects  48 (37.2) 23 (33.8) 20 (39.2) 
Unknown/patient died  7 (5.4) 4 (5.9) 2 (3.9) 
Total  129 (100) 68 (100) 51 (100) 
 
Partial thickness burns 
 
Of 57 patients treated with GPA for partial thickness injury, 26 patients (45.6%) burns healed 
without further treatment. In 16 patients (28.1%) GPA did not become adherent and treatment 
was continued with topical anti-microbials or membranous dressings, such as Aquacel®, until 
healing was achieved. Fifteen patients (26.3%) required surgery (Table 3). The average 
duration of treatment with GPA in the whole group was 6.6 days (0–20). The average duration 
of treatment in the group that healed completely was almost 8 days (7.9 days), varying from 5 
to 12 days. The average number of applications per wound was 1.9 and the application rate 
varied from 1 to 5 applications. In 51% of the cases (29 treatments) GPA was applied only 
once. In 14 cases one change of GPA was sufficient, in another 14 cases more than one 
change of GPA were needed. In two patients bacterial contamination of the wound by 
Staphylococcus aureus was identified. Hospital stay averaged 9.6 days. 
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Table 3 - Results of treatment of partial thickness burns with GPA 
Further treatment  Partial thickness   
No. of treatments % 
None (complete healing)  26 45.6 
Topical treatment (only)  16 28.1 
Autografting  15 26.3 
Total  57 100 
 
 
Improvement of wound condition 
 
Twelve wounds (13.6%) out of 88 healed without further operative treatment. In 72 cases 
(81.8%) the wound was closed by autografting (Table 4). Three patients (4.5%) died 
during treatment. Seventy-three cases involved treatment of burns and the first use of GPA in 
this group occurred on an average of 24.7 days post burn (2–104 days). The average number 
of applications treatment was 2.5 (1–15). Fifty-three out of 85 cases (62%) needed a change 
of GPA. Fifty wounds showed positive cultures for Pseudomonas aeruginosa or S. aureus. 
The mean duration of treatment with GPA was 8.5 days and ranged from 2 to 49 days. The 
72 autografting procedures were performed at a mean of 10.3 days (2–64 days) following 
GPA treatment. In 35 patients (48.6%) no further operative treatment was necessary after the 
first and only autologous skin graft, in 27 patients (37.5%) repeated skin grafts were needed 
(Table 5). The average hospital stay was 75.2 days. 
 
Table 4 - Results of improvement of wound condition with GPA 
Further treatment  No. of treatments % 
No operative 
treatment  
12 13.6 
Autografting  72 81.8 
Unknown/patient 
died  
4 4.5 
Total  88 100 
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Table 5 - The outcome of autologous skin grafting after improvement of the wound condition 
with GPA 
Result after autografting  No. of treatments % of total (n=72) 
No further operative treatment  35 48.6 
Repeated autografting  27 37.5 
Unknown/patient died  10 13.9 
Total  72 100 
 
Scar release 
 
The duration of treatment with GPA and the number of applications varied. The period 
between the scar release and autografting was 7.2 days (5–18 days). The average number of 
applications of GPA needed to obtain a viable wound bed was 1.8 (1–8). In 8 releases, more 
than 2 GPA applications were performed. Five of those cases involved the popliteal space. 
No cases of wound colonisation were found. The total range of GPA applications in the 
released popliteal spaces varied from 1 to 8 applications (Table 6). In all 52 sites of 
contracture release and GPA application, a viable wound bed was obtained with a 
subsequent autograft take of 100%. 
 
Table 6 - Contracture sites treated with GPA 
Contracture sites No. of scars 
Total no. of applications 
of allograft 
Mean Range 
Neck  11 15 1.4 1–2 
Axilla  9 11 1.2 1–2 
Popliteal space  7 30 4.3 1–8 
Trunk  6 7 1.2 1–2 
Shoulder  5 7 1.4 1–2 
Groin  4 5 1.3 1–2 
Other (arm, leg, eye)  9 19 2.1 1–4 
Unknown  1 2 2.0  
Total  52 96   
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Discussion 
 
Although many membranous dressings have been developed in the last decades, the 
application of human cadaver skin still has a prominent place in the treatment of burns. 
Glycerol preservation of human cadaver skin has been shown to eradicate viral and bacterial 
contamination and has made the product safe
5
. Moreover the introduction of glycerol-
preserved human allograft skin has made the use of allograft material easier as no deep 
freeze facilities are necessary. From our study, two different principles of GPA application can 
be distinguished. Firstly GPA is used in excised wounds and on granulating wounds. As 
vascular contact occurs GPA becomes firmly attached to the wound bed. The mitigation of 
the immunogenic reaction in the wound is of advantage in the sandwich grafting technique, as 
slow rejection of the cadaver skin and limited inflammation of the wound allows the widely 
meshed autograft to grow over the wound surface and close the wound. The sandwich 
grafting procedure has become the primary treatment of choice in the Beverwijk Burn Centre 
for extensive deep burns, which explains the relatively high re-grafting rate of substantial 
areas in 48/129 cases (37.2%). We found that the sandwich grafting technique allows a better 
take of widely meshed autograft then with using a mesh graft without an additional 
membranous covering
8
. However, as the enlargement of the skin grafts in the Meek micro 
graft technique is very efficient and only small areas of skin are required this technique is 
preferable in very extensive burns or in elderly patients or patients in a poor general 
condition. This very efficient use of autograft skin s the reason that in the Beverwijk Burn 
Centre GPA or artificial dermal substitutes as a temporary cover for excised wounds in 
extensive burns
12
 to delay autografting, is not utilised. Compared to the results of the 
sandwich grafting technique in the period 1984–1985
8
 in this study a larger part of the 
procedures were performed in a secondary stage. The results of treatment were similar to 
primary stage operations. This favorable result is due to the fact that only wounds with low 
bacterial contamination are treated with a sandwich graft in a secondary stage. The second 
mechanism for the use of GPA is used in the treatment of partial thickness burns. In these 
cases GPA is a biologic dressing put on a less viable dermis. Adherence of the biological 
dressing to the wound is probably due to fibrin adhesion. As vascular contact is absent there 
is no immunogenic rejection of the cadaver skin, but the dressing will loosen from the wound 
when epithelialisation progresses. The main advantages of the use of GPA in partial 
thickness burns are the reduction of pain, easy and painless dressing changes and reduction 
of hypertrophic scarring. In our Burn Centre all partial thickness wounds that are not healed 
within 10–12 days are grafted: in 15 of the 57 cases parts of the wound were eventually 
treated with a split skin graft. As method for improvement of the wound bed, GPA was either 
left on the wound until it became detached by outgrowing epithelial islands as in the sandwich 
grafting technique, or it was removed from the wound in order to apply a autologous graft. In 
both cases, vascular contact between GPA and wound bed occurred. Firm adherence of GPA 
to the wound surface, with bleeding on removal of the allograft, is an indication that the 
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wound is ready to accept an autograft, and has been described as the “take test”. 
Nevertheless, following a positive take test, a single skin graft procedure was sufficient in only 
48.6% of cases. However, the wounds that were treated by GPA in this way were generally of 
very poor quality, due to heavy wound colonisation, exposed tendon or bone tissue and in 
patients in a poor general condition. 
The use of GPA in scar release procedures has evolved in clinical practice, prompted by our 
familiarity with GPA in other aspects of wound treatment. This application also incorporates a 
take test, but the use of GPA in this context has not been described previously. Although the 
subsequent graft take was favorable, and re-grafting was not necessary, the procedure has 
not yet been properly studied. A prospective, comparative study is therefore in preparation. 
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Chapter 4 
 
 
A historical appraisal of the use of cryopreserved and 
glycerol-preserved allograft skin in the treatment of partial 
thickness burns 
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Abstract 
 
Two studies into the use of allograft skin in the treatment of partial thickness burn injuries in 
this burn centre have provided the opportunity to discuss changes and similarities over a 20 
year period. The first study described results obtained with cryopreserved allografts in partial 
thickness burns in the period 1979–1981. The second study concerned patients with partial 
thickness injuries treated with glycerol-preserved allografts in the period 1998–2000. A 
reduction was noted concerning the need for secondary autografting in the group treated with 
glycerolized allografts. The probability that this difference has occurred by chance is small (P 
= 0.089). Various other factors that might account for the differences in outcome, include 
general improvements in health and social welfare, differences in treatment protocols, and 
differences in allograft properties. A prospective comparative trial is indicated to study direct 
differences between the two types of allograft. 
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Introduction 
 
Treatment of partial thickness burns with human cadaver skin has a number of advantages 
over the treatment with non-membranous dressings, such as paraffin-impregnated gauze, or 
topical antimicrobials such as 1% silver sulfadiazine cream
1
. Immediate pain reduction after 
application of the allograft skin dressing, prevention of desiccation of the wound bed with 
prevention of deepening of the wound, less need of early wound excision and lower 
occurrence of hypertrophic scarring were described by Hermans et al.
2
. For these reasons, in 
the Beverwijk Burns Centre, cryopreserved human allograft (CryoPA) skin became the 
treatment of choice from 1979 on for partial thickness burns, especially scald burns in 
children. In 1982, the skin bank of the Dutch Burn Foundation, the supplier of allograft skin to 
our hospital, changed the preservation of human cadaver skin into the concentrated glycerol 
procedure
3
. Subsequently, glycerol-preserved allograft skin (GPA) was used for the treatment 
of partial thickness burns. GPA was reported to be superior to CryoPA in the sandwich 
grafting technique in major full thickness burns
4
. Moderate rejection of the allograft skin and a 
moderate inflammation reaction in the wound bed led to a more reliable take and outgrowth of 
the autograft. Possibly, this is mediated by a reduced immunogenicity of GPA
5
. Clinical 
experience suggested that GPA was at least as good as CryoPA in the treatment of partial 
thickness burns and GPA became the treatment of choice for this indication. However, the 
effect of GPA in the treatment of partial thickness burns was not studied at that time. 
Recently, in the context of a comparative study with a membranous dressing, we performed a 
retrospective survey on the use of GPA in a similar patient group to that studied by Hermans 
et al. The results of treatment with GPA, defined by the need to perform subsequent wound 
excision and autologous skin grafting, were compared to the results published by Hermans et 
al.
2
 
 
Patients and methods 
 
All patients with partial thickness burns treated with CryoPA in the period 1979–1981 and the 
patients treated with GPA in the period 1998–2000 were treated according to a similar 
protocol. Partial thickness burns less than 20% TBSA were covered with allograft skin within 
24 h of injury. Chemical and electrical burns were excluded. An example of the treatment of a 
scald of the trunk and arm is shown in Fig. 1. All patients received penicillin prophylactically 
for 5 days to eradicate haemolytic Streptococcus strains. In the CryoPA group, the wounds 
were covered with CryoPA on the day of the injury; the allograft skin was fixated to the wound 
bed with adhesive strips and paraffin-impregnated gauze. In the GPA group, the wounds 
were treated with silver sulfadiazine cream dressing on post-burn day 0. On post-burn day 1, 
GPA was applied to the wound and fixated with Mepitel®. In both groups, allograft skin was 
re-applied if it did not become adherent within 4 days post-burn. If the allograft skin did not 
become adherent after 4 days post-burn, the wound was considered not suitable for 
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treatment with this membranous dressing. Any wound surface not healed within 10–12 days 
was tangentially excised and closed with a split thickness skin graft. 
  67 
Fig. 1 - (a) Two year old girl with partial thickness scald burn of trunk and left arm, day 1 post-
burn after initial treatment with 1% silver sulfadiazine cream and debridement of the wound. 
(b) Strips of GPA applied to the wound on the trunk. (c) Fixation of GPA with Mepitel®. (d) 
Strips of GPA applied to the wound on the arm, almost complete fixation with Mepitel®. (e) 
Seven days post-burn, healing of trunk, incomplete healing of arm. (f) Fifteen days post-burn, 
small skin defect remaining on left upper arm. 
 
   
(a)      (b) 
   
(c)      (d)  
   
(e)      (f) 
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Results 
 
In the patient group treated with CryoPA, 39.6% required a subsequent autologous skin graft; 
in the GPA group the percentage was 26.3. The results are summarized in Table 1. 
 
Table 1 - Treatment of patient group with CryoPA and GPA 
Treatment Number of 
treatments 
Mean percentage of 
burn (%) 
Number of 
autotransplantation (%) 
CryoPA (1979-1981) 106 8.5 42 (39.6)
a 
GPA (July 1996-July 2001) 57 7.9 15 (26.3)
a 
a
P = 0.089, Pearson Chi-square. 
 
 
Discussion 
 
The difference in outcome of the treatment of partial thickness burns with CryoPA and GPA 
are of interest, although the difference is not statistically significant in this retrospective, 
historic comparison between two groups. Although treatment procedures of both groups were 
similar, there are some differences to be noticed. For practical reasons, the wounds in the 
GPA group were treated with 1% silver sulfadiazine cream on day 0 post-burn. This may have 
given a decontamination of the wound, thereby improving the conditions for wound healing. 
The time period in which GPA were applied was also less fraught, which might improve 
operating conditions, and fixation of the allograft skin by Mepitel® in the GPA group may be 
superior to fixation with paraffin gauze. Another possibility is that the glycerol remnants of the 
cadaver skin may have had a favorable effect on the outcome. In vitro assay of the 
immunogenicity of GPA showed a diminished inflammatory response compared to CryoPA
5
. 
The moderation of the inflammation process may contribute to a better wound healing. These 
considerations certainly merit further study by means of a prospective, comparative trial. In 
the last 20 years, Western Europe has enjoyed sustained economic growth and prosperity. 
Improvements in nutrition, hygiene, and health care, which are associated with increasing 
welfare, may also influence wound healing in patients with partial thickness burn injuries. 
Despite these reservations, however, our data are sufficient to encourage the continued use 
of GPA for the treatment of partial thickness burns. 
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Part III 
 
 
Hydrofiber dressings in the treatment of partial thickness 
burns 
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Justification  
 
Introduction 
In 1996 we were asked by Convatec, the producer of a new carboxymethylcellulose based 
hydrofibre dressing, to investigate the possible application this dressing in burn wound 
treatment. In a pilot study we discovered many similarities with human allograft skin when 
applied to a partial thickness burn. If properly dressed with a loose gauze dressing, that 
allowed evaporation of wound exudate, the hydrofiber became adherent to the wound bed 
and could be left in situ until the wound had healed. In 2001 the first publication on the use of 
Hydrofiber dressing, Aquacel®, in 84 patients with partial thickness burns, was published
1
. As 
the results of the treatment were satisfactory and seemed comparable to the treatment with 
human allograft skin, two years later a RCT followed
2
. Hoekstra et al
3
, in an animal study 
shed light on the mode of action of this wound dressing. 
 
Clinical studies on Aquacel® and Aquacel Ag® 
Since these first publications, 22 clinical studies were published. Remarkably all studies 
except for four on split thickness donor sites were on the silver containing Hydrofiber. 
Probably topical antimicrobials were considered of less importance in these split skin donor 
sites. All studies on burn treatment and treatment of Toxic Epidermal Necrolysis (TEN) were 
with the silver containing Aquacel®. Clinical studies on Aquacel® and Aquacel Ag® from 
2001 to 2012 are summarized in table 1. 
In a letter to the editor Mishra et al
26
 stated Aquacel Ag® as their treatment of choice for 
partial thickness burns in adults and children in terms of pain control and rapid wound 
healing. Their findings matched the outcomes of the studies of Caruso et al
4,5  
and our own 
findings (
1,2
). In a telephone survey they found that ‘only’ 25% of the burn units in the UK used 
Aquacel Ag® for burn treatment. They stated that further randomized controlled trials 
assessing its use in several conditions were warranted. Aquacel® and Aquacel Ag® were 
found to be reliable dressings for partial thickness burns with good results on time to 
epithelialisation, prevention of infection, reduction of pain, length of hospital stay and costs. 
Our first publications of the application of Aquacel® on partial thickness burns are followed by 
thirteen publications by others on similar indications for Aquacel®. Our initial RCT compared 
Aquacel® to allograft treatment, which is also a membranous dressing. Later comparative 
studies were mostly comparing Aquacel® to cream-based wound treatments, usually Silver 
sulfadiazine or petrolatum gauze. This probably explains the more outspoken results in terms 
of reduction of surgical treatments and pain with Aquacel® in later studies. It is not clear why 
the majority of subsequent studies have been done with the silver containing dressing, as 
prevention of infection was adequate in our two series and there is no evidence that these 
dressings performed better with regard to infection control. This question remains to be 
answered in future studies. 
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After 2007 nine RCT’s on split thickness donor sites were published. In all studies treatment 
of SSGDS was adequate concerning time to healing and pain control, in some studies it was 
considered more expensive than other dressings. 
 
Table 1 - Clinical studies to Aquacel® and Aquacel Ag® in the treatment of partial thickness 
burns, TEN and Donor sites 
Reference (year) Type of study Sample Wound type Type of Aquacel® 
Vloemans AF et al (2001)
1 
CohS 84 PT Plain 
Vloemans AF et al (2003)
2 
RCT 80 PT Plain 
Caruso DM et al (2004)
4 
NRCT 24 PT Ag 
Barnea Y (2004)
5 
RCT 23 SSGDS Plain 
Caruso DM et al (2006)
6 
RCT 84 PT Ag 
Lohana P et al (2006)
7 
CohS 22 PT Ag 
Huang SH et al (2008)
8 
CS 1 TEN Ag 
Kaźmierski M et al (2007)
9 
CS 114 Deep PT Ag 
Paddock HN et al (2007)
10 
Retrospect CohS 79 PT Ag 
Paddock HN et al (2007)
11 
Retrospect CohS 77 PT Ag 
Hindy A (2009)
12 
RCT 60 PT Ag 
Lohsiriwat V et al (2009)
13 
RCT 20 SSGDS Ag 
Saba SC et al (2009)
14 
Retrospect CohS 20 PT Ag 
Blome-Eberwein S et al (2010)
15 
RCT 70 SSGDS Ag 
Demirtas Y et al (2010)
16 
RCT 100 SSGDS Plain 
Huang SH et al (2010)
17 
CS 9 TEN Ag 
Muangman et al (2010)
18 
RCT 70 PT Ag 
Wang TH et al (2010)
19 
CohS 9 SSGDS Plain 
Al-Ahbad M et al (2011)
20 
CS 1 Deep PT Ag 
Bailey S et al (2011)
21 
RCT 20 SSGDS Ag 
Dornseifer U et al (2011)
22 
RCT 50 SSGDS Plain 
Dokter J et al (2012)
23 
Retrospect CohS 804 PT Ag 
Duteille F et al (2012)
24 
CohS 23 PT hand burns Ag 
Mabrouk A et al (2012)
25 
RCT 40 PT face burns Ag 
 
NRCT=Non-Randomized Controlled Trial, PT=Partial Thickness Burns, RCT=Randomized 
Controlled Trial, SSGDS=Split Skin Graft Donor Sites, CohS=Cohort Study. 
 
 
Conclusion 
The two first publications on Aquacel® in the treatment of partial thickness burns have not 
lost their value. As the depth of the partial thickness burns in none of the studies was 
objectivised by Laser Doppler Imaging and the role of the silver addition to the dressing is not 
clear yet, future studies on Aquacel® are justified. 
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Abstract 
 
A newly developed, carboxymethylcellulose based hydrofibre dressing, Aquacel®, was tested 
for the treatment of partial thickness burns. In this study 84 patients with mainly partial 
thickness burns were included, 76 patients received 1 or 2 days pre-treatment with a topical 
antimicrobial agent. Clinical behavior showed a strong resemblance with cadaver skin 
treatment with respect to adherence to the wound. Adverse reactions, incidence of clinical 
wound infection, healing time and the need for wound excision and grafting were analysed, as 
was the final outcome using the ‘Vancouver Scar Scale’. The mean size of the wounds 
treated with the hydrofibre dressing was 6.0% body surface area (min: 1%, max: 18%). Two 
patients clinically showed signs of a wound infection during treatment, but in general wound 
cultures were low or negative. In 42 patients (50%) the wounds healed completely within 10 
days, in six patients (7%) small defects remained that healed by further treatment with a 
topical antimicrobial cream. In 36 patients (43%) excision and grafting of the remaining 
deeper parts of the wounds was performed as this is the standard therapy in the centre for all 
burned areas that have not healed within 2–3 weeks post-injury. The extent of the surgical 
procedures was limited since 66.1% of the wound area had healed already at the end of the 
hydrofibre treatment. In 54 patients the outcome of the treatment after 2–3 months was 
analysed by means of the Vancouver Scar Scale, which showed favourable results in 
general, and especially for patients who did not require surgery. Compared to earlier 
experience with allograft skin it was concluded that hydrofibre dressing is a safe, suitable and 
easy to use material for treatment of partial thickness burns. 
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Introduction 
 
Partial thickness burns are a common type of thermal trauma admitted to a burns centre, and 
the majority of the victims are children. Particularly when the burns are small, they are not a 
major cause of mortality, but the morbidity related to the injury is extensive. They are very 
painful, and treatment may be traumatizing as well. The long-term physical and psychological 
consequences, particularly when hypertrophic scarring or keloid develop, are well known. The 
most commonly used topical treatment for partial thickness burns is the application of silver 
sulfadiazine cream (SSD) 1%
1
. This cream combines a fairly broad antimicrobial spectrum 
with easy application on most parts of the body
2
. The antimicrobial efficacy of SSD 1% is 
probably the main reason why the use of this material is so widespread, since wound 
infection is considered a major threat in burn care. However, it has been shown that the 
incidence of infection in small partial thickness burns does not increase when occlusive or 
membranous materials are used
3
. Indeed, in several clinical trials the efficacy of biological 
and non-biological membranous materials was compared to the efficacy of ‘conventional’ 
materials, including SSD 1%, usually with results which were favourable for the membranous, 
occlusive dressings, particularly with respect to speed of re-epithelialisation, pain relief and 
long term cosmetic appearance. Human cadaver skin, or allograft skin, is an example of such 
a membranous dressing. Compared to treatment with SSD, pain scores, healing time and the 
incidence of hypertrophic scarring were decreased when partial thickness burns were treated 
with allograft skin
4–6
. It is for these reasons that this material is still the ‘golden standard’ in the 
hospital and in many other burn centres. Also in mixed burns with predominant partial 
thickness areas, cadaver skin is used as the primary method of treatment. Usually the 
deepest areas of the original burn that do not heal with the allograft treatment are excised and 
grafted at a secondary stage (usually after PBD 14–21). In this way the more superficial parts 
can heal undisturbed. Using this technique, excisions that are too wide or too deep can be 
avoided, which is known to be the consequence of early tangential excision in mixed partial 
thickness burns
7
. However, it needs to be realised that the use of human cadaver skin 
requires an experienced physician and nursing staff. Moreover, procurement may be difficult 
and theoretically the use of donor tissue can transmit diseases from donor to acceptor, 
although the glycerol preservation technique used at the Euro Skin Bank has been shown to 
inactivate different types of bacteria and viruses, including HIV
8,9
. For reasons of 
infrastructure, religion or poor social acceptance by society, cadaver skin is not always 
available. It is therefore obvious that an easily applicable, off the shelf alternative to cadaver 
skin would be a worthwhile contribution to the range of treatments for partial thickness burns. 
In 1996, a newly developed hydrofibre material,
 
Aquacel
*
, was introduced in the clinic. The 
dressing is composed of 100% sodium Carboxymethylcellulose with a low degree of 
carboxymethylation and is indicated for the treatment of skin wounds, including partial- 
 
*
 Aquacel®, ConvaTec, a division of Bristol-Myers Squibb. 
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thickness burns. It has a strong capacity for absorption and transportation of fluid without 
lateral spreading through the dressing. 
Initially, hydrofibre was used as a cover dressing over topical antimicrobial creams and 
ointments such as Silversulfadiazine, Fusidine and Povidon Iodine. While treating the first 
patients with such  
 
a combination of materials, it was observed that the dressing allowed for adequate drainage 
of exudate and that the material became adherent to the woundbed, thus avoiding dead 
space. Further experience taught us that the dressing, when left on the burn for a prolonged 
period, developed a parchment-like structure and once the underlying wound had re-
epithelialised still allowed for an easy removal from the wound site. Thus, the clinical 
behaviour of hydrofibre strongly resembled that of cadaver skin. To evaluate the clinical 
results and outcomes, a non-comparative, prospective pilot study in partial thickness burns 
was initiated. The obtained results were put in a historical perspective by comparing the 
obtained data with an earlier investigation as summarised in Table 4
10
. 
 
Patients and methods 
 
All patients with fresh partial thickness burns, superficial, deep and mixed in origin, were 
eligible for enrolment in the study. The dressing protocol used was similar to the one used for 
treatment with human cadaver skin. Wound debridement was performed and blisters were 
removed. To decontaminate the burn, in most cases pre-treatment with a topical antimicrobial 
agent was started as a first treatment: in 73 cases this was SSD 1%, in one case Povidon 
Iodine and Fucidin ointment was used for one patient. In one patient, the wound was only 
covered with paraffin gauze dressing. Eight patients did not receive any form of pre-
treatment. Cultures were taken of all burns. Some patients received systemic antibiotic 
therapy, in line with the standard treatment protocol in the hospital (as determined by the size 
of the burn and whether or not a patient was hospitalised) to prevent wound infection with 
Streptococcus haemolyticus. The administration of antibiotics would be discontinued when 
cultures would not show contamination with S. haemolyticus group b. All parts of the body 
that were suitable for treatment with sheet-like dressings were included in the study. 
This means that concave areas, such as the axilla and the groin, were excluded. These areas 
were treated with a topical antimicrobial cream. The criteria to be studied in the protocol were 
safety (i.e. incidence of infection) and efficacy (i.e. rate and speed of re-epithelialisation, long-
term cosmetic results).At PBD (post burn day) 0 or 1 the hydrofibre dressing was applied to 
the wound bed with an overlap of approximately 3 cm over non-burned surrounding skin. The 
material was fixated with an airy cotton dressing to allow drainage. Every day or every second 
day the outer (cotton) dressing was removed and the hydrofibre dressing was checked for 
adherence. Parts of the dressing that had slipped off the wound or that were not adherent 
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were replaced with a new sheet of hydrofibre material. If attachment was not obtained after 
the first application, a new sheet was applied, up and until post burn day 5. After that period 
further treatment with a topical antimicrobial dressing was used until wound excision and 
grafting. Persistent detachment was considered a sign of a deep wound and:or infection of 
the underlying lesion. A burn was defined as healed when 95% or more of the original burned 
area was re-epithelialised. Depending on the extent of a remaining defect and the area of the 
body, areas that were not re-epithelialised after dislodgement of the hydrofibre dressing, were 
excised and grafted, on average on PBD 14 (min: 11, max: 22). Excision and grafting of non-
healed areas after PBD 14–21 is a common procedure in our centre, since this is known to 
improve the rate and quality of healing. If such an area was too small for excision or if no 
consent for the operation was given by the patient or the legal representative, treatment was 
continued with a topical antimicrobial cream. To obtain an impression of the final outcome of 
the treatment, 2–3 months after the initial injury, scar evaluation was performed in the 
majority of the patients, by using the ‘Vancouver Scar Scale’
11
. 
 
Results 
 
Between October 1996 and July 1998, 84 patients with mainly superficial and deep partial 
thickness burns, less than 20% body surface area, referred to the burn centre within 48 h post 
burn, were included in the study. Scalds were involved in 72 patients, 11 patients sustained a 
flame burn and one patient was burned by hot fat. The mean age of the patients was 6.6 
years (min: 0.34, max: 59.26). The mean overall size of the burns was 8.5% total body 
surface area (TBSA), with a minimum of 1% and a maximum of 20%. The average wound 
size treated with the hydrofibre dressing (Table 1), was 6.0% (S.D.: 3.8%, min: 1%, max 
18%). As expected, many of the cultures taken were negative. Positive cultures showed 
primarily Staphylococcus aureus or Pseudomonas aeruginosa. Other microorganisms were 
found less frequently. These included haemolytic S. group b, Escherichia coli, Klebsiella 
oxytoca, Enterobacter cloacae, Acinetobacter spp., and Streptococcus pneumoniae. In all 
cases where bacteria were cultured, the counts were very low. The outer (cotton) dressing 
was changed every day or every other day, primarily to inspect the test dressing. In the 
majority of patients (N 67) the hydrofibre dressing was left in situ, without change, until 
spontaneous dislodgement occurred. In 17 patients the hydrofibre dressings needed to be 
reapplied. In those patients the overall number of dressing changes was 1.6 (min: 1, max: 2). 
The overall hydrofibre treatment period for all patients was 9 days (S.D.: 3, min: 1, max: 17). 
In 42 patients (50%) the wounds treated with the hydrofibre dressing healed completely 
(Table 1). Obviously, the treatment period mentioned previously, also reflects the average 
healing time for these patients. In six patients (7%) the defects that remained were so small 
that further treatment with a topical antimicrobial cream was justified. Complete wound 
healing usually occurred within a few days. In 36 patients (43%) wound excision and grafting 
was necessary for some or all of the deeper parts of the wound. Operation took place, on 
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average, on postburn day 14 (min: 11, max: 22). The size of the original partial thickness 
burns that had to be operated and that healed without operation is described in Table 1. On 
average, 82.9% of the original wound surface of all burns healed spontaneously, without any 
excision and/or grafting. For the non-operated and the operated burns, these percentages 
were 95 and 66.9%, respectively (Fig. 1). Some patients were lost to follow up. In 54 patient 
(64.3%) the ‘Vancouver Scar Scale’ [11] could be used to judge the healing results, 24 of 
these patients belonged to the group not requiring surgery and 30 patients to the operated 
group. The scores are summarized in Table 2. All scores were significantly lower in the non-
operated group than in the operated group. A typical treatment procedure is documented in 
Fig. 2. In five patients treatment with hydrofibre was interrupted at or before PBD 5 (Table 3). 
In patients 1, 4 and 5 the burn was mainly deep partial — full-thickness on admission and, at 
hindsight, failure of the hydrofibre treatment with respect to induce complete re-
epithelialisation could have been expected. In patient 2 fever developed on post burn day 4, 
the dressings became discolored and smelly and wound infection was diagnosed clinically. 
The temperature normalized after treatment with a topical antimicrobial dressing. In patient 3 
fluid suppletion in the shock phase was insufficient and dehydration and tachycardia 
occurred. Although fever was absent, wound sepsis was diagnosed clinically. However, 
cultures turned out to be negative. The hydrofibre dressing was removed and topical 
treatment was continued with SSD 1% (Table 3). 
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Table 1 - Patient and treatment characteristics 
 
 All patients Non-operated patients Operated patients 
Patients (n) 84 48 36 
Age at admittance in years (mean (min-max) SD) 6.68 (0.34-59.26) 11.85 7.25 (0.61-50.15) 11.83 5.92 (0.34-59.26) 11.92 
TBSA (mean (min-max) SD) 8.5% (1%-20%) 5.2% 6.7% (1%-19%) 4.4% 11.1% (3%-20%) 5.2% 
Study burn in TBSA (mean (min-max) SD) 6.0% (1%-18%) 3.8% 5.1% (1%-18%) 3.4% 7.2% (1%-17%) 4.0% 
Duration of treatment (days) (mean (min-max) SD) 9.2 (1-17) 3.3 9.2 (3-17) 3.2 9.2 (1-14) 3.4 
N of patients with complete healing (n / %) 42 / 50.0% 42 / 87.5% 0 / 0% 
N of patients requiring surgery (n / %) 36 / 42.9% - 36 / 100% 
Wound area healed at end of treatment (% of wound surface) 82.9% (0%-100%) 25.5% 95% (50%-100%) 13.7% 66.1% (0%-94.5%) 28.5% 
Time of surgery (PBD) (mean (min-max) SD) 14 (11-22) 2 - 14 (11-22) 2.3 
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Table 2 - Vancouver scale at first follow up: mean (min–max), S.D. 
                                        
All patients Non-operated 
patients 
Operated patients P-value 
Follow up (days)  78.6 (28–228) 41.5 85.8 (38–228) 45.2 73.1 (28–191) 37.5 – 
Vascularity (0–3)  1.06 (0–2.50) 0.68 0.72 (0–2.00) 0.57 1.32 (0–2.50) 0.64 0.0011 
Pliability (0–5)  1.04 (0–5.00) 1.05 0.38 (0–2.00) 0.52 1.55 (0–5.00) 1.07 0.00002 
Pigmentation (0–3)  1.15 (0–3.00) 0.78 0.78 (0–2.30) 0.63 1.44 (0–3.00) 0.77 0.0021 
Height (0–3)  0.41 (0–2.00) 0.56 0.19 (0–1.50) 0.38 0.58 (0–2.00) 0.61 0.0108 
 
 
 
Fig.1 - Total % of healing with hydrofibre (expressed as percentage of original wound area) 
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Table 3 - Clinical data on patients with adverse experiences 
 
Patient  Sex  Age 
(years)  
Aetiology  Localisation  TBSA (%)  Wound culture  Removal 
hydrofiber 
on PBD 
Reason for 
removal 
Diagnosis  Operated surface, 
% of originally 
enrolled burn 
Operated surface, 
expressed as 
TBSA 
1  F  5  Scald  Back  13  Negative  4  Non adherence  Deep burn  40  5.20  
2  F  1  Scald  Thorax  18  Staph. aureus,  5  Fever  Infection  25  10.50  
      Bacillus species   Discoloration     
3  M  1  Scald  Buttocks, Legs  20  Negative  2  Suspected sepsis 
Tachycardia/ No  
Dehydration  25  4.25  
        fever     
4  F  59  Scald  Legs  7  Negative  5  Non adherence  Deep burn  20  4.75  
5  F  3  Scald  Back  19  Negative  4  Non adherence  Deep burn  75  1.00  
 
 
 
Table 4 - Clinical data on treatment by SSD or early tangential excision and split skin graft and SSD or human cadaver skin and split skin graft in later stage in 
two time periods 
 1975–1978 1979–1981  
 SSD or early tangential excision and split skin graft SSD or human cadaver skin and split skin graft in later stage  
No. patients  93  122  
% TBSA  11.1 (range 3–18)  8.5 (range 2–15)  
No. autografts  50  42  
No. allografts  0  106  
% hypertrophic scar>10% of original surface  52  10  
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Fig. 2 - Treatment of a partial thickness wound with hydrofibre. (a) Partial thickness burn at 
PBD 1, onset of hydrofibre treatment. (b) Appearance of hydrofibre during treatment. (c) End 
of treatment, PBD 12, hydrofibre is being removed. (d) Complete healing of the burn under 
hydrofibre. (e) Appearance of the healed wound at PBD 16. (f) Cosmetic result after 3 
months: no hypertrophic scarring, just a slight hypopigmentation. 
 
 
 
Discussion 
 
Many studies have shown that uncomplicated wound healing of partial thickness burns can be 
obtained without the use of topical antimicrobial agents, provided that an appropriate dressing 
material is chosen. Membranous dressing materials, such as human cadaver skin, 
DuoDERM
12
 and DuoDerm CGF, Omiderm
13
, Biobrane
14
, and Mepitel
15
, have been shown to 
provide reasonable to good healing results when used in partial thickness burns. A close 
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contact to the wound surface or the surroundings of the wound seems crucial without being 
incorporated into the wound. As the healing progresses, the dressing material becomes 
detached. Upon the re-epithelialisation of the wound underneath, it can be removed as a dry 
‘crust’. The (synthetic) materials that provide a moist environment, without becoming attached 
to the wound surfaces, also allow a rapid healing but are often associated with leaking. The 
hydrofibre material, tested in this study, seems to combine the advantages of biological and 
synthetic materials (i.e. adherence to the woundbed without ingrowth, minimal numbers of 
dressing changes, shelf availability, easy storage and procurement), without some 
disadvantages (i.e. rejection, possible transmission of diseases, allergenic reactions). 
The material provided rapid wound healing without the necessity for frequent dressing 
changes and was easy to apply. As it turned out, the dressings could also be used over joints 
such as the elbow, knee and ankle without failure of attachment. However, in the last phases 
of the healing process the formation of a hard crust over joints caused some discomfort in 
some patients. In any burn study with only a limited number of patients, it is difficult to draw 
conclusions with respect to the final cosmetic results (i.e. the incidence of hypertrophic 
scarring), since this depends on a great number of variables that cannot be individually 
analysed and correlated. The ‘Vancouver Scar Scale’ was used as an instrument to get an 
impression of the outcome of the healing quality. For most patients the evaluation was done 
after 2–3 months post burn. At this time any hypertrophy, although possibly not at its 
maximum level, will be visible. Onset of hypertrophy after 2 months post burn is unlikely. 
Based on the results of the ‘Vancouver Scar Scale’ evaluations, some preliminary and careful 
comments can be made. Especially the findings for pliability and height of the scar, 
parameters related to a possible hypertrophic condition of the scar, are favourable in the non-
operated group. Overall significantly lower scores were obtained in patients with burns that 
healed without skin grafting. This obviously reflects the depth of the original burn. The deeper 
burns are likely to heal with more scarring. However, the scores also reflect the good results 
that can be obtained in patients with partial thickness burns and the limited need for surgery 
in this type of burn. The data obtained with hydrofibre was compared with those obtained 
previously with allografts and SSD treatment with respect to cosmetic results and the need for 
excision and grafting in a secondary stage (Table 4)
10
. Hydrofibre treatment seems to have 
many advantages over the use of topical antimicrobial agents. The material seems to be 
related to a low incidence of scar formation similar to previous results with cadaver skin in 
children, as summarised in Table 4. The relatively high incidence of grafting in all the groups 
is caused by the fact that all areas not healed after 14–21 days post burn — conform protocol 
— are grafted. However, in general the areas that require grafting in a secondary stage-
expressed as a percentage of the original size of the burns — are considerably smaller than 
in the early surgery group (Table 4). In the present study this is documented for the hydrofibre 
treatment: in those burns that required operation only 33.9% of the original burn area had to 
be grafted. The incidence of serious hypertrophic scarring, defined as a hypertrophic scar 
over more than 10% of the original burned area, dropped from 52 to 10%. 
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To fully establish the value of this hydrofibre dressing, a randomised prospective study, 
comparing hydrofibre with human cadaver skin for the treatment of partial thickness burns 
seems justified and is currently being undertaken. 
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Abstract 
Membranous dressings for the treatment of partial and mixed thickness burns are among the 
most innovative and promising new developments of the last years. In this study, we present 
data of a randomised prospective comparative study on a carboxymethylcellulose based 
dressing, Hydrofibre® and glycerolized human allograft skin. In a 2-year period, 80 patients 
(40 for each material) were enrolled in the trial. Study wounds (<10% TBSA) that had not re-
epithelialised after 14 ± 3 days were debrided and grafted or, if small enough, managed with a 
topical antimicrobial agent.  
Mean total TBSA was 8.3 ± 5.2%, study burn 3.6 ± 2.1% for the Hydrofibre® group and 7.3 ± 
4.3% total, 3.1 ± 2.1% study burn for the allograft skin group (n.s. Wilcoxon rank sum test).  
No significant differences between groups were established in number of patients with 
superficial/deep burns. In both groups about 2/3 of the patients healed completely with the 
dressings applied (24/40 versus 27/40 for Hydrofibre
®
 versus allograft skin, respectively).  
However, a higher incidence of post-study excision and grafting was found in the Hydrofibre
®
 
group (45% versus 15% in the allograft skin group, P = 0.004, Mann–Whitney).  
At 10 weeks follow-up no significant differences were seen in scar colour, pigmentation, 
pliability, height or itching (Vancouver Scar Scale). Skin elasticity, measured by the 
Cutometer
®
, was significantly better for the allograft group (P = 0.010,Wilcoxon). These 
differences were no longer found at 6 months and 1-year follow-up. Incidence of hypertrophy 
after 6 months was higher, but not significantly, in the Hydrofibre
®
 compared to the allograft 
skin group (52.5% versus 30%, P = 0.09, chi-square). In view of the results from our 
comparative study on Hydrofibre® versus allograft skin, we prefer the use of allograft skin for 
the category of larger burns of mixed depth, usually presented to burn centres. However, for 
partial thickness and small burns Hydrofibre® can be the first choice in treatment. 
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Introduction 
 
Approximately 30% of the patient population of a burn centre are children with partial 
thickness burns. Since this is a vulnerable category of patients, the treatment outcome is an 
important issue. Considerable morbidity is still associated with this type of burns: 
complications during treatment may extend as far as toxic shock syndrome
1
. After re-
epithelialisation of the wound hypertrophic scarring often leads to disfigurement, sometimes to 
repeated hospital admissions for reconstructive procedures and long-lasting or even 
permanent impairment. Therefore, it is of paramount importance that the primary treatment of 
scald burns is safe (with respect to, infection prevention), comfortable (with respect to pain 
reduction), and allows for good outcomes with respect to prevention of hypertrophic scarring. 
The most commonly used topical treatment for partial thickness burns is silver sulfadiazine 
(SSD) cream 1%
2
. The antimicrobial efficacy of SSD 1% is probably the main reason why the 
use of this material is so widespread, since wound infection is considered a major threat in 
burn care. However, it has been shown that the incidence of infection in small partial 
thickness burns does not increase when occlusive or membranous materials are used 
3,4
. 
Indeed, in several clinical trials the efficacy of biological and non-biological membranous 
materials was compared to the efficacy of “conventional” materials, including SSD, usually 
with favorable results for the membranous, occlusive dressings, particularly with respect to 
speed of re-epithelialisation, pain relief and long term cosmetic appearance
5–9
, without 
increasing the risk of infection
3,7
. Superficial partial thickness burns are usually managed with 
topical therapy. These wounds, when treated properly, will heal spontaneously within 1–2 
weeks, without hypertrophic scarring. For deep partial thickness and full thickness wounds the 
general accepted therapy consists of early excision and grafting. A dilemma exists in mixed 
partial thickness burns: excision and grafting may be necessary for the deeper areas, while 
the more superficial areas will heal without surgical intervention within 2 weeks. Moreover, the 
assessment of the depth of a burn shortly after the accident is very difficult, even for an 
experienced physician. This accounts especially for partial thickness burns. Studies with laser 
Doppler imaging showed that an accurate diagnosis could only be made at day 3 postburn
10–
12
. For medical practice this is too late as it may interfere with the therapy. This dilemma may 
be overcome by using secondary (also called late) excision and grafting. With this technique, 
the more superficial areas are offered an environment that is beneficial for spontaneous 
healing, and all areas that are not re-epithelialised within 10–17 days (depending on several 
factors, including, for example, the anatomical location of the burn) are excised and grafted. 
In mixed partial thickness burns, secondary excision is usually the preferred approach in the 
burns unit of the Red Cross Hospital in Beverwijk (The Netherlands). Burns are prone to 
secondary deepening: several mechanisms (including desiccation and infection) may cause 
the burn to become deeper over time
3–15
. Certain dressings are assumed to give better 
protection against this detrimental phenomenon. For this reason, partial thickness burns are 
treated preferentially with glycerol preserved allograft skin (Euroskin®) in our unit. This 
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material has several advantages over cream based topical antimicrobials in particular
7,16,17
. 
However, in spite of these advantages, global use of allograft skin is limited, primarily for 
practical reasons. These include the costs of the material and of setting up and maintaining a 
skin bank, infrastructural requirements (i.e. the availability of harvesting teams) as well as 
religious and social unacceptability of using donor organs. The use of allograft skin also 
requires experience, which cannot be obtained by health care providers who do not treat 
burns very regularly (i.e. first line physicians, general practitioners). 
Because of these practical aspects, the Beverwijk burn centre has been looking for an 
alternative for allograft skin. Several innovative “off-the-shelf” materials have become 
available during the last decade. Among those dressings is Aquacel
®
, Hydrofibre
®
, a 
hydrocolloid containing, fleece type dressing. A pilot study done with this material showed 
promising results
18
. Based on these results, it was decided to do a randomised, comparative 
trial with Hydrofibre
®
 dressing versus Euroskin®. The trial was performed in accordance to 
Good Clinical Standard Practice and the Helsinki guidelines. 
 
Materials 
 Human allograft skin (Euroskin
®
) 
Allograft skin was harvested from volunteer cadaveric donors, using the standard protocol of 
the Euro Skin Bank (Beverwijk, The Netherlands), and conserved in 85% glycerol. Before 
usage, the allograft skin was rinsed in saline 0.9% to wash out the glycerol. It was then 
applied to the cleaned and debrided burned area and fixed with staples and/or fixation 
bandages. 
 
Hydrofibre® 
The Hydrofibre® dressing, also known as Aquacel
®
, is a sterile, white fibrous dressing derived 
from a pure hydrocolloid. It is a soft, pliable, conformable material that absorbs fluid rapidly. 
The dry dressing converts to a soft, coherent gel-sheet. Prior to the comparative trial 
described in this paper, the material was tested in a pilot study
18
. 
 
Patients 
In both groups, 40 patients were enrolled. The mean age was 9.1 years (10 months to 62 
years) in the Hydrofibre® group and 11.7 years (10 months to 56 years) in the human 
allograft skin group. In the Hydrofibre® group, 22 patients were of the male sex and in the 
human allograft skin group 25 subjects were male. General health was excellent in 90% of all 
subjects (both groups). In both groups, five subjects (12.5%) suffered from concomitant 
diseases: these were not considered to have a negative impact on wound healing. Statistical 
significance between the two treatment groups did not occur among any of these data sets. 
 
Methods 
Study protocol 
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The study protocol was approved by the ethics committee of the Red Cross Hospital. With 
respect to the burned areas, the following inclusion criteria were used: the burn had to be a 
fresh (not older than 24 h postburn) and superficial or mixed (superficial and deep) partial 
thickness burn with respect to depth. The study burn could not exceed 10% total body surface 
area (TBSA) while the subject could not have a total burn surface exceeding 20% TBSA. Burn 
size was measured using the Lund and Browder charts, the study wound was also measured 
planimetrically with a Polaroid
®
 fixed focus camera in combination with Adobe
®
 software
19,20
. 
Exclusion criteria included a known immunocompromised state, a poor prognosis, known 
sensitivity or allergy to any of the treatment materials, and known abnormalities in wound 
healing. Also excluded were electrical burns, chemical lesions or frostbite, and/or burns of the 
ears. If the patient fitted the inclusion criteria and did not meet any of the exclusion criteria, a 
continuous burn area was designated as the study wound, and randomised to one of the 
materials after obtaining informed consent from the patient or his/her legal representative. 
Participation in the study was for a maximum of 14 ± 3 days or until the burn had re-
epithelialised, whichever came first, or participation ended if the dressings failed to become 
adherent within 4 days. Subjects were evaluated again at approximately 10 weeks after re-
epithelialisation of the study burn, to assess the quality of the scar. Primary treatment 
consisted of topical antimicrobial cream (silver sulfadiazine 1%) on day 0 to decontaminate 
the wound, followed by cleansing of the wound and debridement of blister remnants 
preparatory to the application of either non-meshed strips of allograft skin or Hydrofibre
®
 
dressing on PBD 1. The human allograft skin was covered and fixed to the surrounding skin 
with a silicone mesh dressing (Mepitel
®
, Mölnlycke, Göteborg, Sweden) and gauze, or fixated 
with a polyamide gauze (SurfaSoft
®
, Mediprof, Moerkapelle, The Netherlands) and staples 
under a light anaesthesia (Ketanest
®
, Parke & Davis, Capelle a/d/IJssel, The Netherlands). 
Hydrofibre
®
 was fixed only with a double layer of plain gauze dressings and a tubular, widely 
woven fixation dressing. In a previous study, it was shown that Hydrofibre
®
 does not need to 
be changed during the healing period of the burn. Similar to allograft skin, the material 
becomes adherent, usually for a period of up to 14 days, during which the underlying partial 
thickness burn has healed 
18
. This benign adherence is based on a layer of fibrin that builds 
up between the dressing and the wound and not on the growth of tissues into the dressing
21
. 
The subsequent dressing protocol used was similar for both treatments and based on 
expected adherence of the dressing materials to the wound.  Subjects were seen by the 
investigator during every dressing change. In principle, only the outer dressings were 
removed (if Surfasoft
®
 was used, this was removed on postburn day 5). If the primary 
materials (Hydrofibre
®
, human allograft skin) failed to adhere, they were reapplied until the 
fourth postburn day. If the dressing still had not become adherent by that time, the wound was 
considered not appropriate for treatment with allograft skin or Hydrofibre
®
 and topical 
antimicrobial treatment was started. The primary dressings were only removed when they had 
become dislodged after initial adherence had occurred. 
During dressing changes, a number of performance characteristics were recorded. If the burn 
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was considered to be clinically infected (wound and patient have the clinical symptoms of 
infection), the dressing was removed and the subject withdrawn from the study. Participation 
in the trial was allowed for up to 17 days. The re-epithelialisation percentage after the set 
study time was judged both visually (investigator assessment), as well as with the use of 
indirect planimetry. Depending on the size of residual defects, they were debrided and 
grafted, or, if small enough, managed with a topical antimicrobial cream. 
At 10 weeks post re-epithelialisation, a follow-up visit was arranged, to analyse scar quality. 
Planimetry was used to measure the size of any hypertrophic area, so that the surface could 
be expressed as a percentage of the original burn. The Burn Scar Index (also known as the 
Vancouver Scar Scale) was used as well, and extended with items as ‘itching’ and ‘patient 
opinion’
22
. Hypertrophy was defined as obtaining a score of 1 or greater in the relevant item 
‘thickness’ of the Vancouver Scar Scale. Skin elasticity of the study area and a relevant 
control area were measured using the Cutometer 575® (Courage and Khazaka Electronic 
GmbH, Cologne, Germany) 
23
. 
 
Additional data collection 
In addition to data collected in line with the study protocol, the following data were collected: 
• The number of patients who underwent surgical intervention for treatment of the study area; 
this intervention was sometimes planned immediately after termination of the study protocol, 
in which case it was indicated as ‘further treatment’ in the outcome of the study. In several 
cases, the planned and registered further treatment was ‘antimicrobial cream’. However, if 
this treatment did not enhance further re-epithelialisation within 3 to 5 days, surgical 
intervention (skin grafting) was planned. To avoid an underestimation of the actual number of 
surgical interventions, this was registered separately. 
• Scar assessment using skin colour and pigmentation measurements: The Dermascan® 
spectrometer was used to evaluate abnormalities in skin colour and pigmentation of the study 
area versus normal skin
24,25
. Full scar evaluations were carried out at 6 months and 1 year 
postburn, in order to be able to evaluate long-term outcome of the therapies under study. 
 
Statistics 
Results were analysed using standard statistical programs (SAS). Chi-square was used to 
compare categorical data between both treatment groups, Fisher’s exact was used for 
categorical variables with sample sizes smaller than 5. Wilcoxon rank sum test was used for 
numerical variables that tended to have non-Normal distributions. Mann–Whitney was used to 
compare non-parametric data of independent samples. The significance criteria were set at P 
< 0.05. Analysis of variance (ANOVA) was used for numerical variables that tended to have a 
normal distribution. 
 
Conflict of interest 
A-M.S. and M.S. were appointed as clinical trial researchers for this study based on a clinical 
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trial grant from Bristol–Myers Squibb. 
 
Results 
 
Wound healing 
Typical examples of treatment of partial thickness burns with human allograft skin and 
Hydrofiber
®
 dressing are shown in Figs. 1 and 2. One non-dressing-related severe adverse 
event was reported: one subject in the allograft skin regime experience a severe upper 
respiratory infection. Although the differences were not statistically significant, the burns in the 
Hydrofibre
®
 group were larger on average (3.6% + 2.1 TBSA) than those in the human 
allograft skin group (3.1%+1.8 TBSA). More subjects in the Hydrofibre
®
 group suffered from 
mixed superficial and deep partial thickness burns (N = 32, 80%) than in the human allograft 
skin group (N = 29, 72.5%). Also these differences were not statistically significant.  
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Fig. 1 - A 2-year-old boy with a scald burn. After initial application of silver sulfadiazin cream 
on day 0 and covering of the wound with human allograft skin the dressing was not adherent 
on day 3 postburn (a); strips of human allograft skin were reapplied (b); the human allograft 
skin formed a dry scab that could easily be removed at postburn day 7 (c); the wound had 
healed over 95% and needed no further dressing (d); two months postburn a hypertrophic 
scar was present at the upper part of the lower leg (e); after 6 months it had gradually 
reduced to a flat scar (f, g). 
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Fig. 2 -  A 2-year-old girl with a scald burn to the ventral side of the trunk. After initial 
treatment with silver sulfadiazin cream on day 0, Hydrofibre
®
 dressing is applied on postburn 
day 1 (a, b); on postburn day 2 the Hydrofibre
®
 dressing was removed because of insufficient 
adherency and a new Hydrofibre
®
 dressing was applied (c); spots of hypertrophic scarring at 
the cranial site of the wound 3 months postburn (d); gradually increasing to a maximum at 6 
months postburn (e) and thereafter decreasing to a flat scar 1 year postburn (f). 
 
 
 
 
The distribution of anatomical localisations of the burns was largely similar among both 
groups, and in each group one subject was taken into the operating theatre for the first 
dressing application. At the end of study participation, investigator assessment for complete 
re-epithelialisation (defined as ≥95% of the original study burn) was positive for 21 subjects 
(52%) in the Hydrofibre® group and for 24 subjects (60%) in the human allograft skin group 
(not statistically significant). When planimetry was used, these numbers were 24 (60%) and 
27 (67%) for Hydrofibre® and human allograft skin, respectively (not statistically significant). 
Since planimetric measurements are more accurate, results obtained by this method were 
used where re-epithelialisation data were necessary for other calculations. 
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The overall percentage of re-epithelialisation (including those subjects in whom re-
epithelialisation was not complete at the end of the study) was 78.3% for the Hydrofibre
®
 
group and 84.7% for the human allograft skin group (not statistically significant). After 
participation in the study was complete, 8 patients out of the 19 that had not healed 
completely in the Hydrofibre
®
 group and 2 out of the 16 with incomplete healing in the human 
allograft skin group had to undergo excision and grafting (P = 0.025, Fisher’s exact test). 
After follow-up treatment with topical antimicrobials, a further 10 patients in the Hydrofibre® 
group and a further 4 patients in the human allograft skin group finally had to undergo 
excision and grafting, which brings the total of operated patients to 18 (45%) in the 
Hydrofibre® group versus 6 (15%) in the human allograft skin group (P = 0.004, Mann–
Whitney). These data are summarised in Table 1. 
The average period until patients ended participation (either because their wounds were 
completely re-epithelialised or because of other reasons) was 10.1 days for the Hydrofibre
® 
managed subjects and 8.5 days for those subjects managed with human allograft skin (P = 
0.008, analysis of variance). Non-adherence of the dressing was observed in 17.5% of all 
Hydrofibre
®
 dressing changes and in 30% of all dressing changes in the human allograft skin 
group (not statistically significant). With respect to results on dressing comfort, Hydrofibre
®
 
was considered “easy to use” more frequently than human allograft skin (80.5 and 74.7%, 
respectively), approaching statistical significance (P = 0.051, Fisher’s exact). 
Wearing comfort when the dressing was in situ was better for Hydrofibre
®
, although no 
statistical significance was reached. Both dressings were considered easy to remove (87.7% 
of the dressings versus 92.2% for Hydrofibre
®
 and allograft, respectively). The number of 
dressings that were accompanied by pain upon dressing removal was not statistically 
different. In those subjects who experienced pain, the rating of pain level was not statistically 
different among the different materials tested, although dressing changes with Hydrofibre
®
 
scored lower (=better) on the visual analogue scale used. 
 
Table 1 - Incidence of spontaneous healing versus surgical interventions for Hydrofibre® and 
allograft skin groups 
 
Treatment (n = 40) 
Outcome  
No. patients with 
healing ≥95% (within 
study time) 
No. patients with healing after 
further treatment with local 
therapeutics 
No. patients 
requiring operation 
Hydrofibre  21 (52.5)  1 (2.5)  18∗
  
(45) 
Allograft skin  24 (60)  10 (25)  6∗
  
(15) 
∗ P = 0.004, Mann–Whitney. 
 
Outcome 
Skin elasticity was measured using the Cutometer 575®. In all cases, elasticity of the study 
area was expressed relative to the elasticity of a similar unaffected anatomical area (usually 
the contralateral side). The results are depicted in Fig. 3. At 10 weeks post-wounding, a 
statistically significant better elasticity was found in the human allograft skin group versus the 
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Hydrofibre
®
 group (0.97 versus 0.73, respectively, P = 0.010, Wilcoxon). This difference could 
be attributed to the patients that had not healed completely. After 6 months and 1 year, no 
statistically significant differences were noted in skin elasticity between both treatment 
groups. Other parameters measured by the Cutometer 575
®
, such as maximal deformation 
and immediate recovery of the skin were also higher in the allograft group, but did not reach 
statistical significance. The viscoelastic properties measured by the Cutometer 575
®
 did not 
differ between both groups. Hypertrophy was determined after 10 weeks and 6 months. The 
size of the study area that experienced hypertrophy was measured by planimetry. After 6 
months hypertrophy of the total group in percentage of the study burn area was 11.5% (range 
0–94%) for the Hydrofibre
®
 group versus 6.54% (range 0–59%) for allograft (n.s.) If we 
consider only those subjects that actually developed hypertrophy, the data were: 20.8% 
(range 0.24–94%) for the Hydrofibre
®
 group and 18.0% (range 0.46–59%) for the allograft 
group. Results after 10 weeks were essentially the same, indicating that hypertrophy 
developed relatively early in the healing process and persisted rather long. Incidence of 
hypertrophy was also measured: 21 out of 40 (52.5%) patients in the Hydrofibre
®
 group 
versus 12 out of 40 (30%) patients in the allograft group developed some hypertrophy (P = 
0.09, chi-square) after 6 months. Severe hypertrophy (defined as ≥10% of the study area) 
was experienced by 13 patients (32.5%) in the Hydrofibre® group versus 7 patients (17.5%) 
in the allograft group (n.s.). Scar assessment using an extended version of the Vancouver 
Scar Scale (mainly items on itching, pain and patient’s opinion were added) gave very similar 
results for the Hydrofibre
®
 and the human allograft skin group. Comparison of the data on the 
physician’s assessment of scar color and measurements of skin color using the Dermascan
®
 
showed a good correlation between the two data sets (Fig. 4). The erythema index for the 
study area was compared to a control area. No statistically significant differences were noted 
between the two groups. Although in both methods the units are arbitrary and cannot be 
compared directly, the scar maturation in time can be clearly noted from a reduction in skin 
colour as well as a reduction in the erythema index. Skin color assessment by means of the 
Vancouver Scar Scale normalised to 0 in time, whereas the erythema index approached that 
of the control areas. Scar maturation could also be noted from the reduction of itching that 
coincided with an improvement of the patient’s opinion (or his/her representatives in case of 
small children) on his/her scars (Fig. 5). Note that in Fig. 5A (patient’s opinion) the scale goes 
from 0 (worst possible scar) to 10 (normal skin), with the highest number reflecting a more 
positive judgment on the scar. 
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Fig. 3 - Skin elasticity measurements using Cutometer® 575. Elasticity (Ue) of the study area 
is expressed relative to the elasticity of normal skin of a similar anatomical location of the 
same individual. ∗ indicates a statistically significant difference (P = 0.010, Wilcoxon Rank 
Sum) between the Hydrofibre® and allograft group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 a - Assessment of scar color using the Vancouver Scar Scale (a) and the Dermascan 
spectrometer 
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Figure 4b - Dermascan measurements were performed for the study area (indicated ‘scar’) 
and normal skin of a similar anatomical location of the same individual (indicated ‘control’). 
 
 
 
 
Figure 5 a, b - Patient’s opinion in time. 
Fig 5 a - Note that 10 is the score for normal skin, whereas 0 is the score for the worst 
possible scar. An improvement of the patient’s judgment in time was seen for the Hydrofibre® 
as well as the allograft group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5b - Itching of the study area was reduced in time for both treatment groups. 
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Discussion 
 
The proper treatment of partial thickness burns has been the subject of debate and research 
for a number of years. It is generally agreed that early excision and grafting of deep burns 
reduces morbidity and mortality, whereas early excision of partial thickness burns remains a 
subject of debate. Removal of necrotic tissue reduces the risk of wound infection, however, 
surgical debridement down to viable tissue causes blood loss and inevitable sacrifice of 
healthy tissues
26
. When a burn diagnosed as partial thickness on the day of the accident, 
turns out to be—at least for the central part—full thickness, membranous dressings such as 
those described in this study will not become adherent. This can be used as a diagnostic tool. 
In cases of a non-adherent membranous dressing the local therapy is changed to topical 
antimicrobials to prevent infection. Nowadays, modern dressing materials enable a good 
conservative treatment, where risk of infection is not increased and maximal preservation of 
viable tissue can be achieved
4
. Since many years the use of allograft skin as a biological 
dressing for partial thickness burns has been advocated and glycerolised allograft has 
become the standard treatment for this category of burns in the Beverwijk Burn Centre
7,17
. 
However, the limited availability of allograft skin as well as the requirement of specific skills in 
its use reduces its potential as a first choice treatment for general practitioners and 
emergency room facilities. Putative advantages of a synthetic dressing for the treatment of 
partial thickness burns over allograft skin would be: off-the-shelf-availability also outside 
specialised burn centres, easy handling and fixation and possibly a cheaper treatment. 
Therefore, an alternative treatment regime, with potentially equally good results in terms of 
infection control, pain reduction and undisturbed re-epithelialisation was studied in a 
randomized controlled study. 
 
Wound healing 
One of the most striking observations in this comparative trial was the reduced incidence of 
surgical interventions in the human allograft skin group. Although both groups were not 
significantly different, there may have been some relation between this outcome and the fact 
that burns in the Hydrofibre
®
 group tended to be slightly larger and deeper. Differences in the 
final outcome with regard to skin elasticity at 10 weeks postburn are most likely related to this 
initial difference in incidence of surgical interventions. Nevertheless, this finding suggests that 
there is a direct relationship between surgical intervention needed for the closure of deep 
partial thickness wounds and a less favourable outcome in terms of scar quality. Data in the 
literature on frequency of skin grafting in similar trials are scarce. Peeters et al. described that 
31% of a group of 84 children with scald burns needed additional surgery after primary 
treatment with allograft skin
27
. A comparative study from Rose et al., on larger (30–34% 
TBSA) partial thickness burns indicated that 22% of the wounds treated with allograft versus 
10% of wounds treated with antimicrobials were operated
7
. These data were not statistically 
significantly different. Our results in the human allograft skin group (15% operations) are in 
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fact much better than previous results described by Brans et al.
28
 where more than 50% of the 
patients needed surgery. These differences may result from a change in the glycerolization 
procedure used by Euro skin bank, a different treatment regime (application of the dressings 
on day 1 rather than day 0 postburn, with pretreatment of the wounds with silver sulfadiazine 
cream for 1 day), or general improvements in patient care over time
29
. 
Also with regard to incidence of hypertrophic scarring not many quantitative data can be 
found in literature. The paper of Rose et al.
7
 describes that 18.5% of the patients in the 
allograft group versus 33% in the antimicrobial group experienced hypertrophy. The criteria 
how these data were established remain unclear, however. Again, the data on hypertrophy in 
our study groups were very similar: 17.5% incidence of severe hypertrophy (≥10% of the burn 
area) in the human allograft skin group versus 32.5% in the Hydrofibre
®
 group after 6 months 
postburn. In the group studied by Peeters et al.
27
 some 13% experienced hypertrophy, 
whereas Brans et al.
28
 reported an incidence of 21% moderate hypertrophy and 26% severe 
(>10% of the burned area) hypertrophy. There was a significant difference in duration of 
treatment between the two groups: 10.1 days for the Hydrofibre
®
 group versus 8.5 days for 
the human allograft skin group. Although these data were statistically significantly different, 
we think that the clinical relevance of this difference may be limited. Due to the fact that 
Hydrofibre® formed a relatively stiff crust when adherent to the wound bed, removal was 
done with utmost care to prevent renewed damage to the newly epithelialized skin. Therefore, 
edges of the dressing were cut away in repeated sessions on subsequent days, until the 
whole dressing was peeled-off completely. Removal of the adherent allograft skin was less 
problematic and may therefore have been completed at an earlier stage. Thus, the 
differences found in the duration of treatment may not actually reflect a longer healing time in 
either of the groups. 
 
Outcome 
Scar assessment was performed using different quantitative and subjective techniques. 
Although the study protocol ended after the 10 weeks follow-up evaluation, we decided to 
include scar assessments after 6 months and 1 year, to obtain a better view on the course of 
scar maturation in time. For this evaluation, we used several objective measurement 
techniques: Dermascan
®
 colour/pigmentation assessment and Cutometer 575
®
 for skin 
elasticity measurements, as well as the extended Vancouver Scar Scale subjective scar 
assessment. Evaluation of scar colour showed a good normalization after 1 year: the scores 
on the Vancouver Scar Scale approached 0 (normal skin) for both treatment groups, and the 
erythema measurements for study are and control areas showed similar results. Furthermore, 
it can be noted from the erythema measurements that the values for the control areas were 
constant in time, suggesting that this instrument indeed produces reliable measurements. 
Pigmentation indices for control skin as well as the study areas were constant in time (results 
not shown). A full validation of this instrument for scar assessment is currently being 
performed (L. Draayers, manuscript in preparation). Itching intensity is also an important 
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parameter for scar maturation. Also for this parameter, the scores approached 0 after 1 year 
postburn. Skin elasticity, as measured by the Cutometer
®
, was comparable to that of the 
control areas after 1 year. Finally, the patient (or his/her legal representatives) were asked to 
give their opinion as a general impression on scar quality. Generally, an increase in this 
judgment was noted in time, correlating with scar maturation. 
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Conclusion and recommendations 
 
Based on our earlier experience with human allograft skin and Hydrofibre® dressing and the 
results of this study we nowadays use Hydrofibre® dressings for partial thickness burns, not 
exceeding 5% TBSA and human allograft skin for burns between 5 and 20% TBSA. Larger 
burns and burns that are mainly partial thickness, but have minor deep dermal parts are 
treated with topical antimicrobials; secondary excision and grafting is performed within 12 
days postburn. 
 
 
Acknowledgements 
 
The contribution of Dr. Paul P.M. van Zuijlen, MD, in the statistical analysis of the data is 
gratefully acknowledged. This study was supported by grants from Bristol-Myers Squibb. 
  108 
References 
 
1. Johnson D, Pathirana PD. Toxic shock syndrome following cessation of prophylactic 
antibiotics in a child with a 2% scald. Burns 2002;28(2):181–4. 
2. Hermans MH. Results of a survey on the use of different treatment options for partial and 
full thickness burns. Burns 1998;24(6):539–51. 
3. Hermans MHE, Hutchinson JJ. The incidence of infection under dressings: a prospective 
comparative trial of hydrocolloid dressing, DuoDERM CGF, versus conventional 
dressings in the treatment of leg ulcers, burns and donor sites: an interim report. Exerpta 
Med1990;35–41. 
4. Hutchinson JJ. Prevalence of wound infection under occlusive dressings: a collective 
survey of reported research. Wounds 1989;1:123–33. 
5. Hermans MH, Hermans RP. Duoderm, an alternative dressing for smaller burns. Burns 
Incl Therm Inj 1986;12(3):214–9. 
6. Barret JP, Dziewulski P, Ramzy PI, Wolf SE, Desai MH, Herndon DN. Biobrane versus 
1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg 
2000;105(1):62–5. 
7. Rose JK, Desai MH, Mlakar JM, Herndon DN. Allograft is superior to topical antimicrobial 
therapy in the treatment of partial thickness scald burns in children. J Burn Care Rehabil 
1997;18(4):338–41. 
8. Demling RH. Use of biobrane in management of scalds. J Burn Care Rehabil 1995;16(3 
Pt 1):329–30. 
9. Bugmann P, Taylor S, Gyger D, Lironi A, Genin B, Vunda A, et al. A silicone-coated nylon 
dressing reduces healing time in burned pediatric patients in comparison with standard 
sulfadiazine treatment: a prospective randomized trial. Burns 1998;24(7):609–12. 
10. Kloppenberg FW, Beerthuizen GI, ten Duis HJ. Perfusion of burn wounds assessed by 
laser Doppler imaging is related to burn depth and healing time. Burns 2001;27(4):359–
63. 
11. Droog EJ, Steenbergen W, Sjoberg F. Measurement of depth of burns by laser Doppler 
perfusion imaging. Burns 2001;27(6):561–8. 
12. Pape SA, Skouras CA, Byrne PO. An audit of the use of laser Doppler imaging (LDI) in 
the assessment of burns of intermediate depth. Burns 2001;27(3):233–9. 
13. Zawacki BE. Reversal of capillary stasis and prevention of necrosis in burns. Ann Surg 
1974;180(1):98–102. 
14. Zawacki BE. The natural history of reversible burn injury. Surg Gynecol Obstet 
1974;139(6):867–72. 
15. Jackson DM. In search of an acceptable burn classification. Br J Plastic Surg 
1970;23(3):219–26. 
16. Jackson DM. A clinical study of the use of homografts for burns. Br J Plastic Surg 
1954;7:26. 
17. Pruitt Jr BA, Levine NS. Characteristics and uses of biologic dressings and skin 
substitutes. Arch Surg 1984;119(3):312–22. 
18. Vloemans AF, Soesman AM, Kreis RW, Middelkoop E. A newly developed hydrofibre 
dressing, in the treatment of partial thickness burns. Burns 2001;27(2):167–73. 
19. Lund CC, Browder NC. The estimate of area of burns. Surg Gynecol Obstet 
1944;79:352–8. 
20. van Zuijlen PPM. Perspectives on burn scar evaluation and artificial skin. Faculteit 
Geneeskunde, University of Amsterdam; 2002. ISBN:90-9015126-5. 
21. Hoekstra MJ, Hermans MH, Richters CD, Dutrieux RP. A histological comparison of acute 
inflammatory responses with a hydrofibre or tulle gauze dressing. J Wound Care 
2002;11(3):113–7. 
22. Sullivan T, Smith J, Kermode J, McIver E, Coutemanche DJ. Rating the burn scar. J Burn 
Care Rehabil 1990;11(3):256–60. 
23. van Zuijlen PPM, van Trier AJ, Vloemans JF, Groenevelt F, Kreis RW, Middelkoop E. 
Graft survival and effectiveness of dermal substitution in burns and reconstructive surgery 
in a one-stage grafting model. Plast Reconstr Surg 2000;106(3):615–23. 
24. Fullerton A, Fischer T, Lahti A, Wilhelm KP, Takiwaki H, Serup J. Guidelines for 
measurement of skin colour and erythema: a report from the Standardization Group of the 
European Society of Contact Dermatitis. Contact Dermatitis 1996;35(1):1–10. 
  109 
25. Takiwaki H, Serup J. Measurement of erythema and melanin indices. In: Serup J, Jemec 
GBE, editors. Non invasive methods and the skin. Boca Raton: CRC Press; 1995. 
26. Eldad A, Din A, Weinberg A, Neuman A, Lipton H, Ben-Bassat H, et al. Cryopreserved 
cadaveric allografts for treatment of unexcised partial thickness flame burns: clinical 
experience with 12 patients. Burns 1997;23(7–8):608–14. 
27. Peeters R, De Caluwe D, Neetens C, Hubens A. Use of glycerolized cadaver skin for the 
treatment of scalds in children. Burns 1994;20(Suppl 1):S32–3. 
28. Brans TA, Hoekstra MJ, Vloemans AF, Kreis RW. Long-term results of treatment of 
scalds in children with glycerol-preserved allografts. Burns 1994;20(Suppl 1):S10–3. 
29. Vloemans AF, Middelkoop E, Kreis RW. A historical appraisal of the use of cryopreserved 
and glycerol-preserved allograft skin in the treatment of partial thickness burns. Burns 
2002;28(Suppl 1):S16–20. 
  
  110 
  
  111 
Part IV 
 
 
Mepitel® for skin graft fixation 
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Justification  
 
Historical perspective  
Previous to the market-introduction of a silicone net dressing (Mepitel®) we were asked by 
the manufacturer to investigate its possible application for burn wounds.  
Wound dressings for burns can be considered as part of a wound management system, 
consisting of several components. The first layer is a wound contact layer, which allows 
adequate drainage of the wound exudate, is non-adhesive to the wound, but adhesive to the 
surrounding intact skin. It should also be able to transfer topical antimicrobials to the wound 
surface. The second layer may contain topical antimicrobials, such as Betadin®, 
Nitrofurazone® or silver. The main functional requirement of this layer is absorption of wound 
exudate and release of the topical antimicrobials. Nowadays, also topical negative pressure 
can fulfil the function of a second layer. 
We considered Mepitel® to be an intermediate first layer wound dressing, with enough open 
spaces to allow drainage of wound fluids. We expected a non-traumatic and painless dressing 
change because of the silicone covering of the nylon net. Moreover the adherence of the 
material to healthy skin was thought to be useful for fixating an underlying structure, such as a 
strip of allograft skin or an autologous split thickness skin graft. 
Therefore a clinical study was initiated investigating the properties of Mepitel® as an 
intermediate fixating dressing for split skin grafts in children
1
. This article was the first 
published clinical study on Mepitel®. One year later, Williams
2
 described several advantages 
of Mepitel® over paraffin gauze, with regard to pain free secondary dressing changes and 
removal, without damage to the wound.  
 
Clinical studies on Mepitel® 
Over the years, several possible indications for application of Mepitel® were given such as 
coverage of burns, painful surgical and traumatic wounds, abrasions and fixation of skin 
grafts, treatment of dermatological diseases such as epidermolysis bullosa. Many clinical 
studies on these subject followed. In 2009 White et al
3
 summarized the published clinical data 
of randomized controlled trials (RCT), non-randomized controlled trials and case-studies on 
the application of Mepitel®. Following the example of White, we did an electronic search in 
PubMed to identify clinical data in relation to burns, skin disorders and Mepitel® (search term: 
Mepitel, 48 hits, selected for relevance in clinical studies on burns, donor sites, trauma and 
surgery, dermatological disorders and leg ulcers, 33 studies identified). The summary of the 
33 clinical studies is given in table 1.
  113 
Table 1 - Summary of clinical studies on Mepitel®, 1994 – 2011. 
 
Reference Type of study Sample (n) Wound type/skin injury 
Vloemans AF et al (1994)
1 
NRCT 38 Split skin graft 
Adamietz IA et al (1995)
4 
NRCT 21 Skin protection in irradiated skin 
Dahlstrøm KK (1995)
5 
RCT 64 Wound bed preparation 
Williams C (1995)
2 
CS 4 Surgical, traumatic digit amputation, toenail avulsion 
Platt AJ et al (1996)
6 
RCT 38 Split skin graft 
Bugmann P et al (1998)
7 
RCT 76 Paediatric burns 
Gotschall CS et al (1998)
8 
RCT 63 Paediatric burns 
Lapioli-Zufelt A et al (1998)
9 
CS  1 Epidermolysis bullosa 
Spitz C et al (1998)
10 
CS 1 Epidermolysis bullosa 
O’Donovan DA et al (1999)
11 
RCT 45 Fingertip injuries 
Taylor R (1999)
12 
CS 1 Mycosis fungoides 
Gates A (2000)
13 
CS 1 Leg ulcers 
O'Donoghue JM et al (2000)
14 
RCT 30 Split skin donor sites 
Newman JP et al (2000)
15 
NRCT 125 Laser resurfacing 
Terril PJ et al (2000)
16 
RCT 99 Hand surgery wounds 
Williams G et al (2001)
17 
CS 2 Paediatric burns 
Meuleneire F (2002)
18 
NRCT 59 Skin tears 
Young MJ (2002)
19 
CS 1 Diabetic foot ulcers 
Burton F et al (2004)
20 
NRCT 52 Traumatic wounds 
Chavez B (2004)
21 
CS 1 Split skin graft 
Hall S (2004)
22 
CS 1 Epidermolysis bullosa 
Kennedy-Evans KL(2004)
23 
CS 1 Skin tears 
Moisides E et al (2004)
24 
RCT 20 Negative Pressure therapy 
Lahiri A et al (2006)
25 
CS 1 Aplasia cutis congenita 
Terrazas SG (2006)
26 
CS 1 Negative Pressure Therapy in burns 
Dissemond J et al (2006)
27 
CS 1 Negative Pressure Therapy in burns 
Poulidakis S et al (2008)
28 
CS 1 Negative Pressure Therapy in burns 
Ahmadi H et al (2009)
29 
CS 1 Paediatric burns 
Rando T (2009)
30 
CS 2 Leg ulcers  
Markl P et al (2010)
31 
CS 2 Split skin donor sites 
Strand et al (2010)
32 
Cohort Study 48+126 Paediatric burns 
Campanella et al (2011)
33 
RCT 15 Split skin donor sites 
Greenwood JE et al (2011)
34 
CS 1 Negative pressure therapy 
 
Randomized controlled trials (RCT), non-randomized controlled trials (NRTC), cohort studies 
and case-studies (CS) on the application of Mepitel®, in chronological order. 
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Indications for Mepitel® 
A chronological overview of the number of publications in time is depicted in fig. 1. Since the 
first publication in 1994, almost every year some clinical studies were published on Mepitel® 
as a dressing for several indications, even in recent years. Since 1996, four studies appeared 
on Mepitel® as an intermediate dressing for negative pressure therapy. Economic aspects of 
two different treatment modalities on burn wound treatment in children were described by 
Strand et al
32
 in a retrospective cohort study. 
Table 2 shows the number of studies per indication. Most studies were on surgical and 
traumatic wounds and on several dermatological skin disorders that are associated with a 
vulnerable wound or skin that was easily disrupted with conventional dressings. Five studies 
were on burns, three of which were about treatment of burns with Mepitel® compared to a 
conventional or newer dressing
7,8,32
. Two studies were on long-term side effects of 
Mepitel®
17,29
. 
In five studies Mepitel® was combined with negative pressure therapy as an a-traumatic 
wound contact layer as the foams often used in this therapy are sometimes difficult to remove 
and may damage the wound bed 
25-28,34
. In a pre-hospital study Jones et al investigated the 
influence of three interface dressings on the delivery of topical negative-pressure therapy
35
. 
This study showed that Mepitel® did not influence the pressure in 70% of the cases, but in 
30% a reduction of wound surface pressure was found.  
Three clinical studies were on split skin donor site treatment. In the study by O'Donoghue JM 
et al
15
 calcium alginate proved to be superior; in the study of Markle P et al
31
 Biatain-Ibu® 
was considered better; remarkably, in both studies treatment with Mepitel® was found to be 
painful. In one study in 15 children, Mepitel® was compared to Surfasoft® in donorsites 
treated with ReCell®
33
. Mepitel® was less painful to remove.  
Besides a case study by Chaves
21
, there was one more comparative study on skin graft 
treatment with Mepitel® by Hall
22
. The remaining three case studies were on leg ulcers and 
diabetic foot treatment
13,19,30
. 
O’Donoghue et al
14
 described problems in dressing removal by plug formation of wound 
exsudate within the fenestrations of the dressing. In our first description of the clinical use of 
Mepitel, we also noticed this. An adequate solution for this problem by soaking the dressing 
was also described.  
 
Conclusion 
Eighteen years after the first publication, Mepitel® is still widely used in clinical practice on a 
wide range of traumatological, surgical and dermatological skin conditions. The main reason 
the dressing is used is the described non-adherence to wounds and the atraumatic removal 
from wounds and vulnerable skin. In recent years Mepitel® is also combined with negative 
pressure therapy. 
Mepitel® is still a valuable addition to the range of dressing materials for various types of 
wounds.
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Fig. 1 - Frequencies of publications on Mepitel® from 1994 to 2011 
 
 
 
Table 2 - Number of studies on Mepitel® arranged by indication. 
 
Indication Number of studies 
Surgical and traumatic wounds 7 
Dermatological disorders 7 
Burns 5 
Negative pressure therapy 5 
Split skin donor sites 3 
Split skin grafts 3 
Ulcers 3 
Total 33 
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Chapter 7 
 
 
Fixation of skin grafts with a new silicone rubber dressing 
(Mepitel®) 
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Abstract.  
 
A new silicone rubber dressing material, Mepitel
®
 was tested as an alternative to Surfasoft
®
 
and staples or sutures and a vaseline gauze for the fixation of 45 split skin grafts in 38 
children. Almost all grafts took completely. No graft was lost because of inadequate fixation. 
The main advantage over fixing the graft with SurfaSoft
® 
combined with staples, or a Vaseline 
gauze combined with sutures, is that the removal of the dressing is painless, and neither the 
graft nor the wound is disturbed. 
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Introduction 
 
Whether a split skin graft takes is dependent on the quality of the wound bed, but the amount 
of ingrowth of the graft can be affected by several other factors. Freshly applied split skin 
grafts are vulnerable to mechanical displacement during the first postoperative days, when 
ingrowth is not yet fully established. Wounds grafted with widely expanded mesh grafts 
(expansion ratio more than one to two) are prone to desiccation and infection, as the grafts 
fail to provide effective wound coverage until epithelialisation is advanced. This may also 
cause loss of the graft. Finally the graft may be destroyed at the time of removal of the 
dressing material, due to adherence of the graft and the open wounds to the dressing. 
Dressing materials for split skin grafts should ideally meet the following requirements. 
Mechanical displacement from the wound bed must be impossible. The dressing material 
must allow drainage of serous wound exudate and haematoma, and also allow antibacterial 
solutions to reach the wound. At the time of removal, the dressing should not adhere to the 
graft and open areas of the wound. It is a common practice to use vaseline gauze as a 
dressing, with the graft fixed to the wound bed with stitches, though a better technique is the 
combination of Surfasoft® and staples
1
. A new dressing material, Mepitel
®
 (Mölnlycke), was 
tested in an open prospective study to see if it was an improvement for the fixation of split 
skin grafts. 
 
Material and methods 
 
Mepitel consists of a polyamide net, impregnated with a silicone gel. It has an open structure 
with 14 pores/cm
2
 each with a diameter of 1.2 mm. After the split skin graft had been applied 
to the wound bed, Mepitel was placed over the graft and over a margin of surrounding healthy 
skin (Figs. 1,2). No stitches or staples were used. A cotton wool gauze soaked in an 
antibacterial solution was then applied and finally the dressing was completed with a bandage 
and an elastic net dressing. Daily or every other day the outer bandage was changed. On the 
fifth to seventh day after operation the Mepitel dressing was removed and the take of the graft 
was established by two doctors and a trained nurse. The degree of “take” was divided in four 
categories: >95%, complete take; 75-95%, almost complete take; 50- 75%, poor take; <50%, 
almost complete graft loss. All patients were admitted to the Burns Centre or the Childrens 
Burns Centre of the Red Cross Hospital in Beverwijk. As the removal of stitches or staples is 
painful and requires analgesics or even general anesthesia in children, we expected to see 
most benefit in children, so only children below the age of 13 years were entered into the  
study. Thirty-eight children, mean age 4.1 years (range 0.5-13) were included. Third degree 
skin defects were the result of scalds (n = 19), flame burns (n = 10) and contact burns (n = 4). 
In five cases the skin defect resulted from another traumatic skin lesions. Forty-five split skin 
grafts were performed: on the trunk (n = 8), the arms and legs (n = 15 each); neck and hand 
(n = 1 each), and the trunk, and arm (n = 5). The mean area grafted was 1.9% of the total 
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body surface area (range 0.54%). In two cases a full sheet split skin graft was used, in all 
others we used a mesh graft with expansion ratios of 1:1.5 (n=24), 1:2 (n=15),1:3 (n=2), and 
1:4 ( n=2 ) .The antibacterial dressing consisted of gauze soaked in a Furacine solution 
(nitrofurazone 0.2% in polyethylene glycol 400) or a solution of chlorhexidine 1% in 
polyethylene glycol 400 35%, glycerol 35%, and water. 
 
Fig. 1 - Mesh graft applied to a tangentially   Fig. 2 - Mepitel
®
 covering a split skin grafted 
excised wound bed.              wound bed. 
 
 
Results 
 
There were no wound infections, although two patients developed small haematomas 
underneath the graft. Haematomas and wound exudate drained satisfactorily through Mepitel. 
Removal of the outer dressing was painless, as was the final removal of the Mepitel. No 
analgesia or anesthesia was needed for the changes of dressings. Though Mepitel tends to 
curl at the edges, and there was a little displacement near joints and other areas of the body 
where the skin is mobile, none of the grafts became displaced. No displacement of the skin 
graft was seen in other areas. Three take rates ended up in category 2 (75-95%). Due to 
formation of hematoma underneath the graft and remnants of necrosis in the wound bed, 
parts of the grafts did not take. In 42 cases the take was almost complete, category 1 (>95%). 
 
Discussion 
 
To use Mepitel to fix split skin grafts requires a margin of healthy skin around the wound, so 
its use is therefore limited to minor skin grafts. In this study the maximum size was 6% of the 
total body surface area. In addition it can only be used on flat (trunk) or convex (extremities) 
areas of the body. In concave areas such as the neck, the axilla, and the groin, firm fixation is 
either difficult or impossible. If there is no margin of healthy skin around the wound, (in 
concave areas or for major skin grafts) we prefer to fix grafts with SurfaSoft and staples. 
The main advantage of Mepitel is that it makes it easy and painless to change the additional 
dressings, which allows frequent dressing changes before the final removal of the interface 
dressing and the painless removal of the silicone material from the graft, without disturbance 
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of open wound areas such as spaces between the grafts, the holes in the mesh and at the 
edges of the graft. No anaesthesia is necessary and in some cases the dressing can be 
removed by the child himself. In two cases the Mepitel had become stuck to parts of the open 
wound by small plugs of exudate in the pores. This problem was overcome by soaking the 
dressing with saline before removal. 
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Abstract 
 
A large part of the population of a burn centre consists of children, mostly below 4 years of 
age. These young children often suffer from superficial and deep partial thickness scald burns 
that may easily deepen to full thickness burns. A proper wound therapy, that prevents 
infection and ensures a moist wound condition, might prevent the deterioration of the wound. 
We performed a systematic review to wound management and dressing materials for children 
with burns. 
A search in Medline and Embase revealed forty-five articles for a critical appraisal. The 
articles were divided in randomized controlled trials, cohort studies and a group of case-series 
and case-reports. Total appraisal did not differ much between the groups; level of evidence 
was highest in the randomized controlled trials and lowest in the case-series and case-
reports. 
In fifteen out of thirty comparative studies silver sulfadiazine or Silvazine was the control. The 
dressing that was compared with the control was Biobrane® in four studies and amnion 
membrane in three studies. Tulle gauze, or tulle gauze impregnated with an antibacterial 
addition was the control in seven studies. 
Considering epithelialisation rate, length of hospital stay and pain, membranous dressings like 
Biobrane® and amnion membrane performed better than the control. However hardly any of 
the studies investigated long-term results like scar formation. 
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Introduction 
 
In most burn centres in the world, a large part of the patient population consists of children. In 
the Netherlands, about 45% of the patients admitted to a Burn Centre is below 17 years of 
age. Between 1995 and 2007, 2682 children were admitted to a Dutch burn centre. Almost 
70% of these children was younger than four years. They suffer from scald burn injuries in 
over 84% of the cases. For children between five and seventeen years of age the aetiology of 
the burns is about the same as for adults: roughly 60% flame burns and 20% scalds. The 
majority of scald burns is partial thickness depth, as was seen in the group of young children.
1
 
Recent studies conducted in Western Australia and the Czech Republic showed similar high 
frequencies of scald burn injuries in the group of young children. 
2,3
 
Compared to adults, children have a thin skin, especially those between 0-4 years old. 
Because of their thin skin even a small quantity of hot fluid, such as a cup of tea or a mug of 
soup, may inflict a serious burn. Moreover, burns in children often affect anatomically 
important areas such as the face, neck, shoulder and hands. Dewar et al found that in scalds 
caused by hot beverages in children, the anterior torso was affected in 65%, the upper limbs 
in 51%, the head and neck in 39% and the legs in 26%.
4
 
 
Infection prevention and the promotion of a moist wound environment to prevent deepening of 
the wound nowadays form the basis of the wound treatment in children.
5
 The choice for a 
wound dressing in a child with burns should meet these requirements. However, most wound 
dressings that are currently available on the market were originally developed for the 
treatment of chronic wounds. Since there is abundant choice of different dressing materials 
and topical treatment modalities, it is not easy to determine which materials should be 
preferred for a specific wound type. 
Because of the thin skin in children and the different physiology and specific aetiology of the 
injury, some dressing materials may be better suited for the treatment of burns in the younger 
age group. We performed a literature search to investigate wound management and dressing 
materials specifically for children with burns. 
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Methods 
 
Search strategy 
In April 2011, we conducted a structured literature search in Medline (1996-11 to present) and 
Embase. Our search domain was defined as patients under 18 years of age with burns 
accompanied by the determinant which was considered a topical wound dressing. The 
outcome was defined as (re)epithelialization (short term) and scar formation (long term). 
Synonyms and syntax structure including the domain and determinant are shown in Figure 1. 
In total, 2323 articles were found. After excluding doubles (n=959), an independent 
title/abstract screening was performed by two reviewers based on the following inclusion 
criteria: The presence of our previously described domain and determinant and in case no 
abstract was available the title was included to read the article. Seventeen articles were 
irretrievable and 70 articles were excluded for not containing our third and last criterion for 
relevance: outcome. Finally, 45 articles remained for a critical appraisal. 
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Fig. 1 - Flow diagram for the selection of the studies. 
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Critical appraisal 
 
We performed a critical appraisal based on the Centre for Evidence-Based Medicine 
(Toronto) guidelines (CEBM) by determining items to score for relevance and validity.
6
  
Relevance was scored on articles only concerning children, and only children under the age 
of 4 years old, only partial thickness burns, time post burn of the first application of treatment 
material and at least one item describing the outcome.  
As partial thickness scald burn in children under the age of four are most common, and as 
these children have a thin skin that makes them vulnerable for thermal lesions, we added 
children under the age of four to the domain.  
Partial thickness burns are prone to deepening, also known as conversion, but a wound 
dressing might be able to influence and prevent this process.
5,7
 We therefore defined the 
treatment modality and the time of application as the determinant. As scar formation in 
children is a major problem, follow-up was evaluated as an outcome parameter, with specific 
attention to long-term follow up. (Table 1) 
Our primary interest was in the outcome results; therefore most points were allocated to short 
and long-term outcomes. Short-term outcome results were considered as days of hospital 
stay, time to re-epithelialization, need for grafting and complications such as infection or pain 
at dressing changes. Long-term results were scar formation and contractures that required 
reconstructive surgery. 
Validity was scored at study design, number of patients, blinding, selection bias, length of 
follow-up and loss-to follow-up (Table 1). As the study design determines for a large part the 
level of evidence and thereby the quality of the study, we arranged the studies in three 
groups, a-c (Table 2). Subsequently, all articles were scored using the Levels of Evidence of 
the CEBM.
6
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Table 1 - Critical appraisal based on the Centre for Evidence-Based Medicine (Toronto) 
guidelines
6 
http://ktclearinghouse.ca/cebm/practise/ca/therapyst/validity2 
 
Relevance (domain, determinant, outcome) 
 
1. Patients 
a. Children (<18 years)  1 
b. Adults and children  0 
 
2. Children 
a. All children under the age of 4 years  2 
b. All children, ages mentioned  1 
c. All children, ages not mentioned  0 
 
3. Burns 
a. Only scald burns or only partial thickness burns  2 
b. Partial and full thickness burns, other treatment mentioned for full 
thickness burns  1 
c. Differences between treatment of partial and full thickness burns 
not mentioned  0 
 
4. Time to application of topical treatment or dressing 
a. within 48 hours post burn  1 point 
b. Not mentioned or  >48 hours post burn  0 points 
 
5. Short term outcome; hospital stay, re-epithelialization, need for grafting, 
complications (infection and pain scores) 
a. 4/4  3 
b. 3/4   2 
c. 2/4  1 
d. <2  0 
 
6. Long term outcome 
a. Scar formation and evaluation  3 
b. No long term outcomes  0 
 
Total relevance: max 12 points 
 
Validity 
1. Study design: 
a. Randomized controlled trial  2 
b. Cohort study  1 
c. Other design  0 
 
2. Number of included patients: 
a. ≥ 25 patients  1 
b. <25 patients  0 
 
3. Blinding 
a. Yes  1 
b. No  0 
 
4. Allocation concealment? 
a. Method of randomization mentioned  1 
b. Unclear or not applicable  0 
 
5. Follow-up: 
a. ≥ 1 year  1 
b. < 1 year  0 
 
6. Loss to follow-up:  
a. ≤20%  1 
b. >20%  0 
 
Total validity: max 8 points 
n.a= not applicable 
Study size = number of children included in the study 
? = no information 
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Table 2a - Randomized controlled trials
 
 
Study Study 
design 
Number of 
patients 
(wounds) 
Age in 
months 
Burn depth TBSA(%) Type of treatment Best outcome Difference Total 
appraisal 
out of 20 
Level of 
evidence 
Marichy 
‘84
17
          
 
RCT 49/50 Mean 45 
 
PT & FT 
 
BUS index 14.9 / 
15.1 
Solcoseryl® / Acexamic 
acid or Tulle gras or 
placental extract ointment 
Solcoseryl® Relative Cure Rate 
LOS 
Less septicaemia 
 
8 2b 
Cockington 
‘89
9
        
 
RCT 13/12/14 Not 
specified 
SPT <10 SSD / Jelonet® / Opsite®  Opsite®  Nurses preference 
Infection in Jelonet group 
5 2b 
Bugmann 
‘98
10
           
RCT 30/36 3-180 PT 2,1 SSD / Mepitel® 
 
Mepitel® Healing time 7 1b 
Gotschall 
‘98
11
         
 
RCT 33/30 <144  PT <15 SSD / Mepitel®  Mepitel® Healing time 
Less eschar formation 
Less pain 
Less costs 
 
10 1b 
Lal ‘ 99
12
             
 
RCT 48 /41 Mean 
3.1 
SPT 11.6 SSD / Biobrane® Biobrane® LOS 
Time to healing 
 
12 1b 
Barret ‘00
13
            
 
RCT 10/10 Mean 
3.4 
PT 8.4 SSD / Biobrane® Biobrane®  Pain 
Pain medication requirement 
LOS 
Wound healing time 
 
10 1b 
Kumar ‘04
8
  RCT 33 
(21/20/17) 
Not 
specified 
PT Mean 5 Silvazine® / TransCyte® / 
Biobrane® 
Transcyte® and 
Biobrane® 
superior 
Fewer dressing changes 
Faster healing in the Transcyte® group 
Less autografting in the Transcyte® group 
 
12 1b 
Cassidy 
‘05
16
 
RCT 37/35 36-216 SPT & MPT <10 Duoderm® / Biobrane® No difference Duoderm less expensive 9 1b 
Glat ‘09
14
             
 
RCT 12 /12 2-216 SPT & MPT 1-10 SSD / SilvaSorb Gel® SilvaSorb Gel® Reepitheliazation < 21 days in more cases  
Less pain 
 
9 1b 
Mostaque 
‘11
15
     
RCT 51/51 <144 SPT & DPT 12.2 SSD / Amnion membrane Amnion 
membrane 
Time to epithelialisation 
LOS 
Less dressing changes 
 
9 1b 
TBSA: Total Body Surface Area, PT: partial thickness, SPT: superficial partial thickness, FT: full thickness, MPT: mid-partial thickness, DPT: deep partial thickness, BUS: burned body surface + (3x surface of FT), 
SSD: silver sulfadiazine, LOS: length of stay, SSG: split skin graft 
 
  135 
 
  
  136 
 
Table 2b1 - Cohort studies (comparative) 
 
Study Study 
design 
Number 
of 
patients 
(wounds) 
Age in 
months 
Burn 
depth 
TBSA (%) Type of treatment Best outcome Difference Total 
appraisal 
out of 20 
Level of 
evidence 
Walker ‘77
18
            
 
Prospective 37/73 Mean 55.2 PT & FT Not specified 
 
Amnion membrane / Furacin Amnion 
membrane 
Fewer split skin grafts, 
shorter LOS 
8 3b 
Waymack ‘85
19
    
        
Prospective 10/10 12-180 PT 4-23 Aquaphor gauze / SSD None No difference 8 3b 
Ozcan ‘02
20
             
 
Prospective 49/29/41 38.4 PT 12.3 Enzymatic debridement / 
enzymatic debridement + 
surgical excision / early 
tangential excision 
 
Enzymatic 
debridement 
Shorter LOS, less need for 
surgery, less need for blood 
transfusion 
8 3b 
Rab ‘05
21
           
 
Prospective 22/14 27.7 PT & FT 18.0 Allogeneic cultured 
keratinocytes / autologous skin 
graft 
Allogeneic 
cultured 
keratinocytes 
Less blood volume 
substituted, higher number of 
children without transfusion, 
TBSA covered with SSG 
VSS better 
11 3b 
Akita ’06
22
             
 
Prospective 10/10 8-36 SPT & DPT Mean 7.0  
(2-14) 
Basic fibroblast growth factor / 
Ointment impregnated gauze 
 
Basic fibroblastic 
growth factor 
Better scarring, well organized 
stratum corneum 
11 3b 
Hosseini ‘08
23
  
 
Prospective 51/35 1-180 PT & FT <5 Xenoderm ®/ SSD Xenoderm® Lower mortality, shorter LOS, 
less dressing changes 
6 2b 
Zajicek ‘10
27
           
 
Prospective 43/43 Mean 20 
(15-290) 
SPT Mean 7  
(4-10) 
Xe-Derma® / Askina® 
THINSite® 
 
XeDerma® Lower number of 
reapplications 
8 2b 
Burke ‘76 
25 
Retrospectiv
e 
100/100 
 
4-180  Not 
specified 
<65% AgNO3 0.5% / primary excision Primary excision Mortality and morbidity 
Time to wound closure 
LOS 
 
4 4 
Piserchia 
‘81
26
 
 
Retrospectiv
e 
10/12 7-132  SPT Mean 21.8 Amnion membrane / Sofra tulle® Amnion 
membrane 
Shorter LOS, less wound 
infection, less analgesics 
8 3b 
Tjong ‘83
2
             
 
Retrospectiv
e 
74 / 50 < 156 Not 
specified 
Mean 6.7 / 6.5, < 
15 
SSD or early tangential excision 
and autografting / allograft skin 
 
Allograft skin Less hypertrophic scarring 10 4 
Kudlácková 
88
28
 
Retrospectiv
e 
56/89 
 
Not 
specified 
DPT & FT Mean 12.5  
(4-35) 
SSD / tulle gauze + chloramine 
 
SSD Reduced bacterial 
contamination 
6 4 
Lloyd ‘89 
29
            Retrospectiv
e 
53/31/16 <144 Not 
specified 
<20% Aserbine / Daromide / SSD None None 
 
8 4 
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Table 2b1 - Cohort studies (comparative) [continuation] 
Study Study design Number 
of 
patients 
(wounds) 
Age in 
months 
Burn 
depth 
TBSA (%) Type of treatment Best outcome Difference Total 
appraisal 
out of 20 
Level of 
evidence 
Rose ’97
30
             
 
Retrospective 27/30 Not 
specified 
PT Mean 31  
(20-75) 
Allograft / topical antimicrobial 
therapy 
Allograft skin More rapid re-epithelialization, 
increased patient comfort 
 
12 3b 
Delatte ‘01
31
           
 
Retrospective 43/130/57 Mean 
5.5/5.6/4.9 
PT Mean 9.3 / 4.5 / 
13.9 
Beta-Glucan Collagen / standard 
treatment / split thickness skin 
graft 
none none 8 4 
Lukish ‘01
32
            
 
Retrospective 20/20 37.2±9.6 PT 14.3±1.4 / 
12.7±1.3 
Antimicrobial gent + 
hydrotherapy / TransCyte® 
 
Transcyte® Shorter LOS 8 3b 
Cuttle ‘07
33
           
 
Retrospective 241 / 328 5.2 / 48.8 PT & FT Mean 5.2 / 4.4 Acticoat® / Silvazine® Acticoat® Shorter time to re-
epithelialization for non-grafted 
group, lower percentage of 
children requiring skin graft 
and lower percentage 
requiring long term scar 
treatment 
 
5 2b 
Kazmierski 
‘07
34 
Retrospective 25/31/33/ 
19/17 
3-216 DPT 3-40 Excision and grafting / 
mechanical dermabrasion / 
Duoderm / enzymatic dressing / 
Aquacel Ag® 
Mechanical 
dermabrasion in 
burns <10% 
TBSA, Excision 
and grafting in 
burns >20% 
 
Various reasons 10 2c 
Paddock ‘07
35
           
 
Retrospective 39/40 Not 
specified 
PT <22 Aquacel Ag® / SSD Aquacel Ag® Shorter LOS 6 2b 
Martin ‘09 
36
           
 
Retrospective 109/139 50.9(1-180) 
 
 
PT 9.4 (0.5-40) Duoderm® / Jelonet® Duoderm® Less debridement and 
autologous split skin grafting 
10 2b 
Saba ‘09
37
 
 
Retrospective 10/10 Mean 41.5 
(3-180)  
PT Mean 16.0  
(5-30) 
Aquacel Ag® / Petrolatum gauze 
with Bacitracin Zinc Ointment 
Aquacel Ag® Shorter LOS, less nursing 
time, less pain, shorter time to 
re-epithelialization 
 
9 3b 
TBSA: Total Body Surface Area, PT: partial thickness, SPT: superficial partial thickness, FT: full thickness, MPT: mid-partial thickness, DPT: deep partial thickness, SSD: silver sulfadiazine, LOS: length of stay, SSG: 
split skin graft, VSS: Vancouver Scar Score 
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Table 2b2 - Cohort studies (non-comparative) 
 
Study Study design 
specified 
Number 
of 
patients 
(wounds) 
Age in months Burn depth TBSA (%) Type of treatment Outcome Total 
appraisal 
out of 20 
Level of 
evidence 
Lobe ‘80
38
              Prospective 10 Not specified SPT & DPT Not 
specified 
Polyurethane film ‘Comfortable, fewer dressing changes, faster epithelialization 
in many cases’ 
 
8 4 
Thomson ‘81
39
           Prospective 14 Mean 74.4 
(2.4-192) 
PT Mean 39 
(1-81) 
Amnion 
membrane 
Cost effective 
Acceptable as an intermediate dressing 
 
6 4 
Siim ‘89
40
              Prospective 10 Mean 18  
(10-144)  
Not specified Mean 6.9 
(2-15) 
Amnion 
membrane 
No advantages or disadvantages over conventional exposure 
treatment 
 
7 4 
Yanaga ‘01
41
           Prospective 43 Mean 5.1(4-17) DPT Mean 30.7  
(5-75) 
Cryopreserved 
cultured epidermal 
allografts 
 
‘Early closure of the wound and good functional outcome’ 12 2b 
Letouze ‘04
42
           Prospective 77 12-144 SPT & DPT Mean 42.4 
cm
2 
Lipidocolloid 
dressing 
 
Efficacious and well tolerated 8 2b 
Borsuk ‘07
43
            
 
Prospective 15 Not specified ST and DPT 8 Silver-coated 
nylon dressing 
(Silverleaf®) 
 
As effective as other silver dressings, less traumatic, less 
costly than silver sulfadiazine, absence of dressing residu 
10 2b 
Gravante 
‘07
44
         
 
Prospective 300 Mean 55.7 (SD 
50.9) 12-192 
SPT & DPT 17.7 
(SD13)  
4-50 
 
Hyalomatrix PA 
after dermabrasion 
‘Dermabrasion combined with a dermal substitute could be a 
good and reasonable approach for the treatment of PT burns’ 
13 2b 
De Mey ‘86
45
            Retrospective 725 
 
< 60 PT & FT Mean 7.8 
 
SSD  6 2b 
Gonzalez ‘86
46
         Retrospective 153 
 
Not specified PT & FT Not 
specified 
Abrasion ‘Early assessment of depth and extension of the wound, 
removal of necrotic tissues, thus avoiding the production of 
toxins, decreases loss of fluids and reduction of infection risk, 
rapid wound healing’ 
 
10 4 
Ou ‘97
47
                Retrospective 106 Mean 35 PT 11.4±9 Biobrane® Suitable for PT burns 
 
7 4 
Lang ’05
48
              
 
Retrospective 84 Mean 38.4±34.8 PT Not 
specified 
Biobrane® Effective, less traumatic for superficial burns 12 2b 
TBSA: Total Body Surface Area, PT: partial thickness, SPT: superficial partial thickness, FT: full thickness, MPT: mid-partial thickness, DPT: deep partial thickness, SSD: silver sulfadiazine 
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Table 2c - Case series and case-reports 
 
Study Study design 
specified 
Number of 
patients or 
wounds 
Age in 
months 
Burn depth TBSA (%) Type of treatment Outcome Total 
appraisal 
out of 20 
Level of 
evidence 
Bauer ‘84
49 
Case series 13 Mean 40  
(0.5-10) 
Not specified 40 (25-75) AgNO3 10%  Pain relief, reduction of circulatory 
instability, simply to apply and economical 
 
5 4 
Williams ‘01
50
          Case reports 2 24 and 
96  
PT 12 and 10 Mepitel® Hypopigmentation in interstices of 
dressing 
 
6 5 
Ahmadi ’B 09
51
  
 
Case report 1 216 PT 16 Biobrane® Scars corresponding to pores of dressing 10 5 
Ahmadi ’ M 09
52
  
 
Case report 1 36 PT 5 Furacin and 
Mepitel® 
Scars corresponding to pores of dressing 12 5 
TBSA: Total Body Surface Area, PT: partial thickness, SPT: superficial partial thickness, FT: full thickness, MPT: mid-partial thickness, DPT: deep partial thickness, SSD: silver sulfadiazine, 
LOS: length of stay, na: not applicable 
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Results 
 
Figure 1 shows the steps that were taken for the identification and selection of the studies. In 
the end, the search yielded 45 articles on the treatment of partial and full thickness burns in 
children.  
As expected, there was great heterogeneity between the included studies. None of the 
studies had the same age groups; Total Body Surface Area (TBSA) of subjects and outcomes 
and study designs varied. For these reasons, pooling was impossible. Based on the study 
design, the studies were divided in three groups: randomized controlled trials (group A), 
cohort studies (group B) and a group with case series and case reports (group C) (Table 2). 
The group of cohort studies was subdivided in comparative and non-comparative studies; 
subsequently, each of these groups was sub-divided in prospective studies and retrospective 
studies (Table 2B-1 and 2B-2).  
Total appraisal scores for groups A, B-1, B-2 and group C differed little; mean values were 
9.1, 8.4, 9.0 and 8.3 respectively. As could be expected, the level of evidence was highest in 
group A (1b and 2b), lower in group B (2b to 4) and lowest in Group C (4-5). 
An overview of the treatment modalities is given in table 3.  
  142 
Table 3 - Frequency of treatment modalities in 45 studies. 
 Treatment modality Number 
of studies 
Topical antiseptics SSD  14 
Silvazine® (SSD + chlorhexidine) 2 
Furacin  2 
SilvaSorb gel 1 
AgNO3 0.5% 1 
AgNO3 10%  1 
Daromide 1 
Other topical antiseptics 2 
Other topical products Solcoseryl 1 
Acexamic acid 1 
Placental extract ointment 1 
Basic fibroblast growth factor 1 
Aserbine 1 
Biolocigal dressings Amniotic membrane 5 
Allograft skin 2 
Allogeneic cultured keratinocytes 2 
Xe-derma® / Xenoderm® 2 
Beta glucan collagen 1 
Semisynthetical  Biobrane® 7 
Transcyte® 2 
Silver containing dressings Acticoat® 1 
Silverleaf® 1 
Aquacel Ag® 3 
Synthetic dressings Tulle gauze 5 
Duoderm® / Askina® THINsite® 4 
Mepitel® 4 
Tulle gauze with antibacterial addition 3 
Opsite® 2 
Lipocolloid dressing (Urgotul)® 1 
Enzymatic debridement Enzymatic debridement / enzymatic dressing 2 
Surgical Autologous skin graft 2 
(Tangential) excision or abrasion 2 
Tangential excision and grafting 2 
Hyalomatrix after dermabrasion 1 
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Randomized controlled trials (Group a).  
 
The search revealed ten randomized controlled trials (table 2a).
8-17 
For all but one studies the depth of the burns was estimated by clinical judgement only. One 
study was on partial and full thickness burns, nine were on partial thickness burns. Only in the 
trail of Kumar et al
8
, the depth of the burn was determined by the Laser Doppler Imaging 
measurement (LDI). Silver sulfadiazine (SSD) is considered a standard treatment for burns in 
children in many burn centres, as in seven out of ten articles it was compared to varying types 
of membranous dressings.
9-15
 In two studies SSD was compared with Biobrane® and in two 
other studies it was compared to Mepitel®.
11-13
 In one study SSD was compared to Jelonet® 
and Opsite® and in another study it was compared to amniotic membrane.
9,15
 In a seventh 
study SSD was compared to another topical antiseptic, Silvasorb Gel®.
14 
Silvazine®, a combination of SSD cream with 0.5% chlorhexidine, was compared to two 
membranous dressings, Transcyte® and Biobrane® in one study.
8
 In total SSD treatment 
involved 218 patients in these studies. 
Most notably, however, was the observation that in all of the studies which compared SSD or 
Silvadene® to another wound treatment, the alternative treatment showed better results on 
parameters such as eschar formation, Length of hospital Stay (LOS), healing time, pain score 
and need for analgesics, nurses preference, and need for autografting.  
Two membranous dressings, Duoderm® and Biobrane® were compared in one study: there 
were no differences in clinical parameters but Duoderm® was less expensive.
16 
 
Cohort studies (Group b). 
The thirty-one cohort studies were divided in twenty comparative and eleven non-comparative 
cohort studies (Table 2b-1 and 2b-2)  
 
Comparative cohort studies (group b1).
18-37 
Seven out of twenty studies were prospective.
18-24
  
In the whole group the type of treatment varied extensively. SSD or Silvazine®  (SSD + 
chlorhexidin) was considered standard treatment in seven studies, involving 725 
patients.
19,23,27-29,33,35
  In two studies SSD gave similar results
19,29
 as impregnated gauze 
dressing and other antiseptics respectively, or better results
28
  than the comparator, Tulle 
gauze with an antibacterial addition. In the other four studies, the alternative (to SSD) 
treatment modality scored better.
23,27,33,35
 This involved 435 out of the 725 patients, and 
included comparisons to two silver containing dressings (Aquacel Ag® and Acticoat®) and 
two biological dressings (allograft skin and Xenoderm®). 
 
Non-comparative cohort studies (group b2). 
Although the type of treatment varied greatly, there was some consensus in overall treatment 
modality: seven out of eleven studies included a membranous dressing.
38-41,43,47,48
 Six dressing 
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types can be considered of biological or semisynthetic origin.
39-41,44,47,48
 These studies are 
mainly descriptive in nature and provide little quantitative data on outcome parameters such 
as rate of wound closure, LOS and scarring. De Mey
30
 and Gravante
44
 include a high number 
of patients, but due to the heterogeneity in the patient groups such as types of burn and extent 
and depth of the burns, only general conclusions were drawn. 
 
Case series and case reports (Group c). 
 
Three articles in group c are on long term adverse reactions concerning scars related to the 
texture of the wound dressing, two on Mepitel® and one on Biobrane®.
50-52
  Bauer describes 
a group of children with extensive burns treated by tanning with AgNO3 10%.
49
   
 
 
Discussion 
 
45 Studies were included in this review after critical appraisal according to the Centre for 
Evidence-Based Medicine, Toronto. The reasons for the investigators to do a study on burns 
in children were various. An obvious reason to study only children was because the study was 
performed in a children’s hospital or a pediatric burns centre. More often epidemiological 
reasons were given. Burns in children are a common type of injury. By far the majority of 
burns in children under four years are partial thickness scald burns. For full thickness burns 
the established opinion since long is that early wound excision and grafting help to prevent 
metabolic and infectious complications and will improve survival.
53-55
 For partial thickness 
burns however, there is no consensus on the optimal treatment modality. In many clinics, 
SSD, Tulle gauzes, with or without an antiseptic or SSD are the standard of treatment.
56
 Daily 
(painful) dressing changes with wound exposure may lead to wound colonization, subsequent 
wound infection and deepening of the burn. Moreover, these dressing changes are 
considered time consuming and costly.  
 
Scars and long term follow up 
Partial thickness burns in children may cause permanent scars. Improved wound treatment 
with faster healing and less infections may reduce the severity of scarring.
57-60
  
It is therefore remarkable that only in one of the RCT’s the results of long term follow up are 
included in the study.
9
 However, in Cockingtons study, comparing treatment of partial 
thickness burns with SSD, Jelonet® and Op-site®, only in a few children a three-month-post-
reepithelialization follow up was performed and no significant differences were found. Tjong et 
al, in a retrospective cohort study, showed that treatment with allograft skin caused less 
hypertrophic scarring than treatment with SSD or early tangential excision.
27
 In three case 
reports long term skin abnormalities after uncomplicated wound healing were mentioned. 
Williams et al describe two children with scalds that were successfully treated with Mepitel®, 
an open structured siliconised dressing.
50
 Both children had a fenestrated pigmentation 
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pattern that corresponded to the pores in the dressing. Ahmadi et al noticed a mesh pattern 
that corresponded to the Mepitel® structure, in the healed skin, two years post burn.
52
 The 
same authors presented a patient, who, at almost three years post burn, had scars that 
corresponded to the pores of the Biobrane® dressing.
51 
In the group of twenty comparative cohort studies (Table 2b-1), long-term results were shown 
in two prospective studies
21,22
 and four retrospective studies
26,30.33,36
 Rab et al compared two 
groups of children with scald burn injuries who underwent a surgical excision.
21
 The group 
that was subsequently treated with allogeneic keratinocytes had a significantly lower 
Vancouver Scare Score (VSS) one year post burn than the group that was treated with an 
autologous skin graft. Akita et al covered the superficial and deep partial thickness burn of 
children with bFBF spray (basic fibroblast growth factor) in one group and applied an 
ointment-impregnated gauze in the control group. VSS was lower in the group treated with 
bFBF spray.
22 
In general no conclusive recommendation can be given on the best treatment modality to 
reduce scarring in this patient group, since most of the studies have not reported this 
systematically. 
 
Topical versus membranous dressings 
In the total of 45 trials, SSD or Silvazine® was one of the treatment modalities in 15 studies.
8-
15,19,23,27-29,33,35,
 In these studies SSD was the standard treatment that was compared to a new 
treatment modality, in most cases a biological or synthetic membranous dressing. In only one 
of the comparative studies SSD treatment offered the best outcome. Kudlackova compared 
SSD to Tulle gauze with chloramine.
28
 This study involved 56 SSD treated patients on a total 
of 753 SSD treated patients in all 15 studies on SSD.  
Three RCT’s provided a direct comparison between SSD and Biobrane®.
8,12,13
 All three 
reported superiority for Biobrane® with regard to wound healing time and LOS.  
Besides Biobrane® as a semisynthetical dressing, biological membranous dressings were 
used as well. Membranous dressings, creating a moist wound environment, may be 
favourable in treating partial thickness burns in children. Reducing the number of dressing 
changes, pain, the number of wound infections and deepening of the wound have been were 
reported by the authors as beneficial effects in the studies on membranous dressings. Walker 
et al were the first to study a biological dressing, amnion membrane, in comparison with a 
gauze dressing impregnated with Furacin, a topical antiseptic.
18
 In this study amnion 
membrane proved to be superior with respect to the need for split skin autografting and LOS. 
Bacterial counts were low, loss of fluids and proteins was minimized and pain was reduced. 
Two other studies on amnion membrane showed similar results.
15,26
 The choice for amnion 
membrane as a biological dressing may be driven by geographical circumstances, as these 
clinics are located in developing countries, where amnion membrane is cheap and easily 
available. The study of Thomson et al on amnion membrane mainly concerned monitoring, 
banking and bacterial safety.
39
 In 14 pediatric patients amnion membrane was used as a 
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dressing over partial thickness burns, in 22 other patients it was used over meshed split skin 
autografts and over freshly excised burns, with favourable results. In their recent article 
Mostaque et al describe an oven-dried, radiation sterilized human amnion membrane that is 
considered safe with regard to the risk of transmission of HIV.
15
 With proper harvesting and 
preparation, amnion membrane dressings still are a safe and cheap treatment modality for 
acute burns in children. 
In this review only two studies were identified on another biological dressing, human allograft 
skin. The studies by Rose et al and Tjong et al are both on partial thickness scald burns.
27,30
 
Rose et al compared the allograft treatment with topical antimicrobials, whereas Tjong et al 
compared human allograft treatment with early excision and subsequent autografting or, if the 
wound proved to be superficial after excision, with subsequent treatment with SSD. Roses’ 
study showed a faster epithelialisation and increased patient comfort in the allograft group; in 
the study of Tjong a remarkable reduction in hypertrophic scarring after allograft treatment 
was observed. The need for secondary excision and grafting was reduced.  
A remarkable high number (6) of studies included Biobrane®; four out of seven are in the 
RCT-group.
8,12,13,16,47,48,51,
 Biobrane® is a bilaminar synthetic membrane, consisting of a nylon 
mesh bonded with porcine collagen, covered with a silicone membrane. It is commercially 
available for the treatment of burn wounds since 1979. 
In a study of Kumar, three different wound treatments were compared: Biobrane®, Silvazine® 
(an SSD-chlorhexidine combination) and Transcyte®, a human fibroblast-derived temporary 
skin substitute.
8
 Transcyte® was superior with regard to the number of dressing changes, 
faster healing and less autografting. This was the only study in which the depth of the burn 
was confirmed by the LDI-Doppler method. 
When Biobrane® was compared to another membranous dressing, Duoderm®, there were no 
differences except for the cost of the treatment, which was lower in the Duoderm®-group.
16
 
In two studies in the RCT-group SSD was compared to Mepitel®, a silicone net dressing. 
Healing time was shorter for Mepitel® treated wounds.
10,11
 Gottschall also found less eschar 
formation, less pain and lower costs for the Mepitel® treatment.
11 
In the combined comparative studies 753 patients were treated with SSD, 103 with 
Biobrane®, 98 with amnion membrane and 211 with Tulle gauze. Superior outcome was 
reported for the membranous dressings. 
Although the outcome of the treatment with SSD is inferior to the other treatment modalities in 
most studies, SSD is still widely used in burn wound treatment in many hospitals.
61
 Ignorance 
of recent literature on burn wound treatment may be an explanation, but it must also be 
considered that the use of SSD is still safe with respect to infection.
62
 Moreover the use of 
SSD is very versatile, as many of the dressings that were compared to SSD are not suitable 
for body areas like the face and neck, hands and feet and buttocks and genitals.  
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Dressings containing silver 
Silver containing dressings, which release silver in a more or less controlled way, are a 
relatively recent development in wound care.  
Three recent studies on Aquacel Ag®, a carboxymethyl cellulose dressing in which sodium 
ions are replaced by silver ions, are in the non-randomized controlled trial-group.
35,37
 
Kazmierski et al studied five treatment modalities in children with deep partial thickness 
scalds.
34
 According to the authors, Aquacel Ag® was considered ‘a dressing suitable for 
superficial partial thickness burns and some deep partial thickness burns’. Paddock et al, in a 
cohort study comparing SSD and Aquacel Ag® found a shorter LOS in the Aquacel Ag® 
group.
35
 Compared to petrolatum gauze impregnated with Bacitracin®, the Aquacel® group 
showed less nursing time, less pain, shorter time to re-epithelilazation and a reduced LOS in 
the study by Saba.
37 
A widely used dressing for burn treatment, Acticoat®, appeared only in one comparative 
study.
33
 It was used in 241 patients and performed better than SSD concerning healing time 
and reduced need for grafting. In a non-comparative trial, Borsuk et al treated 15 children with 
a silver-coated nylon dressing, Silverleaf®.
34
 The author considered this dressing as effective 
as other silver containing dressings used for pediatric burns. No conclusion can be drawn as 
to which silver-releasing dressing would perform better, since no direct comparative studies 
amongst the different silver containing dressings could be identified. This corresponds with 
the outcome of the recent Cochrane review on topical silver for preventing wound infection.
63
 
 
Conclusion and recommendation 
 
Despite the high variation in study design and outcome parameters, some general 
conclusions can be drawn from the systematic analysis of these studies on treatment of 
partial thickness burns in children. Analysis of the comparative studies provides enough 
evidence to conclude that membranous dressings perform better on various wound-healing 
parameters than cream based topical antiseptics or gauze treatments. Among the advantages 
mentioned are reduced LOS, reduced healing time and reduced pain. However, application of 
membranous dressings is difficult on anatomic locations, such as hands, face and neck, 
genitals. This represents a limitation of the applicability. This may be the reason that SSD is 
still widely used since it is a very versatile material, which easily can be applied on all body 
areas. 
Within the group of membranous dressings, the group of biological dressings such as amnion 
membrane or allograft skin is still important. Particularly amnion membrane is abundantly 
available in developing countries and safe for the treatment of burns in children. Synthetic 
variants of membranous dressings are silicone containing materials such as Biobrane® or 
Mepitel®, or a cellulose based material such as Aquacel Ag®. Direct comparisons between 
different types of membranous dressings are scarce. Therefore, no indication can be given as 
to which membranous dressings would be best for the treatment of partial thickness burns in 
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children. Furthermore, there is a lack of studies describing the outcome of the wound healing 
process in terms of scar formation.  
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Chapter 9 
 
 
Future developments 
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Introduction 
 
The previous chapters have contributed to better treatment of patients with burns, and of 
children with burns in particular. However, recent developments in wound care have taken 
some of the treatments described in this thesis a step further. For partial thickness burns, 
especially scald burns in children; membranous dressings have become the standard of care. 
The use of GPA for the treatment of partial thickness burns was gradually replaced by 
Hydrofiber® in the Beverwijk Burns Centre. In partial thickness burns up to 15%TBSA 
Hydrofiber® dressing is now the treatment of choice. However, in deep partial thickness burn 
this Hydrofiber® treatment is applied with some restraint, as deepening of the burns in the 
first 48 hours may cause parts of the wound to turn into full thickness burns. With inadequate 
covering, these parts of the wound may become colonised or even infected, thereby causing 
further deepening the wound. Most deep partial thickness burns and mixed deep partial and 
full thickness burns are initially treated with Silver sulfadiazine cream, and excised and 
grafted in an early stage. New developments in determination of wound depth, wound 
excision and grafting techniques and research on dermal matrices may alter this treatment 
regimen in the future.  
 
Study designs 
 
This thesis describes a number of studies on burn wound treatment, especially, but not 
uniquely, applicable on burns in children.  
Design and data analysis of clinical studies in general have developed greatly in the last 10 to 
15 years. From non-comparative case descriptions and cohort studies we have now moved to 
randomized clinical trials and well designed and measurable outcome variables. From the 
latest literature on some of the described treatments we can conclude that the field of trauma 
and burns is relatively slow in picking up these new designs: still cohort studies and case 
series are common in recent publications.  
Also our own studies suffered from several limitations in the design (prospective and 
retrospective cohort studies next to RCT), outcome variables and data analysis. Concerning 
the outcome analysis, much improvement has been implemented in recent years with the 
introduction and validation of objective and subjective scar assessment tools (
1,2
). 
Nevertheless, further improvement is necessary in clinical definitions (e.g. when is a scar 
called a hypertrophic scar?) and unequivocal clinical descriptions of the patient population 
under study (burn depth, burn surface area etc.). Further developments in clinical 
implementation of technology such as laser Doppler Imaging and 3D camera's could assist in 
further improvement of these aspects. 
 
Developments in wound dressings 
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Presently, new developments in the wound dressing area are focussed on dressings that can 
stay on the wound for longer periods of time. This might add to the comfort of the patient, in 
avoiding painful and traumatic dressing changes, and would especially be an improvement in 
wound therapy for children. For superficial partial thickness burns in children we are currently 
analysing new silver containing wound foams in this category such as Mepilex Ag®. This type 
of dressing has been proven safe when compared to treatment with Silver sulfadiazine cream, 
but may be superior with regard to ease and frequency of dressing changes and costs.
3
  
 
Timing of surgery 
 
Primary or secondary wound excision and grafting is still controversial. During the Congress 
of the European Burn Association in The Hague on September 24th, 2011, two well respected 
burn surgeons, A. Kay, Royal Centre for Defence Medicine (UK) and G.I.J.M. Beerthuizen, 
Martini Hospital Groningen (The Netherlands) debated on this subject.
4
 There is evidence that 
early excision and grafting in extensive burns reduces mortality and Length Of Stay, at the 
expense of a greater blood loss.
5
 In this meta-analysis of early excisions, much attention is 
given to the relation between early excision and parameters as mortality, morbidity, length of 
stay etc. However, in this meta-analysis only one paragraph is dedicated to scarring. 
Engrave et al
6
 in a randomized prospective study, found more hypertrophic scarring in the 
group treated conservatively with Silver sulfadiazine, compared to the group that underwent 
early excision and grafting. Considering hand burns, van Zuijlen et al
7
 found no relation 
between early and late excision of the hand in the final hand function. In a prospective study 
by Mohammaddi et al these findings were confirmed.
8 
This does not mean that the argument is settled. Recent animal studies show that in pigs with 
deep partial thickness burns, wound excision three days post burn exhibited the best clinical 
and histological outcome.
9
 In another recent animal study Xin-Long et al showed reduced 
levels of IL-6 and TNF-alpha in the early excised group.
10
 Early excision and grafting had an 
effect on inflammatory mediators and reduced insulin tolerance. These mediators may have 
their effect of the inflammation reaction in the wound and thereby provoke the development of 
scar tissue. Timing of the wound excision, the method of wound excision and the wound 
covering are essential in the treatment of deep burns when considering functional outcome 
and scarring.  
In extensive full thickness burns, excision of the burnt skin to the fascia and covering of the 
wound with a temporary skin covering such as allograft skin, or grafting with a widely meshed 
split skin grafts or micro grafts is still the treatment of choice. 
10-17
 It is a vital indication, as 
removing the burn eschar will reduce the inflammation reaction. The advantages of wound 
excision to the fascia are a faster wound closure and limited blood loss, but the quality of the 
scar is poor. In less extensive burns and burns of mixed depth, the surgeon can focus on the 
quality of the remaining scar.  
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Burn depth, wound excision and wound covering 
 
The depth of the burn can be established reliably 48 hours after burning by laser Doppler 
imaging (LDI).
18
 This enables the surgeon to excise and graft parts of the wound that will not 
heal within 2 to 3 weeks in an early stage. Moreover a recently developed wound excision 
instrument, Hydrosurgery (Versajet®) allows a precise excision of the necrosis whereby vital 
dermal elements in the wound bed remain preserved as much as possible.
19
 Hydrosurgery 
can be applied in intermediate and deep partial thickness wounds. After excision of the 
necrotic tissue, the wound can be closed with a temporary dressing such as a xenograft, 
Transcyte® or Biobrane® to allow further spontaneous healing or with a thin split thickness 
skin graft.
20-22
 Very recently good clinical results were described by Keck at al in a prospective 
study on Suprathel®, an alloplastic copolymer of polylactide, trimethylene carbonate and e-
caprolactone.
23
 In this study deep dermal wounds were tangentially excised and covered with 
Suprathel® as an epidermal skin substitute or thin autografts. Compared with treatment with 
split thickness skin grafts, healing time with Suprathel® was longer, but early results 
concerning scar formation were comparable. As this fully synthetic material may have 
advantages over biological dressings, a future study to precise wound excision by 
hydrotherapy combined with a wound covering with Suprathel® is indicated. 
 
Dermal substitutes and tissue engineering 
 
Depending upon the amount of vital dermis that remains in the wound bed, the excised 
wounds can be covered with a split skin graft only, or combined with a dermal matrix like 
Matriderm®.
24
 In a long term follow up of twelve years, Bloemen et al found improved scar 
parameters in the group treated with a elastin-collagen dermal matrix compared with the 
group with a split skin graft only.
25
 Although the main focus of this thesis is on the most 
abundant type of burn wounds in children, the partial thickness burns, the subject of tissue 
engineered skin cannot be totally neglected. Cell therapy in combination with dermal or even 
full skin substitutes is still under constant development and will result in a next generation of 
tissue engineered constructs. Important improvements have been reached since the original 
establishment of keratinocyte cultures by Rheinwald and Green
26
, both in robustness 
(epidermal cells in carrier materials rather than as epidermal sheet), reproducibility and 
clinical requirements (e.g.culture techniques applying clinical grade culture media). Much 
more predictable and reliable results are obtained with cell culture applications nowadays
27
 
and improvements and new materials are under constant development.
28,29
 The ultimate 
threat for these new constructs lies in the high costs involved with their production. The 
benefit, however, could also be high, since if application of these constructs could reduce the 
number of scar revisions later in the healing process of the patient, cost-effectiveness could 
still be demonstrated.  
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Scar prevention 
With the contemporary knowledge of resuscitation, infection prevention and treatment of 
inhalation trauma, most patients with burns will survive. However the long-term outcome of 
our wound treatment, scar formation, is still poor. In the treatment of deep burns, more 
sophisticated wound excision techniques and development of dermal matrices will improve 
the long-term outcome. All over the world laboratories are busy developing new dermal 
substitutes, sometimes in combination with cell therapy. The group of patients with 
intermediate depth burns, such as children with scald burn injuries that do not need surgery or 
dermal replacement, need not to be forgotten. These burns still may leave awful scars. 
Combined techniques of accurate excision of necrotic dermis and application of dedicated 
wound coverings may help to further improve the outcome of these wounds in the future. 
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Nederlandse samenvatting 
 
Inleiding 
Dit proefschrift beschrijft klinisch onderzoek, dat is uitgevoerd in het Brandwondencentrum 
van het Rode Kruis Ziekenhuis in Beverwijk, met de nadruk op brandwondbehandeling bij 
kinderen. Dit brandwondencentrum is in 1974 opgericht en ingericht naar Amerikaans model, 
als een geïsoleerde afdeling van een perifeer ziekenhuis, met gespecialiseerd paramedisch 
en verpleegkundig personeel onder leiding van een chirurg en intensivist. In dezelfde periode 
zijn de twee andere Nederlandse brandwondencentra in Nederland, in Groningen en 
Rotterdam opgericht, evenals de Nederlandse Brandwonden Stichting. De doelstellingen van 
deze stichting zijn het verbeteren van de behandeling, de verpleging, de verzorging en de 
hulpverlening aan personen met brandwonden. Het bevorderen van de kwaliteit van leven 
van mensen met brandwonden en het voorkomen van brandwonden. Medewerkers van de 
brandwondencentra hebben zich verenigd in de Nederlandse Brandwonden Club, later 
omgedoopt tot een meer professionele naam, de Nederlandse Vereniging voor 
Brandwondenzorg (NVBZ). De NVBZ onderhoudt nauwe banden met de in 1981 opgerichte 
European Burns Association (EBA). In 1986 is het eerste congres van de EBA georganiseerd 
in Groningen. Brandwonden Nederland stond op de kaart! Daarna is  in 1990 de Stichting 
Kind en Brandwond (St K&B) en in 2003 de Vereniging Samenwerkende Brandwonden 
Centra Nederland (VSBN) opgericht. De St K&B richt zich voornamelijk op extra nazorg voor 
kinderen met brandwonden en hun gezinnen. De VSBN heeft als hoofddoel de samenwerking 
tussen de Nederlandse centra, met name op het gebied van wetenschappelijk onderzoek te 
bevorderen. 
 
Epidemiologie 
Dit proefschrift richt zich met name op de brandwondenbehandeling bij kinderen. Om een 
indruk te krijgen van het aantal kinderen dat wordt opgenomen in de Nederlandse 
brandwondencentra, en van de grootte en de diepte van deze brandwonden, is een 
epidemiologisch onderzoek gedaan. Hoofdstuk 2 is hieraan gewijd. 
Hoewel de brandwondencentra al sedert hun oprichting een patiëntenregistratie bijhielden 
waren de gegevens nog nooit gebundeld en was er niet eerder onderzoek gedaan naar 
trends in opnamepatronen, oorzaken van verbranding en grootte van de brandwonden. Om 
gerichte preventiecampagnes op te zetten, maar ook om de benodigde capaciteit van de 
brandwondencentra te kunnen bepalen is het  belangrijk om opnamegegevens van de drie 
centra te analyseren. 
Na 2000 werd in het brandwondencentrum Beverwijk een veranderde opnametrend van 
kinderen waargenomen. Er werden meer kinderen opgenomen, die gemiddeld kleinere 
brandwonden hadden. Daarom werd een epidemiologisch onderzoek gedaan naar kinderen 
opgenomen in de drie Nederlandse brandwondencentra. Gekozen werd voor de periode 
1995-1999 en 2000-2007. De databases van de drie brandwondencentra werden 
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gecontroleerd, waar nodig aangevuld met gegevens uit patiëntenstatussen en ontslagbrieven, 
en vervolgens samengevoegd. Uit het onderzoek bleek inderdaad dat het aantal kinderen dat 
in de drie Nederlandse brandwondencentra werd opgenomen in beide leeftijdsklassen – 0 tot 
en met 4 jaar en 5 tot en met 17 jaar – na 2000 was toegenomen. Na toevoeging van recente 
opnamecijfers bleek deze trend zich tot 2012 te hebben doorgezet. Een tweede uitkomst van 
het epidemiologisch onderzoek was dat hoewel het aantal kinderen met brandwonden in 
Nederland afnam, er toch meer kinderen werden doorverwezen naar de brandwondencentra; 
ook hier bleek de trend zich na 2007 door te zetten. 
Om te kunnen beschikken over opname- en behandelcijfers van de drie brandwondencentra 
van hoge kwaliteit werd in 2009 onder auspiciën van de VSBN, een gezamenlijk 
registratiesysteem, genaamd R3 opgezet. In de toekomst zal R3 gekoppeld worden aan het 
elektronisch patiëntendossier, waardoor de kwaliteit van gegevens verder verbeterd kan 
worden. 
 
Donorhuid 
Heetwaterverbrandingen bij kinderen worden vaak beschouwd als een aparte entiteit. Deze 
brandwonden, hoewel beperkt van oppervlak, laten vaak ernstige littekens na. Het bleek dat 
behandeling van brandwonden bij kinderen met donorhuid betere resultaten gaf dan de 
oorspronkelijke behandeling met antibacteriële crèmes en vroege operatieve behandeling. 
Kinderen hoefden minder vaak geopereerd te worden en er ontstonden dankzij deze 
behandeling minder littekens. De donorhuid werd betrokken van de Nederlandse Huidbank, 
een onderdeel van de Nederlandse Brandwonden Stichting. Van oudsher werd donorhuid 
diepgevroren bij een temperatuur van - 80º C. Dit maakte transport en opslag lastig en 
beperkte het gebruik buiten de brandwondencentra. Een nieuwe bewaarmethode door middel 
van conservering in een hoge dosering glycerol werd ontwikkeld door de Nederlandse 
Huidbank. De donorhuid behield met deze methode zijn structuur, maar verloor zijn vitaliteit. 
Donorhuid werd een koelkastproduct dat eenvoudig kon worden getransporteerd en overal 
kon worden toegepast. De naam van de huidbank werd veranderd in de Euro Skin Bank. De 
overgang van diepgevroren huid (Cryo-PA) naar in glycerol geconserveerde huid (GPA) 
verliep in de kliniek geruisloos. Retrospectief is onderzocht of er verschillen waren in de 
uitkomsten van behandeling van tweedegraads brandwonden met Cryo-PA en GPA. 
(Hoofdstuk 3) De uitkomst van deze studie liet zien dat bij de behandeling met GPA minder 
huidtransplantaties nodig waren om de brandwond te sluiten, maar het verschil was niet 
groot. Op grond van de uitkomsten van deze studie leek een verder prospectief onderzoek 
naar de resultaten van behandeling met beide vormen van donorhuid op zijn plaats. Door 
nieuwe ontwikkelingen op het gebied van behandeling van tweedegraads brandwonden, met 
name door de ontwikkeling van synthetische wondbedekkers, werd een dergelijke studie 
echter nooit uitgevoerd. 
Wel verscheen een tweede retrospectieve studie naar de verschillende 
gebruiksmogelijkheden van GPA. (Hoofdstuk 4) Vier toepassingen werden beschreven: 
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1. Sandwich grafting. Bij uitgebreide diepe brandwonden is een relatief tekort aan 
donorsites, er is te weinig gezonde huid die kan dienen als bron voor huidtransplantaten. 
De huidtransplantaten die worden gewonnen, moeten door middel van de meshtechniek 
worden vergroot in oppervlak. Van een strook huid wordt een net gemaakt dat vier tot zes 
maal zo groot is als het oorspronkelijke oppervlak. Dit huidnet geeft veel open plekken in 
de getransplanteerde wond. Wondgedeelten in de mazen van het net kunnen uitdrogen 
en geïnfecteerd raken. Door over het huidnet een laag donorhuid aan te brengen werden 
deze open plekken afgedekt, waardoor uitdroging en infectie werden voorkomen. Deze 
methode wordt de sandwich grafting genoemd. De eigen huid van de patiënt, het 
autotransplantaat, groeit eerst vast aan de wond en daarna groeit het epitheel uit over het 
wondoppervlak. Omdat de donorhuid, die ook aan de wond is vastgegroeid, langzaam 
wordt afgestoten, dekt de eigen huid van de patiënt geleidelijk de hele wond af. Bij dit 
proces blijft (een deel van) het dermisgedeelte (de lederhuid) van de donorhuid achter; de 
eigen huid van de patiënt groeit hier overheen. Dit fenomeen wordt creeping substitution 
genoemd. De geïncorporeerde  donorhuiddermis wordt vervolgens geleidelijk omgezet in 
eigen dermis van de patiënt. Daarbij wordt het vezelpatroon van de donorhuid 
overgenomen, hetgeen gunstig is voor de littekenvorming. Glycerol donorhuid bleek zeer 
geschikt voor deze procedure. In 57% van de gevallen genas de wond volledig, of was 
hertransplantatie van slechts een klein gebied nodig. Gelet op het feit dat het om 
patiënten met zeer diepe en uitgebreide brandwonden gaat zijn dit gunstige resultaten. 
2. Behandeling van tweedegraads brandwonden. Bij de in deze studie beschreven patiënten 
genas 46% van de wonden volledig onder donorhuid; in 28% van de patiënten moest de 
behandeling worden afgebroken, omdat de donorhuid onvoldoende adherent werd aan 
het wondoppervlak. Met een andere verbandtechniek genas de wond vervolgens uit 
zichzelf; in 26% van de patiënten moest een deel van de wond met een huidtransplantaat 
worden gesloten. 
3. Verbetering van de wondconditie. Een aantal omstandigheden, zoals een slechte 
algemene conditie van een patiënt, een zeer diepe wond met peesweefsel of blootliggend 
bot in de wondbodem of bacteriële  kolonisatie van de wond, kan leiden tot een slecht 
genezende wond. Door de slechte kwaliteit van de wondbodem is het dan vaak niet 
mogelijk om de wond met een huidtransplantaat te sluiten. Behandeling met 
antibacteriële zalven of crèmes, geven vaak een onvoldoende resultaat. Door uitdroging 
en persisterende wondkolonisatie kan de necrose, het dode weefsel in de wond, zich 
uitbreiden, waardoor de wond dieper wordt. Afdekken van de wond met donorhuid kan tot 
verbetering van de wondconditie leiden. Als bij het verwijderen van de donorhuid, een 
aantal dagen na het aanbrengen, kleine bloedinkjes optreden en als de huid als het ware 
als een strook klittenband loslaat, spreken we van een positieve ‘take-test’. Dit wijst op 
een te verwachten goed resultaat van de behandeling met het eigen huidtransplantaat. 
Bij 88 wonden bij 55 patiënten pasten wij deze behandeling toe. In 13% van de gevallen 
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genas de wond alsnog spontaan; 82% van de wonden kon vervolgens worden 
getransplanteerd, enkele meerdere malen, tot een volledige wondsluiting werd verkregen. 
4. Gebruik van donorhuid bij correctie van een strak litteken. Littekens hebben de neiging 
om samen te trekken. Als een litteken over een gewricht loopt, kan de functie van het 
gewricht beperkt worden. Insnijden van het litteken levert de benodigde ruimte op voor 
herstel van de volledige bewegingsvrijheid van het gewricht. De wond die hierbij ontstaat 
moet worden gesloten met een huidtransplantaat. Direct sluiten met een 
huidtransplantaat kan een matig resultaat opleveren, omdat in de dagen na het insnijden 
de wond nog verder ontspant en groter wordt. Het direct aangebrachte huidtransplantaat 
zou dan opnieuw te klein zijn. Het is daarom beter eerst de wond tijdelijk af te dekken met 
donorhuid en ongeveer een week later, als de wond niet meer groter wordt, het 
definitieve huidtransplantaat aan te brengen. Deze methode leverde bij 52 littekens een 
vitaal wondbed op met een 100% ingroei van het huidtransplantaat. 
Na het verschijnen van de artikelen over donorhuidtoepassingen zijn veel synthetische en 
semisynthetische verbandmiddelen ontwikkeld, die de plaats van donorhuid lijken te hebben 
ingenomen. In een literatuuronderzoek is gekeken of en voor welke indicaties donorhuid in de 
recente periode wordt toegepast. Het blijkt dat zowel Cryo-PA als GPA tot op de dag van 
vandaag in veel brandwondencentra worden toegepast voor de behandeling van 
tweedegraads brandwonden en voor de behandeling van zeer diepe en uitgebreide 
brandwonden. Een in 2011 uitgevoerde literatuurstudie liet zien dat er geen verschil is in 
klinisch resultaat bij de behandeling van tweedegraads brandwonden met Cryo-PA of GPA. 
Wel is donorhuid in veel klinieken vervangen door (semi-)synthetische verbandmiddelen bij 
de behandeling van tweedegraads brandwonden. In het Beverwijkse brandwondencentrum 
wordt donorhuid momenteel voornamelijk toegepast als tijdelijke bedekking van geëxcideerde 
wonden bij gebrek aan geschikte donorsites en als middel om de wondconditie te verbeteren. 
 
Hydrofiberverband 
Hoofdstuk 5 beschrijft de eerste ervaringen met een synthetisch verbandmiddel, bestaande 
uit Na-carboxymethylcellulose, voor de behandeling van tweedegraads brandwonden. In deze 
studie werden 84 patiënten, merendeels kinderen met heetwaterverbrandingen, met dit 
hydrofiberverband, Aquacel®, behandeld. In een pilotstudie, bij de eerste patiënten die met 
Aquacel® werden behandeld, viel in de loop van de behandeling een sterke gelijkenis op met 
de behandeling met donorhuid. Eerst werd het hydrofiberverband adherent aan het 
wondoppervlak, daarna werd het vochtige verband langzaam droger, tot het een korst vormde 
die van de wond losliet op plaatsen waar deze genezen was. De eenvoud van de 
verbandprocedure en de gunstige behandelresultaten leidden tot het prospectieve 
vervolgonderzoek. In de onderzochte groep werd bij de helft van de patiënten een volledige 
genezing bereikt onder het hydrofiberverband, bij 7% resteerden kleine oppervlakkige 
wonden, die met een zalf- of crèmebehandeling spontaan genazen. In 43% van de gevallen 
was een huidtransplantatie nodig van diepere wonddelen. Vooral bij patiënten die zonder 
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huidtransplantatie genazen, gaf de behandeling een gunstig litteken. Als deze behandeling 
werd vergeleken met de eerdere behandeling met donorhuid, bleek dat hydrofiber een veilig, 
goed toepasbaar en eenvoudig toe te passen middel was voor de behandeling van 
tweedegraads brandwonden. Als logisch vervolg op dit onderzoek is een gerandomiseerd 
gecontroleerd onderzoek gedaan waarbij GPA  werd vergeleken met Aquacel® bij de 
behandeling van tweedegraads brandwonden. 
 
In hoofdstuk 6 worden de resultaten van deze gerandomiseerde studie beschreven. In een 
periode van twee jaar werden 80 patiënten met tweedegraads brandwonden behandeld met 
donorhuid of Aquacel®, 40 in iedere groep. In de hydrofibergroep waren de wonden iets 
groter dan in de donorhuidgroep, maar het verschil was niet significant. In beide groepen 
waren de wonden even diep. In de met Aquacel® behandelde groep moesten meer patiënten 
een huidtransplantatie ondergaan van wondgedeelten die niet waren genezen onder het 
hydrofiberverband dan in de met donorhuid behandelde groep. Een belangrijk resultaat van 
wondbehandeling is het uiteindelijke resultaat, de littekenvorming. De littekenvorming werd 
gemeten tien weken, een half jaar en een jaar na verbranding. Aanvankelijk was de 
huidelasticiteit in de donorhuidgroep significant beter, maar na een half jaar en een jaar werd 
geen verschil meer gemeten. De incidentie van littekenhypertrofie na een jaar was groter in 
de hydrofibergroep, maar het verschil was niet significant. Op grond van de resultaten van het 
onderzoek geven we de voorkeur aan donorhuid voor de behandeling van de diep 
tweedegraads brandwonden, zoals die vooral in de brandwondencentra worden gezien; 
hydrofiber is zeer geschikt voor de kleinere tweedegraads brandwonden. 
De genoemde twee klinische studies waren ook de eerste die werden gepubliceerd over dit 
onderwerp. Ook voor Aquacel® werd een literatuuronderzoek gedaan om na te gaan of  het 
gebruik nog actueel is. Er zijn nadien nog 22 studies verschenen, waaronder elf randomized 
controlled trials. Vijftien studies betroffen de behandeling van tweedegraads brandwonden. 
Opvallend daarbij is dat in deze studies de Aquacel-Ag variant is gebruikt, terwijl nooit is 
aangetoond dat de toevoeging van zilver een meerwaarde heeft. In geen van de klinische 
studies naar de behandeling van tweedegraads brandwonden is de diepte van de 
verbranding geobjectiveerd door middel van de Laser Doppler Imaging. Dit rechtvaardigt het 
uitvoeren van nieuwe studies om beter te kunnen vaststellen voor welke diepte brandwonden 
Aquacel® het meest geschikt is. 
 
Mepitel® 
De eerste klinische ervaringen met Mepitel®, een siliconen wondverband, worden 
beschreven in hoodfstuk 7. Mepitel® bestaat uit een open polyamideweefsel, gecoat met 
siliconen. Het materiaal hecht aan gezonde huid, maar niet aan een open wond. Door de 
openingen in het netwerk kan wondvocht ontsnappen en kunnen antibacteriële middelen die 
in het bovenliggende verband zijn aangebracht het wondoppervlak bereiken. Vanwege de 
open structuur en de hechting aan intacte huid leek het een goed middel om 
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huidtransplantaten te fixeren. De gebruikelijke nietjes om het transplantaat met het 
overliggende verband aan de huid en het wondbed te fixeren zouden dan kunnen worden 
weggelaten. Vooral bij kinderen leek dit van groot voordeel. In een klinisch onderzoek werden 
45 huidtransplantaten bij 38 kinderen gefixeerd met Mepitel® in plaats van het gebruikelijke 
vaselinegaas of Surfasoft® met nietjes. Bij 42 transplantaten was het transplantaat bijna 
volledig ingegroeid; bij drie transplantaten was het transplantaat niet over hele oppervlak 
ingegroeid vanwege een klein hematoom of vanwege onvoldoende kwaliteit van het 
wondbed. Geen van de transplantaten was van plaats verschoven. Er was geen algehele 
anesthesie nodig om het verband te kunnen verwijderen; op plaatsen waar het Mepitel® toch 
verkleefd was aan de wond, was bevochtigen voldoende om het los te maken. Sommige 
kinderen konden zelf het verband verwijderen. 
Deze klinische studie naar het gebruik van Mepitel® bij huidtransplantaten was de eerste 
gepubliceerde klinische studie naar een toepassing van Mepitel®. Ook door andere 
onderzoekers is vastgesteld dat dit middel niet verkleefde aan de wond, waardoor 
verwijdering niet leidde tot wondbeschadiging en niet pijnlijk was voor de patiënt. Achttien jaar 
na de eerste publicatie verschenen nog drie studies over bedekking van huidtransplantaten, 
en dertig studies over andere toepassingen. Mepitel® heeft zijn plaats gevonden bij de 
behandeling van brandwonden, chirurgische en traumatische wonden en dermatologische 
aandoeningen gepaard gaande met een kwetsbare huid. 
 
Systematische review 
Veel van de in dit proefschrift onderzochte behandelmethoden worden vooral bij kinderen 
toegepast. Kinderen, vooral jonger dan 4 jaar, hebben vaak een typisch ongeval. Ons eigen 
onderzoek (hoofdstuk 2) laat zien dat bijna de helft van de patiënten die wordt opgenomen in 
een van de Nederlandse brandwondencentra, jonger is dan 17 jaar. Zeventig procent hiervan 
is jonger dan 4 jaar. Omdat ze sneller en meer mobiel zijn dan hun ouders of toezichthouders 
denken, zijn ze in staat om potten en bekers thee  of koffie op tafel te om te gooien of de 
waterkoker van het aanrecht te trekken. Door hun dunne huid, kan een relatief kleine 
hoeveelheid hete vloeistof al een ernstige verbranding geven. Daarnaast kunnen 
brandwonden in de eerste dagen na het ontstaan dieper worden; een brandwond van 
gedeeltelijke dikte kan overgaan in een brandwond van volledige dikte. De peilers van de 
behandeling van deze kritische brandwonden is het voorkomen van uitdroging van het 
wondbed en het voorkomen van infectie. Door middel van een systematische review, hebben 
wij onderzocht welke wondbehandelingsmethoden en verbandmiddelen er klinisch zijn 
onderzocht bij kinderen. Hoofdstuk 8 vermeldt de resultaten van dit onderzoek. Het 
onderzoek leverde 45 artikelen op. Er waren tien prospectieve gerandomiseerde 
onderzoeken; 31 cohort studies, waarvan twintig vergelijkend en vier niet-vergelijkend. De 
overige vier artikelen waren beschrijvingen van enkele gevallen. 
De tien gerandomiseerde studies leverden het sterkste bewijs, gevolgd door de vergelijkende 
studies. In de helft van de dertig vergelijkende studies, was zilversulfadiazine crème – al of 
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niet met toevoeging van chloorhexidine – de controlebehandeling. Biobrane® was in vier 
studies het materiaal dat ermee werd vergeleken en amnionmembraan in drie studies. In 
zeven studies was een al of niet met een antimicrobieel middel geïmpregneerd vaselinegaas 
de controle. Vrijwel geen enkele studie liet langetermijnresultaten – littekenvorming – zien. 
Bij analyse van de vergelijkende studies bleek dat membraneuze verbandmiddelen betere 
resultaten geven wat betreft opnameduur, genezingsduur en pijn, dan behandelingen op 
basis van antimicrobiële crèmes of vaselinegazen. Membraneuze verbandmiddelen zijn onder 
te verdelen in biologische membranen, zoals donorhuid en amnionvlies, semisynthetische 
membranen zoals Biobrane® en synthetische membranen zoals Mepitel® en Aquacel®. 
Vergelijkend onderzoek tussen de verschillende membranen zijn helaas schaars. Mede door 
het ontbreken van langetermijnresultaten is op basis van deze studies niet aan te geven welk 
van de membraanverbanden de voorkeur verdient bij de behandeling van brandwonden bij 
kinderen. 
 
De toekomst 
In hoofdstuk 9 komt een aantal toekomstige ontwikkelingen betreffende wondbehandeling bij 
kinderen aan de orde. In dit proefschrift is beschreven dat de studies op het gebied van 
donorhuid, hydrofiberverband en Mepitel® weliswaar gedateerd mogen lijken, maar dat 
recent onderzoek laat zien dat geen van deze behandelmethoden gedateerd of verlaten zijn; 
integendeel, alle genoemde behandelingen worden nog steeds toegepast en er verschijnen 
nog jaarlijks artikelen van klinisch en preklinisch onderzoek. 
De studiemethode van een aantal artikelen in dit proefschrift is verouderd, met betrekking tot 
studieopzet, uitkomstvariabelen en data-analyse. Hoewel op dit moment nog veel case-
studies en cohortstudies worden gepubliceerd, worden ook op het gebied van 
wondbehandeling gerandomiseerde studies de standaard. Uitkomstvariabelen worden 
nauwkeuriger door gevalideerde objectieve en subjectieve littekenmetingen. Ook methoden 
om oppervlak en diepte van de brandwond te bepalen zullen in de toekomst beter 
geobjectiveerd worden door de introductie van Laser Doppler Imaging en 3D-camera’s. 
Met betrekking tot nieuwe synthetische wondbehandelingsmaterialen zijn er recente 
ontwikkelingen. Voor de behandeling van oppervlakkig tweedegraads brandwonden lijken 
zilverbevattende foamverbanden, zoals Mepilex Ag® te leiden tot een verhoogd comfort voor 
de patiënt. Omdat deze verbanden een week op de wond kunnen blijven zitten, wordt het 
comfort voor de patiënt verbeterd en kan de opnameduur verkort worden. Ook de resultaten 
op het gebied van de wondbehandeling lijken gunstig, hoewel de langetermijnresultaten 
vooralsnog ontbreken. Diep tweedegraads brandwonden en mengverbrandingen worden na 
initiële behandeling met zilversulfadiazinecreme vroeg geëxcideerd en getransplanteerd. 
Ontwikkelingen op het gebied van een meer betrouwbare bepaling van de diepte van de 
brandwond, nauwkeuriger excisietechnieken en de ontwikkeling van dermale matrices zullen 
in de toekomst mogelijk tot een ander behandelbeleid leiden. 
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De discussie over vroege en late wondexcisie bij brandwondpatiënten is nog niet beslecht. 
Over de vroege wondexcisie bij uitgebreide en diepe brandwonden is veel overeenstemming, 
vroege excisie heeft een vitale indicatie, necrotisch weefsel, een bron van toxinen wordt 
weggenomen, met als gevolg een verminderde ontstekingsreactie. Morbiditeit, mortaliteit en 
opnameduur worden beperkt bij vroege excisie, ten koste van een groter bloedverlies. Het 
eindresultaat, het resterende litteken is echter in de regel slecht van kwaliteit. 
De ontstekingsreactie bij kleine, niet-levensbedreigende brandwonden, kan ook een rol 
spelen bij het eindresultaat van de behandeling, de littekenvorming. Op de verdieping van 
brandwonden, door het lokale ontstekingproces in de wond, is nog geen antwoord gevonden. 
Door het creëren van een vochtig wondmilieu, het voorkomen van wondinfectie en door het 
beperken van wondbeschadiging bij verbandwisselingen, wordt geprobeerd verdieping van de 
wond te beperken. Er zijn recente technische ontwikkelingen die het mogelijk maken om de 
necrose van de brandwond nauwkeuriger te excideren, waarbij vitaal weefsel gespaard blijft. 
Het behulp van hydrosurgery (Versajet®) is dit mogelijk. In een aantal studies werden 
wonden op deze manier geëxcideerd en vervolgens bedekt met een xenograft, Transcyte® of 
Biobrane. Een nieuw ontwikkeld synthetisch verbandmiddel, Suprathel®, kan mogelijk in de 
toekomst ook met deze excisietechniek worden gecombineerd. 
Bij diepe brandwonden treedt verlies van dermis op, dat bij transplantatie met een dun 
gespleten huidtransplantaat slechts gedeeltelijk wordt aangevuld. Dit verlies lijkt 
gecompenseerd te kunnen worden door het huidtransplantaat aan te vullen met een dermale 
matrix, zoals Matriderm®. In onze kliniek is aangetoond dat deze methode een beter litteken 
geeft. Combinatie van een dermale matrix met gekweekte keratinocyten zou wellicht in de 
toekomst betere resultaten kunnen geven bij de behandeling van derdegraads brandwonden. 
De kosten van deze techniek zijn hoog, maar als de littekenvorming gunstig is, kan het 
wellicht toch kosteneffectief zijn. 
Met de huidige stand van de medische techniek zijn patiënten met uitgebreide en diepe 
brandwonden goed te behandelen. Resuscitatie, infectiepreventie en behandeling van het 
inhalatietrauma hebben de mortaliteit bij uitgebreide brandwonden aanmerkelijk gereduceerd. 
Op het gebied van littekenpreventie moet echter nog veel werk worden verzet. 
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hebt een belangrijke eigenschap met je voorganger gemeen, je geeft me de ruimte. Je 
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Collega’s chirurgen en plastisch-chirurgen. Jullie betrokkenheid bij het brandwondencentrum 
is in de afgelopen jaren aanzienlijk toegenomen. Dit is een goede ontwikkeling. Het klinisch 
werk wordt intensiever en er is een noodzaak tot kwaliteitsverbetering en grotere 
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vakanties (graag ook nog een paar met rugzak en tentje) en onze katten. 
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